WO2002020012A2 - Method for treating allergies using substituted pyrazoles - Google Patents

Method for treating allergies using substituted pyrazoles Download PDF

Info

Publication number
WO2002020012A2
WO2002020012A2 PCT/US2001/027479 US0127479W WO0220012A2 WO 2002020012 A2 WO2002020012 A2 WO 2002020012A2 US 0127479 W US0127479 W US 0127479W WO 0220012 A2 WO0220012 A2 WO 0220012A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperazin
pyrazolo
tetrahydro
propyl
Prior art date
Application number
PCT/US2001/027479
Other languages
French (fr)
Other versions
WO2002020012A3 (en
Inventor
J. Guy Breitenbucher
Hui Cai
James P. Edwards
Cheryl A. Grice
Yin Gu
Darin J. Gustin
Lars Karlsson
Haripada Khatuya
Steven P. Meduna
Barbara A. Pio
Siquan Sun
Kevin L. Tays
Robin L. Thurmond
Jianmei Wei
Original Assignee
Ortho Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/928,122 external-priority patent/US7309703B2/en
Priority to NZ524680A priority Critical patent/NZ524680A/en
Priority to CNB018182720A priority patent/CN100384420C/en
Priority to AU8873001A priority patent/AU8873001A/en
Priority to DE60122171T priority patent/DE60122171T2/en
Priority to CA002421505A priority patent/CA2421505A1/en
Application filed by Ortho Mcneil Pharmaceutical, Inc. filed Critical Ortho Mcneil Pharmaceutical, Inc.
Priority to EP01968486A priority patent/EP1315491B1/en
Priority to MXPA03001964A priority patent/MXPA03001964A/en
Priority to AU2001288730A priority patent/AU2001288730B2/en
Priority to JP2002524496A priority patent/JP2004508329A/en
Publication of WO2002020012A2 publication Critical patent/WO2002020012A2/en
Publication of WO2002020012A3 publication Critical patent/WO2002020012A3/en
Priority to HK03105865A priority patent/HK1053606A1/en
Priority to CY20061101469T priority patent/CY1106196T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • This invention relates to the use of substituted pyrazoles for the treatment of an allergic condition.
  • Atopic allergies afflict at least 20% of populations in developed countries and comprise a wide range of IgE-mediated diseases such as hay fever, asthma, atopic dermatitis, and food allergies.
  • Exposure of an allergic subject to relevant allergens cross-links allergen specific IgE bound to mast cells, triggering degranulation and release of proinflammatory mediators, such as histamine and eicosanoids, which cause the weal-and-flare response on a skin test. Characteristically, this early response is followed by a prolonged late reaction in which inflammatory cells, particularly eosinophils and activated TH-2 CD4 T cells, are recruited to the site of allergen exposure.
  • Inflammatory cytokines such as IL-4 and IL-5, both produced by TH-2 cells, are important for IgE production by B cells and for eosinophilia, respectively.
  • Immunotherapies targeting CD4 T cells have been shown to be effective in reducing the production of IgE, the activation of proinflammatory cells, and the release of inflammatory mediators.
  • CD4 T cells The activation of CD4 T cells is a major factor in the initiation and maintenance of the allergic response. Allergens are taken up by specialized antigen presenting cells (APCs) such as dendritic cells and B cells. Protein allergens pass through the endosomal or lysosomal system where they are degraded by different proteases. These peptide fragments are bound by the MHC class II molecules which, at the cell surface, are heterotrimeric complexes consisting of two transmembrane glycoprotein chains ( ⁇ and ⁇ ) that form a binding scaffold for the third component, a peptide of 11-20 amino acids. The antigen-MHC class II molecule complex is recognized by CD4 T cells and leads to the activation of the T cell. Activated T cells in turn activate several other components of the immune system, such as B cells and macrophages, that are crucial for the body's response to pathogens, but also lead to the symptoms of allergies.
  • APCs antigen presenting cells
  • Class II molecules like other transmembrane proteins, are translocated into the endoplasmic reticulum (ER) after synthesis, where they associate with a third protein, the invariant chain (li).
  • the invariant chain molecule is a type II transmembrane protein that serves as a class ll-specific chaperone, promoting the exit of class ll-li complexes from the ER and preventing class II molecules from binding to peptides and unfolded proteins in the ER and in the secretory pathway.
  • a targeting motif in the cytoplasmic tail of li directs the class ll-li complexes from the secretory pathway into the endosomal system.
  • the li Before the MHC class II molecules can present antigen the li must be removed by a series of proteases that break down li.
  • the resultant li peptide fragments called class ll-associated invariant chain peptides (CLIP), occupy the peptide binding groove of the class II molecule, and in most cases are not spontaneously released.
  • CLIP class ll-associated invariant chain peptides
  • the CLIP protects the class II binding pocket from collapsing both during intracellular transport and after li degradation in the endosomal system. Binding of antigenic peptides generated from endocytosed proteins requires an empty, and yet open binding site. The CLIP therefore must be released while the open binding site is stabilized to allow the binding of other peptides.
  • Human Leukocyte Antigen - DM ('HLA-DM') mediates both of these functions, thus promoting the binding of antigenic peptides. After acquiring peptides, the class II molecules are transported to the cell surface via routes that are largely unknown.
  • Cathepsin S ('CatS') is a cysteine protease expressed in lymphatic tissues. CatS mediates invariant chain proteolysis, which is a prerequisite for peptide loading of MHC class II molecules (Riese et al. (1996) Immunity 4:357). CatS has 50-60% homology with cathepsins L and K, but differs from them in that it has a broad pH optimum that extends to alkaline pH. CatS modulates antigen presentation in animal models, and inhibitors are effective in an asthma model (Riese et al. (1998) J. Clin. Invest. 101 :2351 ). Mice deficient in cathepsin S have an impaired ability to present exogenous proteins by professional antigen presenting cells (Nakagawa et al. (1999) Immunity 10:207; Shi et al. (1999) Immunity 10:197).
  • Compounds that inhibit the proteolytic activity of human cathepsin S are expected to find utility in the treatment of chronic autoimmune diseases including, but not limited to, lupus and rheumatoid arthritis; and have potential utility in modulating the immune response to tissue transplantation.
  • Methods of modulating autoimmunity with an agent that modulates cathepsin S activity, e.g., proteolysis of the li chain, as well as methods of treating a subject having an autoimmune disorder, methods of evaluating a treatment for its ability to modulate an immune response are described in WO 99/58153.
  • the compound 2-[4-[4-(3-methyl-5-phenyl-1 H-pyrazol-1-yl)butyl]-1- piperazinylj-pyrimidine is known from EP-382637, which describes pyrimidines having anxiolytic properties. This compound and analogs are further described in EP-502786 as cardiovascular and central nervous system agents. Pharmaceutical formulations with such compounds are disclosed in EP-655248 for use in the treatment of gastric secreation and as anti-ulcer agents. WO- 9721439 describes medicaments with such compounds for treating obsessive- compulsive disorders, sleep apnea, sexual dysfunctions, emesis and motion sickness.
  • the compounds 5-methyl-3-phenyl-1 -[4-(4-phenyl-1 -piperazinyl)butyl]- 1 H-indazole and 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1- piperazinyl)butyl]-1 H-indazole, in particular the hydrochloride salts thereof, are known from WO-9853940 and CA 122:314528, where these and similar compounds are described as kinase inhibitors in the former reference and possessing affinity for benzodiazepine receptors in the latter reference.
  • the present invention features the use of cathepsin S inhibitors to treat allergic conditions, including but not limited to atopic allergies.
  • allergic conditions including hay fever, asthma, atopic dermatitis and food allergies.
  • Allergens include dust, pollen, mold, and pet dander or pet hair.
  • the invention provides a method for treating a subject suffering from an allergic condition, in particular an atopic allergic condition, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a cathepsin S inhibitor.
  • the invention provides a method for treating a subject suffering from an IgE-mediated allergic condition, in particular an atopic allergic condition, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a cathepsin S inhibitor.
  • a third aspect of the invention provides the use, or the use for the manufacture of a medicament, of a cathepsin S inhibitor for treating an allergic condition, more in particular for treating IgE-mediated allergic conditions, still more in particular treating hay fever, asthma, atopic dermatitis or food allergies.
  • the invention also features anti-allergic pharmaceutical compositions comprising as active ingredient an effective amount of a cathepsin S inhibitor, and a pharmaceutically acceptable carrier.
  • the active ingredient can be formulated in any manner suitable for the particular allergic condition, including aerosol, oral and topical formulations and time-release formulations.
  • the present invention concerns the treatment of an allergic condition using one or more compounds which can be represented by formula (I):
  • R 1 is taken together with W as described below;
  • R 2 is hydrogen, halogen, C,_ 5 alkoxy, C,. 5 alkyl, C 2 . 5 alkenyl, C ⁇ haloalkyl, cyano, or R 48 R 49 N; alternatively, R 1 and R 2 can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic; each of R 3 and R 4 is independently hydrogen or C,. 5 alkyl; each of R 5 and R 6 is independently hydrogen, C,_ 5 alkyl, C 2 . 5 alkenyl, C,.
  • R 4 0 is H, C .,. 5 alkyl, C 2 . 5 alkenyl, phenyl, benzyl, phenethyl, C ⁇ heterocyclyl, (C ⁇ s heterocyclyl)C ⁇ alkylene, amino, or mono- or di(C _ 5 alkyl)amino, or R 58 OR 59 -, wherein R 58 is H, C ⁇ alkyl, C 2 .
  • R 59 is C ⁇ g alkylene, phenylene, or divalent C ⁇ heterocyclyl
  • R 62 can be H in addition to the values for R 40 ;
  • R 8 is hydrogen, C ⁇ alkyl, C 3 . 5 alkenyl, phenyl, or C ⁇ heterocyclyl; alternatively, R 7 and R 8 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
  • R 9 is C,_ 5 alkyl, phenyl, naphthyl, or C .,_ 5 heterocyclyl;
  • R 21 is hydrogen, C,. 5 alkyl, C 3 . 5 alkenyl, phenyl, naphthyl, C ⁇ heterocyclyl,
  • R 22 is hydrogen, C ⁇ alkyl, C 3 . 5 alkenyl, phenyl, or C ⁇ heterocyclyl; alternatively, R 21 and R 22 can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R 23 , R 26 , R 27 , R 30 , R 33 , R 44 , R 45 , and R 50 is C ⁇ alkyl, phenyl, naphthyl, or
  • R 24 is hydrogen, C, ⁇ alkyl, C 3 . 5 alkenyl, phenyl, naphthyl, C _ 5 heterocyclyl,
  • R 25 is hydrogen, C,. 5 alkyl, C 3 . 5 alkenyl, phenyl, or C ⁇ heterocyclyl; alternatively, R 24 and R 25 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R 10 and R 11 is independently hydrogen, C ⁇ alkyl, C 2 .
  • R 0 and R 11 or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R 28 , R 29 , R 31 , R 32 , R 34 , R 35 , R 46 , R 47 , R 51 and R 52 is independently hydrogen, C,.
  • R 28 and R 29 , R 31 and R 32 , R 34 and R 35 , R 46 and R 47 , or R 51 and R 52 independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; n is 1 or 2; • G represents C 3 . 6 alkenediyl or C 3 .
  • alkanediyl optionally substituted with hydroxy, halogen, alkoxy, oxo, hydroximino, CO 2 R 60 , R 60 R 61 NCO 2 , (L)-C L4 alkylene-, (LJ-C ⁇ alkoxy, N 3 , or [(L)-C ⁇ alkylenejamino; each of R 60 and R 61 is independently hydrogen, C 3 .
  • R 60 and R 61 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
  • L is amino, mono- or di-C,. 5 alkylamino, pyrrolidinyl, morpholinyl, piperidinyl homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with C, ⁇ alkyl, benzyl, C 2 . 5 acyl, C,.. 5 alkylsulfonyl or alkyloxycarbonyl;
  • X is nitrogen or R 12 C;
  • Y is nitrogen or R 13 C;
  • Z is nitrogen or R 14 C;
  • R 14 is hydrogen, halogen, C ⁇ 5 alkoxy, C ⁇ alkyl, C 2 . 5 alkenyl, cyano, nitro, R 24 R 25 N, C 2 .
  • R 12 and R 13 or R 12 and R 2 or R 13 and R 14 can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;
  • R 16 is hydrogen, C,. 5 alkyl, C 3 . 5 alkenyl, phenyl, benzyl, or C .,_ 5 heterocyclyl; alternatively, R 15 and R 16 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R 17 and R 53 is C,. 5 alkyl, phenyl, or C ⁇ heterocyclyl; each of R 54 and R 55 is independently hydrogen, C ⁇ alkyl, C 2 .
  • R 54 and R 55 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
  • X a is O, S, or N; and X b is O, S or SO 2 ;
  • R 20 is hydrogen, C,. 5 alkyl, phenyl, benzyl, naphthyl, or C ⁇ heterocyclyl;
  • R 43 is hydrogen, C ⁇ alkyl, C 3 . 5 alkenyl, phenyl, or C ⁇ heterocyclyl; alternatively, R 42 and R 43 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; R 44 is C
  • R 48 is hydrogen, C ⁇ alkyl, C 3 . 5 alkenyl, phenyl, naphthyl, C ⁇ heterocyclyl, C
  • R 49 is hydrogen, C, .5 alkyl, C 3 . 5 alkenyl, phenyl, or C ⁇ heterocyclyl; alternatively, R 48 and R 49 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and
  • each of the above hydrocarbyl or heterocarbyl groups is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano, C ⁇ alkyl, C ⁇ alkoxy, -COOH, C 2 . 6 acyl, [di(C .,. 4 alkyl)amino]C 2 . 5 alkylene, [di(C ⁇ alkyl)amino] C 2 . 5 alkyl-NH- CO-, and C 1- ⁇ haloalkoxy;
  • the disclosed compounds are high-affinity inhibitors of the proteolytic activity of human cathepsin S.
  • the preparation of pharmaceutically acceptable salts of compounds of formula (I) may be desirable.
  • Certain compounds of the present invention may have one stereogenic atom and may exist as two enantiomers. Certain compounds of the present invention may have two or more stereogenic atoms and may further exist as diastereomers. It is to be understood by those skilled in the art that all such stereoisomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
  • Another aspect of the invention provides pharmaceutical anti-allergic compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
  • a further embodiment of the invention is a process for making an anti-allergic pharmaceutical composition comprising mixing a disclosed compound as described above, with a suitable pharmaceutically acceptable carrier.
  • compositions comprising more than one compound of formula (I) and compositions comprising a compound of formula (I) and another pharmaceutically active agent.
  • the invention features a method of treating allergic disorders or conditions mediated by the cathepsin S enzyme, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above. If more than one active agent is administered, the therapeutically effective amount may be a jointly effective amount.
  • the compounds described herein inhibit the protease activity of human cathepsin S, an enzyme involved in the immune response. In preferred embodiments, cathepsin S inhibition is selective. As such, the disclosed compounds and compositions are useful in the prevention, inhibition, or treatment of allergic conditions, particularly atopic allergic conditions.
  • FIG. 1 shows the inhibition of human T cell proliferative responses to two species of dust mites, Derp and Der f.
  • Top panel FIG. 1A: Dilution curve for purified PBMC from an allergy donor were cultured with titrated doses of allergen extracts prepared from Derp and Derf for seven days. Proliferation of T cells was scored by measuring 3 H-thymidine incorporation for 18 h at the end of culture.
  • Bottom panel, FIG. 1 B Effect of titrated doses of LHVS on proliferative responses of T cells to dust mite extracts.
  • FIG. 2 is shows the inhibition of human T cell proliferative responses to ragweeds but not ConA by LHVS.
  • Top panel FIG. 2A: Dilution curve for purified PBMC from an allergy donor were cultured with titrated doses of allergen extracts prepared from Ragweed short and Ragweed giant for seven days. Proliferation of T cells was scored by measuring 3 H-thymidine incorporation for 18 h at the end of culture.
  • Bottom panel, FIG. 2B Effect of titrated doses of LHVS on proliferative responses of T cells to ragweed extracts.
  • FIG. 3 shows the inhibition of human T cell proliferative responses to
  • Example 11 Example 11
  • Example 36 Example 36
  • Purified PBMC from an allergy donor were cultured with allergen extracts prepared from Derf in the presence of titrated doses of indicated example compounds for seven days. Proliferation of T cells was scored by measuring 3 H-thymidine incorporation for 18 h at the end of culture.
  • a target of the present invention was to determine whether the presentation of particular antigens in a human system is affected by the inhibition of cathepsin S. According to the invention, it now has been found that inhibitors of cathepsin S block the presentation of several crude allergen extracts in a human ex vivo assay, thereby supporting the use of cathepsin S inhibitors for the treatment of such allergic conditions.
  • Blocking li degradation should decrease antigen presentation to CD4 T cells and disrupt the normal immune response.
  • a cathepsin S inhibitor should specfically affect the activation of CD4 T cells, thus limiting the extent of concomitant immunosuppression, an undesirable side effect of corticosteroid therapy.
  • the immunological component of the allergic reaction can be blocked to varying degrees, with the advantage over current therapies of being more selective, having fewer or reduced side effects, or both.
  • the present invention is based, in part, on the finding that cathepsin S inhibitors can block the presentation of crude allergen extracts in a human ex vivo assay. This ex vivo system closely mimics the process that occurs in the whole body wherein antigens enter the blood stream, and are presented by antigen presenting cells, which in turn activate CD4 T cells. In the case of treating a subject, the inhibitor or a metabolite thereof would also be present in the blood as in the ex vivo assay.
  • the invention features the treatment of an allergic condition using pyrazole compounds of formula (I).
  • Alkyl includes optionally substituted straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group.
  • Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1- methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on.
  • Alkyl includes cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • Alkenyl includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon double bond (sp 2 ).
  • Alkenyls include ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl, and so on.
  • Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein.
  • Alkenyl includes cycloalkenyl. Cis and trans or (E) and (Z) forms are included within the invention.
  • Alkynyl includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon triple bond (sp).
  • Alkynyls include ethynyl, propynyls, butynyls, and pentynyls.
  • Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten- 4-ynyl, are grouped as alkynyls herein.
  • Alkynyl does not include cycloalkynyl.
  • Alkoxy includes an optionally substituted straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule.
  • Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t- butoxy, pentoxy and so on.
  • Aminoalkyl”, “thioalkyl”, and “sulfonylalkyl” are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO 2 .
  • Heteroalkyl includes alkoxy, aminoalkyl, thioalkyl, and so on.
  • Aryl includes phenyl, naphthyl, biphenylyl, tetrahydronaphthyl, and so on, any of which may be optionally substituted.
  • Aryl also includes arylalkyl groups such as benzyl, phenethyl, and phenylpropyl.
  • Aryl includes a ring system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system may be bicyclic, bridge, and/or fused. The system may include rings that are aromatic, or partially or completely saturated.
  • ring systems include indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl, benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl, and so on.
  • Heterocyclyl includes optionally substituted aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO 2 , CO, CONH, COO) in the ring.
  • a heterocyclic radical may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or 1-pyrazolyl.
  • a monocyclic heterocyclyl has between 4 and 7 ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5 heteroatoms or heteroatom moieties in the ring, and preferably between 1 and 3.
  • a heterocyclyl may be saturated, unsaturated, aromatic (e.g., heteroaryl), nonaromatic, or fused.
  • Heterocyclyl also includes fused, e.g., bicyclic, rings, such as those optionally condensed with an optionally substituted carbocyclic or heterocyclic five- or six-membered aromatic ring.
  • heteroaryl includes an optionally substituted six-membered heteroaromatic ring containing 1 , 2 or 3 nitrogen atoms condensed with an optionally substituted five- or six- memebered carbocyclic or heterocyclic aromatic ring.
  • Said heterocyclic five- or six-membered aromatic ring condensed with the said five- or six-membered aromatic ring may contain 1 , 2 or 3 nitrogen atoms where it is a six-membered ring, or 1 , 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where it is a five-membered ring.
  • heterocyclyls include thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl.
  • heterocyclyls or heterocyclic radicals include morpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino,and more preferably, piperidyl.
  • heteroaryl examples include thienyl, furanyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl.
  • Acyl refers to a carbonyl moiety attached to either a hydrogen atom (i.e., a formyl group) or to an optionally substituted alkyl or alkenyl chain, or heterocyclyl.
  • Halo or “halogen” includes fluoro, chloro, bromo, and iodo, and preferably chloro or bromo as a substituent.
  • Alkanediyl or "alkylene” represents straight or branched chain optionally substituted bivalent alkane radicals such as, for example, methylene, ethylene, propylene, butylene, pentylene or hexylene.
  • Alkenediyl represents, analogous to the above, straight or branched chain optionally substituted bivalent alkene radicals such as, for example, propenylene, butenylene, pentenylene or hexenylene. In such radicals, the carbon atom linking a nitrogen preferably should not be unsaturated.
  • “Aroyl” refers to a carbonyl moiety attached to an optionally substituted aryl or heteroaryl group, wherein aryl and heteroaryl have the definitions provided above. In particular, benzoyl is phenylcarbonyl.
  • two radicals, together with the atom(s) to which they are attached may form an optionally substituted 4- to 7-, 5 - to 7-, or a 5- to 6- membered ring carbocyclic or heterocyclic ring, which ring may be saturated, unsaturated or aromatic.
  • Said rings may be as defined above in the Summary of the Invention section. Particular examples of such rings are as follows in the next section.
  • “Pharmaceutically acceptable salts, esters, and amides” include carboxylate salts (e.g., C 1-8 alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic) amino acid addition salts, esters, and amides which are within a reasonable benefit risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
  • Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate.
  • alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
  • alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium
  • non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
  • amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine.
  • Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C ⁇ alkyl amines and secondary di (C ⁇ alkyl) amines.
  • Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms.
  • Preferred amides are derived from ammonia, C ⁇ alkyl primary amines, and di (C ⁇ alkyljamines.
  • Representative pharmaceutically acceptable esters of the invention include C ⁇ alkyl, C 5 . 7 cycloalkyl, phenyl, and phenyI(C ⁇ alkyl esters.
  • Preferred esters include methyl esters.
  • Patient or subject includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experiment, treatment or prevention in connection with the relevant disease or condition.
  • the patient or subject is a human.
  • Composition includes a product comprising the specified ingredients in the specified amounts as well as any product which results directly or indirectly from combinations of the specified ingredients in the specified amounts.
  • “Therapeutically effective amount” or “effective amount” means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • each radical includes substituted radicals of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims.
  • the context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or more hydrogen atoms removed (multivalent).
  • An example of a bivalent radical linking two parts of the molecule is G in formula (I) which links two rings.
  • radicals or structure fragments as defined herein are understood to include substituted radicals or structure fragments.
  • Hydrocarbyls include monovalent radicals containing carbon and hydrogen such as alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl (whether aromatic or unsaturated), as well as corresponding divalent radicals such as alkylene, alkenylene, phenylene, and so on.
  • Heterocarbyls include monovalent and divalent radicals containing carbon/ hydrogen, and at least one heteroatom.
  • Examples of monovalent heterocarbyls include acyl, acyloxy, alkoxyacyl, heterocyclyl, heteroaryl, aroyl, benzoyl, dialkylamino, hydroxyalkyl, and so on.
  • alkyl should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents. The substituents may be the same (dihydroxy, dimethyl), similar (chlorofluoro), or different (chlorobenzyl- or aminomethyl-substituted).
  • substituted alkyl examples include haloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, perfluoromethyl, and 3-iodocyclopentyl), hydroxyalkyl (such as hydroxymethyl, hydroxyethyl, 2- hydroxypropyl, aminoalkyl (such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and 2-aminopropyl), nitroalkyl, alkylalkyl, and so on.
  • haloalkyl such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, perfluoromethyl, and 3-iodocyclopentyl
  • hydroxyalkyl such as hydroxymethyl, hydroxyethyl, 2- hydroxypropyl
  • aminoalkyl such as aminomethyl, 2-aminoethyl, 3-aminopropyl,
  • 6 alkyl)amino group includes independently selected alkyl groups, to form, for example, methylpropylamino and isopropylmethylamino, in addition dialkylamino groups having two of the same alkyl group such as dimethyl amino or diethylamino.
  • Preferred substitutions for Ar include methyl, methoxy, fluoromethyl, difluoromethyl, perfluoromethyl (trifluoromethyl), 1-fluoroethyl, 2-fluoroethyl, ethoxy, fluoro, chloro, and bromo, and particularly methyl, bromo, chloro, perfluoromethyl, perfluoromethoxy, methoxy, and fluoro.
  • Preferred substitution patterns for Ar or A are 4-substituted or 3,4-disubstituted phenyl.
  • the invention features the use of compounds of formula (I) as described in the Summary section for the treatment of an allergic condition.
  • Preferred compounds include those wherein:
  • R 1 is hydrogen, halogen, C ⁇ alkoxy, hydroxy, C ⁇ alkyl, cyano, nitro, R 7 R 8 N, C 2 . 8 acyl, or R 10 R 11 NSO 2 ;
  • R 1 is halogen, cyano, nitro, R 7 R 8 N, or R 10 R 11 NSO 2 ;
  • R 2 is hydrogen;
  • each of R 3 and R 4 is independently hydrogen or C ⁇ alkyl
  • each of R 3 and R 4 is hydrogen
  • one of R 5 and R 6 is hydrogen and the other is a 5-7 membered carbocyclyl or heterocyclyl, optionally substituted;
  • each of R 7 , R 8 , R 21 , R 22 , R 24 , R 25 is independently hydrogen or
  • each of R 7 and R 8 , R 21 and R 22 , and R 24 and R 25 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; (k) at least one of R 7 and R 8 , R 2 and R 22 , and R 24 and R 25 , taken together, is morpholinyl, piperidinyl, or pyrrolidinyl;
  • R 9 , R 23 , R 26 , and R 27 is each independently hydrogen or C ⁇ alkyl
  • (m) G is C 3 . 4 alkanediyl, optionally substituted with hydroxy, (L)- C ⁇ alkyloxy-, or [(L)-C,. 5 alkylenejamino-;
  • (n) G is C 3 alkanediyl, optionally substituted with hydroxy, (L)-C ⁇ alkyloxy-, or [(L)-C.,.. 5 alkylenejamino-;
  • Ar represents a monocyclic ring, optionally substituted with between 1 and 2 substituents selected independently from halogen, G, ⁇ alkyl, cyano, nitro, R 15 R 16 N, CF 3 and OCF 3 ;
  • Ar is a six membered ring substituted with between 1 and 2 substituents selected from halo, CF 3 , OCF 3 , said substitutent or substitutents being at the 4-position or at the 3- and 4- positions, respectively;
  • R 3 and R 4 are hydrogen;
  • Ar represents a monocyclic ring, optionally substituted with between 1 and 2 substituents selected from halogen, C,. 5 alkyl, cyano, nitro, R 15 R 16 N, CF 3 and OCF 3 ;
  • R 2 is hydrogen, R 23 SO , or R 23 SO 2 ;
  • R 13 is hydrogen,
  • R 44 SO , or R 44 SO 2 R 14 is hydrogen, halogen, C ⁇ alkoxy, C ⁇ alkyl, cyano, nitro, or R 24 R 25 N; and G is C 3 alkanediyl, optionally substituted with hydroxy, C ⁇ alkyl, (L)-C ⁇ alkyloxy, or [(L)-C.,.
  • each of R 3 and R 4 is hydrogen;
  • Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen, C, ⁇ alkyl, cyano, nitro, R 15 R 16 N, CF 3 and OCF 3 ;
  • R 12 is hydrogen, R 23 SO , or R 23 SO 2 ;
  • R 13 is hydrogen, R 44 SO, or R 44 SO 2 ;
  • R 14 is hydrogen, halogen, alkyl, cyano, nitro, or R 24 R 25 N;
  • G is C 3 alkanediyl, optionally substituted with hydroxy, (L)-C,. 5 alkyloxy-, or (L)-C,. 5 alkylamino;
  • Ar is phenyl; and
  • Specific preferred compounds include the examples herein, such as: 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2- ol ; 1 -[3-Chloro-2-(4- ⁇ 3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl ⁇ -piperazin-1-yl)-phenyl]-3-methyl- urea ; 1 -[3-Chloro-2-(4- ⁇ 2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-
  • preferred compounds include those wherein Ar is selected from 4-trifluoromethylphenyl, 4-bromophenyI, 4-chlorophenyl, 4-chloro-3- methylphenyl and 3,4-dichlorophenyl.
  • More preferred compounds include the compounds in Examples 19, 27, and 33.
  • the invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, acids, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms.
  • Related compounds also include compounds of the invention that have been modified to be detectable, e.g., isotopically labelled with 18 F for use as a probe in positron emission tomography (PET) or single-photon emission computed tomography (SPECT).
  • the invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. See, e.g., Greene and Wuts, Protective Groups in Organic Synthesis. 3 rd ed., (1999) John Wiley & Sons, NY. Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.
  • Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.
  • substituted methyl ethers include methyoxymethyl, methylthiomethyl, f-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, guaiacolmethyl, f-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2- methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4- methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1- [(2-chloro-4-
  • substituted ethyl ethers include 1-ethoxyethyl, 1-(2- chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1- methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyI, 2-trimethylsilylethyl, 2- (phenylselenyl)ethyl, f-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4- dinitrophenyl, and benzyl.
  • substituted benzyl ethers include p-methoxybenzyl, 3,4- dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6- dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2- picolyl N-oxido, diphenylmethyl, p, p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, ⁇ -naphthyIdiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'- bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-tris(4,5- dichlorophthalimidophenyl)methyl, 4,4',4"
  • silyl Ethers examples include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, t- butyldimethylsilyl, f-butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and f-butylmethoxyphenylsilyl.
  • esters In addition to ethers, a hydroxyl group may be protected as an ester.
  • esters include formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P- phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4- (ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4- methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate(mesitoate)
  • carbonate protecting groups include methyl, 9- fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethyIsilyl)ethyl, 2- (phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p- nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p- nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1 -naphthyl, and methyl dithiocarbonate.
  • assisted cleavage examples include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2- formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-
  • miscellaneous esters examples include 2,6-dichloro-4- methylphenoxyacetate, 2,6-dichloro-4-(1 ,1 ,3,3- tetramethylbutyl)phenoxyacetate, 2,4-bis(1 ,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2- butenoate(tigloate), o-(methoxycarbonyl)benzoate, p-P-benzoate, ⁇ - naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N- phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4- dinitrophenylsulfenate.
  • sulfonates include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.
  • Protection for the amino group includes carbamates, amides, and special -NH protective groups.
  • carbamates examples include methyl and ethyl carbamates, substituted ethyl carbamates, assisted cleavage carbamates, photolytic cleavage carbamates, urea-type derivatives, and miscellaneous carbamates.
  • methyl and ethyl carbamates include methyl and ethyl, 9- fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7- di-f-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, and 4- methoxyphenacyl.
  • substituted ethyl carbamates include 2,2,2-trichloroethyl, 2- trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1 ,1-dimethyl- 2-haloethyl, 1 ,1-dimethyl-2,2-dibromoethyI, 1 ,1-dimethyl-2,2,2-trichloroethyl, 1- methyl-1-(4-biphenylyI)ethyl, 1-(3,5-di-f-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(N,N-dicyclohexylcarboxamido)ethyl, ---butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitro
  • assisted cleavage examples include 2-methylthioethyl, 2- methylsulfonylethyl, 2-(p-toluenesulfonyl)ethyl, [2-(1 ,3-dithianyl)]methyl, 4- methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2- triphenylphosphonioisopropyl, 1 ,1-dimethyl-2-cyanoethyl, m-chloro-p- acyloxybenzyl, p-(dihydroxyboryl)benzyl, 5-benzisoxazolyImethyl, and 2- (trifluoromethyl)-6-chromonylmethyl.
  • Photolytic Cleavage examples include m-nitrophenyl, 3,5- dimethoxybenzyl, o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(o- nitrophenyl)methyI.
  • urea-type derivatives include phenothiazinyl-(10)-carbonyl derivative, N' -p-toluenesulfonylaminocarbonyl, and N'- phenylaminothiocarbonyl.
  • miscellaneous carbamates include f-amyl, S-benzyl thiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl methyl, p-decyloxybenzyl, diisopropylmethyl, 2,2- dimethoxycarbonylvinyl, o-(N,N-dimethylcarboxamido)benzyl, 1 ,1-dimethyl-3- (N,N-dimethylcarboxamido)propyl, 1 ,1-dimethylpropynyl, di(2-pyridyl)methyl, 2- furanylmethyl, 2-iodoethyl, isobomyl, isobutyl, isonicotinyl, p-(p'- methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1 -methyl-1
  • amides examples include:
  • N-formyl N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N- phenylacetyl, N-3-phenylpropionyl, N-picolinoyl, N-3-pyridyIcarboxamide, N- benzoylphenylalanyl derivative, N-benzoyl, N-p-phenylbenzoyl.
  • N-o-nitrophenylacetyl N-o-nitrophenoxyacetyl, N-acetoacetyl, (N'- dithiobenzyloxycarbonylamino)acetyl, N-3-(p-hydroxyphenyl)propionyl, N-3-(o- nitrophenyl)propionyl, N-2-methyl-2-(o-nitrophenoxy)propionyl, N-2-methyl-2- (o-phenylazophenoxy)propionyl, N-4-chlorobutyryl, N-3-methyl-3-nitrobutyryl, N-o-nitrocinnamoyl, N-acetylmethionine derivative, N-o-nitrobenzoyl, N-o- (benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3-oxazolin-2-one.
  • N-phthalimide N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5- dimethylpyrrolyl, N-1 ,1 ,4,4-tetramethyldisilylazacyclopentane adduct, 5- substituted 1 ,3-dimethyl-1 ,3,5-triazacyclohexan-2-one, 5-substituted 1 ,3- dibenzyl-1 ,3,5-triazacyclohexan-2-one, and 1 -substituted 3,5-dinitro-4- pyridonyl.
  • N-diphenylmethylene N-[(2-pyridyl)mesityl]methylene, and N-(N' ,N'- dimethylaminomethylene).
  • acyclic acetals and ketals examples include dimethyl, bis(2,2,2- trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and diacetyl. Cyclic Acetals and Ketals
  • Examples of cyclic acetals and ketals include 1 ,3-dioxanes, 5- methylene-1 ,3-dioxane, 5,5-dibromo-1 ,3-dioxane, 5-(2-pyridyl)-1 ,3-dioxane, 1 ,3-dioxolanes, 4-bromomethyl-1 ,3-dioxolane, 4-(3-butenyI)-1 ,3-dioxolane, 4- phenyl-1 ,3-dioxolane, 4-(2-nitrophenyl)-1 ,3-dioxolane, 4,5-dimethoxymethyl- 1 ,3-dioxolane, O,0'-phenylenedioxy and 1 ,5-dihydro-3H-2,4-benzodioxepin.
  • Examples of acyclic dithio acetals and ketals include S,S'-dimethyl, S.S'-dlethyl, S.S'-dipropyl, S.S'-dibutyl, S.S'-dipentyl, S.S'-diphenyl, S,S'- dibenzyl and S,S'-diacetyl.
  • cyclic dithio acetals and ketals examples include 1 ,3-dithiane, 1 ,3- dithiolane and 1 ,5-dihydro-3H-2,4-benzodithiepin.
  • Examples of acyclic monothio acetals and ketals include O-trimethylsilyl- S-alkyl, O-methyl-S-alkyl or -S-phenyl and O-methyl-S-2-(methylthio)ethyl.
  • cyclic monothio acetals and ketals examples include 1 ,3- oxathiolanes.
  • O-substituted cyanohydrins examples include O-acetyl, O- trimethylsilyl, O-1-ethoxyethyl and O-tetrahydropyranyl.
  • substituted hydrazones include N,N-dimethyl and 2,4- dinitrophenyl.
  • oxime derivatives include O-methyl, O-benzyl and O- phenylthiomethyl.
  • substituted methylene and cyclic derivatives examples include oxazolidines, 1-methyl-2-(1'-hydroxyalkyl)imidazoles, N,N'- dimethylimidazolidines, 2,3-dihydro-1 ,3-benzothiazoles, diethylamine adducts, and methylaluminum bis(2,6-di- ⁇ -butyl-4-methylphenoxide)(MAD)complex.
  • substituted methyl esters include 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl, p-bromophenacyl, ⁇ -methylphenacyl, p-methoxyphenacyl, carboxamidomethyl, and N-phthalimidomethyl.
  • 2-Substituted Ethyl Esters examples include 2,2,2-trichloroethyl,
  • substituted benzyl esters include triphenylmethyl, diphenylmethyl, bis(o-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10- dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6- chromylmethyl, 2,4,6-trimethylbenzyl, p-bromobenzyl, o-nitrobenzyl, p- nitrobenzyl, p-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4- sulfobenzyl, piperonyl, 4-picolyl and p-P-benzyl.
  • silyl esters examples include trimethylsilyl, triethylsilyl, f-butyldimethylsilyl, /-propyldimethylsilyl, phenyldimethylsilyl and di-f- butylmethylsilyl.
  • activated esters include thiols.
  • miscellaneous derivatives include oxazoles, 2-alkyl-1 ,3- oxazolines, 4-alkyl-5-oxo-1 ,3-oxazolidines, 5-alkyl-4-oxo-1 ,3-dioxolanes, ortho esters, phenyl group and pentaaminocobalt(lll) complex.
  • stannyl esters examples include triethylstannyl and tri-n-butylstannyl.
  • amides include N,N-dimethyl, pyrrolidinyl, piperidinyl, 5,6- dihydrophenanthridinyl, o-nitroanilides, N-7-nitroindolyl, N-8-Nitro-1 , 2,3,4- tetrahydroquinolyl, and p-P-benzenesulfonamides.
  • hydrazides examples include N-phenyl and N,N'-diisopropyl hydrazides.
  • the compounds of the present invention may be prepared by conventional synthetic organic chemistry and by matrix or combinatorial methods according to Schemes 1 to 11 below, and representative detailed Examples 1 to 24. Those of ordinary skill in the art will be able to modify and adapt the guidance provided herein to make the disclosed compounds.
  • the present compounds inhibit the proteolytic activity of human cathepsin S and therefore are useful as a medicine especially in methods for treating patients suffering from allergic disorders or conditions which are modulated or regulated by the inhibition of cathepsin S activity.
  • the invention features a method for treating a subject with an allergic condition mediated by cathepsin S, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the invention.
  • the invention also provides a method for inhibiting cathepsin S activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the invention.
  • the compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.
  • a carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for oral administration or parenteral injection.
  • any of the usual pharmaceutical media may be employed. These include water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets.
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are generally employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Such additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • compositions may be administered in various ways, e.g., as a transdermal patch, as a spot- on, as an ointment.
  • Acid addition salts of the compounds of formula (I) due to their increased water solubility over the corresponding base form, are more suitable in the preparation of aqueous compositions.
  • Dosage unit form as used in the specification herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • compositions include the therapeu- tically active non-toxic acid addition salt forms which the disclosed compounds are able to form.
  • the latter can conveniently be obtained by treating the base form with an appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g.
  • hydrochloric or hydrobromic acid sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, palmoic and the like acids.
  • the term addition salt also comprises the solvates which the disclosed componds, as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like. Conversely the salt form can be converted by treatment with alkali into the free base form.
  • Stereoisomeric form defines all the possible isomeric forms which the compounds of formula (I) may possess.
  • the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the (R)- or (S)-configuration; substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration.
  • the invention encompasses stereochemically isomeric forms including diastereoisomers, as well as mixtures thereof in any proportion of the disclosed compounds.
  • the disclosed compounds may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above and following formulae are intended to be included within the scope of the present invention.
  • a therapeutically effective dose would be from 0.001 mg/kg to 5 mg/kg body weight, more preferably from 0.01 mg/kg to 0.5 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 250 mg, and in particular 0.5 to 50 mg of active ingredient per unit dosage form. Examples include 2 mg, 4 mg, 7 mg, 10 mg, 15 mg, 25 mg, and 35 mg dosage forms.
  • Compounds of the invention may also be prepared in time-release or subcutaneous or transdermal patch formulations. Disclosed compound may also be formulated as a spray or other topical or inhalable formulations.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines.
  • the next section includes detailed information relating to the preparation, characterization, and use of the disclosed compounds.
  • Triethylamine (3.1 mL) was added and p- trifluoromethylbenzoyl chloride (3.27 mL, 22 mmol) in CH 2 CI 2 (4 mL) was added dropwise into the solution at 0 °C.
  • the reaction mixture was stirred at 25 °C for 24 h and diluted with aqueous HCI (5%, 25 mL). After stirring for another 30 min, the organic layer was separated, washed with H 2 O (20 mL), dried (Na 2 SO 4 ), and concentrated. The residue was dissolved in EtOH (95%, 18 mL) and treated at 0 °C with hydrazine (2.9 mL, 60 mmol).
  • the reaction mixture was cooled and concentrated in vacuo to give the enamine which was used without further purification.
  • the enamine was dissolved in CH 2 CI 2 (60 mL) and cooled to 0°C. Triethylamine (8.67 mL, 62 mmol) was added, followed by dropwise addition of 4-iodobenzoyI chloride (13.8 g, 52 mmol) dissolved in CH 2 CI 2 (10 mL). The reaction mixture was allowed to warm to room temperature and stirred for 72 h. The reaction mixture was poured over water (200 mL) and the CH 2 CI 2 layer was separated, dried (Na 2 SO 4 ), and concentrated.
  • Ytterbium (III) trifluoromethanesulfonate hydrate (0.193 g, 0.311 mmol) and 1- (2-cyanophenyl)-piperazine (0.292 g, 1.56 mmol) were dissolved in CH 2 CI 2 (2 mL) and added to a solution of 3-(4-iodo-phenyl)-1-oxiranylmethyl-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester in CH 2 CI 2 (5 mL). The reaction mixture was allowed to stir for 48 h at 25 °C.
  • Trifluoroacetic acid (3 mL) was added to a solution of 1- ⁇ 3-[4-(2-cyano-phenyl)- piperazin-1 -yl]-2-hydroxy-propyl ⁇ -3-(4-iodo-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (0.402 g, 0.601 mmol) in CH 2 CI 2 (3 mL) and the reaction mixture was stirred for 2 h. The mixture was concentrated, then diluted with EtOAc.
  • the mixture was diluted with EtOAc (400 mL) and washed with saturated aqueous NaHCO 3 (50 mL), H 2 O (2 x 50 mL), brine (50 mL), dried over Na 2 SO 4 and concentrated.
  • the crude orthoester was dissolved in CH 2 CI 2 (5 mL), cooled to 0 °C, and treated with AcBr (0.18 mL, 2.4 mmol). The mixture was allowed to warm with stirring over 4 h before being worked up as described above.
  • the crude acetyl-bromide obtained was dissolved in MeOH (50 mL), treated with K 2 CO 3 (207 mg, 1.50 mmol) and stirred for 4 h.
  • the enamine was dissolved in CH 2 Cl 2 (200 mL) and cooled to 0°C. To this was added triethylamine (47.2 mL, 339 mmol) followed by dropwise addition of 4-trifluoromethylbenzoyl chloride (42.3 mL, 285 mmol) dissolved in CH 2 CI 2 (82 mL). The reaction mixture was allowed to warm to room temperature and stirred for 20 h. The reaction mixture was washed with 1 N aqueous HCI (250 mL) and the CH 2 CI 2 layer was separated, dried (Na 2 SO 4 ), and concentrated.
  • Pess-Martin periodinane (3.45 g, 8.2 mmol) was added to a solution of 3-[5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-propan-1-ol (3.0 g, 7.4 mmol) in CH 2 CI 2 (20 mL) at 0 °C under N 2 . After 15 min, the reaction was allowed to warm to room temperature and stirred for another 1.5 h. The reaction was diluted with Et 2 O (60 mL) and 20 % aq. NaHCO 3 (35 mL) was added slowly.
  • the aqueous layer was extracted with CH 2 CI 2 (3 x 500 mL) and the combined extracts were dried over Na 2 SO 4 and the solvent was removed under reduced pressure.
  • the crude oil was diluted with EtOH (1 L) and cooled to 0 °C. To this stirred solution was slowly added 115 g (3.57 mol) of hydrazine and the mixture was allowed to warm to rt and stir overnight during which time a white precipitate formed. The volume of the reaction was reduced to -500 mL and cooled. The precipitate was collected to afford 285 g (72% from eneamine) of a white solid.
  • Pess-Martin periodinane (1.43 g, 3.36 mmol) was added portion wise to a stirred solution of 1-(3-hydroxy-propyl)-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7- tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (1.30 g, 3.05 mmol) in CH 2 CI 2 (15 mL) at 0 °C under N 2 .Then the reaction was stirred at 0 °C for 15 min and allowed to warm to room temperature.
  • To a stirred solution of 1.01 g (5.0 mmol) of 1-chloro-2, 6-dinitrobenzene and 0.93 g (5.0 mmol) of 1-terf-butyloxycarbonylpiperazine in acetonitrile (5 mL) was added 1.38 g (10 mmol) of K 2 CO 3 . The mixture was heated to reflux for 48 h. The solvent was removed under reduced pressure. The crude product was partitioned between EtOAc (100 mL) and 20 mL of H 2 O.
  • A. 4-Benzo[d]isoxazol-3-yl-piperazine-1 -carboxylic acid tert-butyl ester To a stirred solution of 100 mg (0.65 mmol) of 3-chloro-1 ,2-benzisoxazole in pyridine (1 mL) was added 145 mg of piperazine-1 -carboxylic acid tert-butyl ester (0.78 mmol) and 0.18 mL of DBU (0.78 mmol). The mixture was stirred at 100 °C overnight and then partitioned between EtOAC (50 mL) and water (20 mL) and separated. The aqueous layer was extracted with EtOAC (2 x 30 mL).
  • Recombinant human cathepsin S (CatS) was expressed in the baculovirus system and purified in one step with a thiopropyl-sepharose column. 10-L yielded -700 mg of CatS and N-terminal sequencing confirmed identity.
  • the assay is run in 100 mM sodium acetate pH 5.0 containing 1 mM DTT and 100 mM NaCl.
  • the substrate for the assay is
  • the K m for the substrate is around 5 ⁇ M but the presence of substrate inhibition makes kinetic analysis difficult.
  • the assay rate is linear over the range of 1-8 ng CatS in 100 ⁇ l reaction.
  • the production of product is linear and yields -7-fold signal after 20 min with only 20%) loss of substrate.
  • Primary assays are run by quenching the reaction after 20 min with 0.1 % SDS and then measuring the fluorescence. For other assays, measurements are taken every min for 20 min. The rate is calculated from the slope of the increase and the percent inhibition is calculated from this (See Tables 1 and 2 below).
  • cathepsin S inhibitors Block the response of human T cells to crude allergen extracts.
  • PBMC Human peripheral blood mononuclear cells
  • PBS phosphate buffered saline
  • PBMC peripheral blood mononuclear cells
  • HDM house dust mites
  • Dermatophagoides Dermatophagoides with Dermatophagoides pteronyssinus (Der p) and D. farinae (Der f) being the two major species present in varying proportions in most countries.
  • the major clinical manifestations are asthma and perennial rhinitis.
  • CD4 T cells was tested in an ex vivo human T cell-proliferation assay. Culturing PBMC with crude extracts from either Derp or Derf, resulted in strong proliferation (Figure 1A). This proliferation consisted primarily of allergen-specific CD4 T cells. When cathepsin S activity was blocked by a specific cathepsin S inhibitor, LHVS (cf. Riese et al. (1996) Immunity 4:357) the proliferation was strongly inhibited ( Figure 1 B). Inhibition by LHVS was specific for responses induced by HDM extracts since T cell proliferative responses induced by ConA, a pan-T cell mitogen, were not affected. Furthermore, this inhibition was observed for all four HDM-allergic donors tested regardless of the different HLA class II haplotypes (DR4; DR7, 15; DR11 , 15; and DR4, 11 ).
  • This system is very similar to an in vivo situation.
  • the allergic subject would be exposed to a crude mixture of allergens that would lead to the proliferation of T cells and an allergic response.
  • the observation of inhibition of CD4 T cell activation by a cathepsin S inhibitor shows that such inhibitors can be effective in treating a generalized population of patients allergic to house dust mites.
  • This system is very similar to an in vivo situation.
  • the allergic subject would be exposed to a crude mixture of allergens that would lead to the proliferation of T cells and an allergic response.
  • the observation of inhibition of CP4 T cell activation by a cathepsin S inhibitor shows that such inhibitors can be effective in treating a generalized population of patients allergic to ragweed.
  • the effect of in vivo administration of cathepsin S inhibitors, in a clinical trial setting, can be monitored by measuring accumulation of an intermediate degradation product of invariant chain (li), i.e. the p10li fragment, in blood of dosed subjects.
  • li invariant chain
  • a cathepsin inhibitor for a certain period of time, for example, between 0.01 and 50 mg/kg/day, to result in a blood concentration of between 1 nM-10 ⁇ M, for 16-30 h
  • blood is drawn and white blood cells are purified, e.g. either by lysis of red blood cells or by a Ficoll- Hypaque gradient centrifugation.
  • li and its intermediate degradation products including the p10li, can be detected using a mouse mAb against li, e.g. Pin1.1 , or rabbit polyclonal antibodies specific for the C-terminus of the p1 ON fragment or against the entire p1 Oli fragment.
  • a mouse mAb against li e.g. Pin1.1
  • rabbit polyclonal antibodies specific for the C-terminus of the p1 ON fragment or against the entire p1 Oli fragment can be detected using a mouse mAb against li, e.g. Pin1.1 , or rabbit polyclonal antibodies specific for the C-terminus of the p1 ON fragment or against the entire p1 Oli fragment.
  • ELISA assay For ELISA assay, a pair of antibodies against li, including Pin1.1 , and a rabbit polyclonal antibody or a mouse monoclonal antibody specific for p10Ii, can be used. The same assay can also be applied to monitor the effect of cathepsin S inhibitors in vivo in animal studies, for example in monkeys, dogs, pigs, rabbits, guinea pigs, and rodents.
  • PBMC from human blood were incubated with the cathepsin S inhibitor, LHVS (morpholinurea-leucine-homo-phenylalanine- vinylsulfonephenyl, also referred to as 4-morpholinecarboxamide, N-[(1 S)-3- methyl-1 -[[[(1 S,2E)-1 -(2-phenylethyl)-3-(phenylsulfonyl)-2- propenyl]amino]carbonyl]butyl]-.
  • LHVS morpholinurea-leucine-homo-phenylalanine- vinylsulfonephenyl, also referred to as 4-morpholinecarboxamide, N-[(1 S)-3- methyl-1 -[[[(1 S,2E)-1 -(2-phenylethyl)-3-(phenylsulfonyl)-2- propenyl]amino]carbonyl]butyl]-.
  • cathepsin S inhibitors Monitoring in vivo inhibition of allergenic response by cathepsin S inhibitors.
  • allergic volunteers are dosed with cathepsin S inhibitors to levels where invariant chain degradation is inhibited. Allergens are deposited subcutaneously, and the size of the cutaneous reactions are determined at 15 min, 6 h and 24 h. Skin biopsies are performed at 24 h.
  • the immediate weal and flare response is not mediated by a T cell response and is not expected to be influenced by cathepsin S inhibitors, while the late phase induration (noticeable at 6 ho.urs, more pronounced at 24 hours) is characterized by activation and infiltration of CP4 T cells (as well as of eosinophils) and should be inhibited by administration of inhibitors of cathepsin S.
  • the skin biopsies are used to determine the cellular composition in the induration, and cathepsin S treated subjects are expected to have fewer activated CD4 T cells present than placebo-treated subjects.
  • prednisone and cyclosporine A will be used as controls for the experiment. Prednisone will inhibit both the immediate and the late phase responses, while cyclosporin A will inhibit only the late phase response.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles of formula (I).

Description

METHOD FOR TREATING ALLERGIES USING SUBSTITUTED
PYRAZOLES
Field of the Invention
This invention relates to the use of substituted pyrazoles for the treatment of an allergic condition.
Background of the Invention Atopic allergies afflict at least 20% of populations in developed countries and comprise a wide range of IgE-mediated diseases such as hay fever, asthma, atopic dermatitis, and food allergies. Exposure of an allergic subject to relevant allergens cross-links allergen specific IgE bound to mast cells, triggering degranulation and release of proinflammatory mediators, such as histamine and eicosanoids, which cause the weal-and-flare response on a skin test. Characteristically, this early response is followed by a prolonged late reaction in which inflammatory cells, particularly eosinophils and activated TH-2 CD4 T cells, are recruited to the site of allergen exposure. Inflammatory cytokines such as IL-4 and IL-5, both produced by TH-2 cells, are important for IgE production by B cells and for eosinophilia, respectively. Immunotherapies targeting CD4 T cells have been shown to be effective in reducing the production of IgE, the activation of proinflammatory cells, and the release of inflammatory mediators.
Current allergy therapies targeting CD4 T cells have met with mixed success. Desensitization with allergen extracts or vaccines is effective for many allergens, such as the Hymenoptera insect sting which can induce life- threatening allergic reactions. The mechanism may be either induction of T cell tolerance or the conversion of TH-2 to TH-1. However, such treatment requires a long-term treatment regime, frequent doctor visits and prior stabilization by other medications, and is associated with a certain morbidity rate and rare deaths. Alternatively, immunosuppressive drugs such as steroids which effectively stabilize ongoing allergy responses, are often associated with severe side effects.
The activation of CD4 T cells is a major factor in the initiation and maintenance of the allergic response. Allergens are taken up by specialized antigen presenting cells (APCs) such as dendritic cells and B cells. Protein allergens pass through the endosomal or lysosomal system where they are degraded by different proteases. These peptide fragments are bound by the MHC class II molecules which, at the cell surface, are heterotrimeric complexes consisting of two transmembrane glycoprotein chains (α and β) that form a binding scaffold for the third component, a peptide of 11-20 amino acids. The antigen-MHC class II molecule complex is recognized by CD4 T cells and leads to the activation of the T cell. Activated T cells in turn activate several other components of the immune system, such as B cells and macrophages, that are crucial for the body's response to pathogens, but also lead to the symptoms of allergies.
Class II molecules, like other transmembrane proteins, are translocated into the endoplasmic reticulum (ER) after synthesis, where they associate with a third protein, the invariant chain (li). The invariant chain molecule is a type II transmembrane protein that serves as a class ll-specific chaperone, promoting the exit of class ll-li complexes from the ER and preventing class II molecules from binding to peptides and unfolded proteins in the ER and in the secretory pathway. A targeting motif in the cytoplasmic tail of li directs the class ll-li complexes from the secretory pathway into the endosomal system.
Before the MHC class II molecules can present antigen the li must be removed by a series of proteases that break down li. The resultant li peptide fragments, called class ll-associated invariant chain peptides (CLIP), occupy the peptide binding groove of the class II molecule, and in most cases are not spontaneously released. The CLIP protects the class II binding pocket from collapsing both during intracellular transport and after li degradation in the endosomal system. Binding of antigenic peptides generated from endocytosed proteins requires an empty, and yet open binding site. The CLIP therefore must be released while the open binding site is stabilized to allow the binding of other peptides. Human Leukocyte Antigen - DM ('HLA-DM') mediates both of these functions, thus promoting the binding of antigenic peptides. After acquiring peptides, the class II molecules are transported to the cell surface via routes that are largely unknown.
In view of the above, inhibition of invariant chain proteolysis will prevent removal of li from the class II binding pocket, which in turn will specifically block antigen binding to the MHC class II molecule.
Cathepsin S ('CatS') is a cysteine protease expressed in lymphatic tissues. CatS mediates invariant chain proteolysis, which is a prerequisite for peptide loading of MHC class II molecules (Riese et al. (1996) Immunity 4:357). CatS has 50-60% homology with cathepsins L and K, but differs from them in that it has a broad pH optimum that extends to alkaline pH. CatS modulates antigen presentation in animal models, and inhibitors are effective in an asthma model (Riese et al. (1998) J. Clin. Invest. 101 :2351 ). Mice deficient in cathepsin S have an impaired ability to present exogenous proteins by professional antigen presenting cells (Nakagawa et al. (1999) Immunity 10:207; Shi et al. (1999) Immunity 10:197).
Compounds that inhibit the proteolytic activity of human cathepsin S are expected to find utility in the treatment of chronic autoimmune diseases including, but not limited to, lupus and rheumatoid arthritis; and have potential utility in modulating the immune response to tissue transplantation. Methods of modulating autoimmunity with an agent that modulates cathepsin S activity, e.g., proteolysis of the li chain, as well as methods of treating a subject having an autoimmune disorder, methods of evaluating a treatment for its ability to modulate an immune response are described in WO 99/58153.
Compounds somewhat similar to those of the present invention are described in the following references. Winters, et. al. (Winters, G.; Sala, A.; Barone, D.; Baldoli, E. J. Med. Chem. 1985, 28, 934-940; Singh, P.; Sharma, R. C. Quant. Struct-Act. Relat. 1990, 9, 29-32; Winters, G.; Sala, A.; Barone, D. in US-4500525 (1985)) have described bicyclic pyrazoles of the type shown below. R never contains a heterocyclic ring and no protease inhibitor activity is ascribed to these molecules; they are described as α1-adrenergic receptor modulators.
Figure imgf000006_0001
Shutske, et. al. claim the bicylic pyrazoles below. The pyridine ring is aromatic in their system (Shutske, G. M.; Kapples, K. J.; Tomer, J. D. US- 5264576 (1993)). Although reference is made to R being a linker to a heterocycle, the claims specify only R = hydrogen. The compounds are referred to as serotonin reuptake inhibitors.
Figure imgf000006_0002
The compound 2-[4-[4-(3-methyl-5-phenyl-1 H-pyrazol-1-yl)butyl]-1- piperazinylj-pyrimidine is known from EP-382637, which describes pyrimidines having anxiolytic properties. This compound and analogs are further described in EP-502786 as cardiovascular and central nervous system agents. Pharmaceutical formulations with such compounds are disclosed in EP-655248 for use in the treatment of gastric secreation and as anti-ulcer agents. WO- 9721439 describes medicaments with such compounds for treating obsessive- compulsive disorders, sleep apnea, sexual dysfunctions, emesis and motion sickness. The compounds 5-methyl-3-phenyl-1 -[4-(4-phenyl-1 -piperazinyl)butyl]- 1 H-indazole and 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1- piperazinyl)butyl]-1 H-indazole, in particular the hydrochloride salts thereof, are known from WO-9853940 and CA 122:314528, where these and similar compounds are described as kinase inhibitors in the former reference and possessing affinity for benzodiazepine receptors in the latter reference.
Summary of the Invention The present invention features the use of cathepsin S inhibitors to treat allergic conditions, including but not limited to atopic allergies. Examples of an allergic condition include hay fever, asthma, atopic dermatitis and food allergies. Allergens include dust, pollen, mold, and pet dander or pet hair.
In one aspect, the invention provides a method for treating a subject suffering from an allergic condition, in particular an atopic allergic condition, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a cathepsin S inhibitor.
In another aspect, the invention provides a method for treating a subject suffering from an IgE-mediated allergic condition, in particular an atopic allergic condition, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a cathepsin S inhibitor.
A third aspect of the invention provides the use, or the use for the manufacture of a medicament, of a cathepsin S inhibitor for treating an allergic condition, more in particular for treating IgE-mediated allergic conditions, still more in particular treating hay fever, asthma, atopic dermatitis or food allergies. The invention also features anti-allergic pharmaceutical compositions comprising as active ingredient an effective amount of a cathepsin S inhibitor, and a pharmaceutically acceptable carrier. The active ingredient can be formulated in any manner suitable for the particular allergic condition, including aerosol, oral and topical formulations and time-release formulations.
The present invention concerns the treatment of an allergic condition using one or more compounds which can be represented by formula (I):
Figure imgf000009_0001
(I) wherein:
R1 is hydrogen, azido, halogen, C,.5 alkoxy, hydroxy, C^ alkyl, C2.5 alkenyl, cyano, nitro, R7R8N, C 2.8 acyl, R9OC=O, R10R11NC=O, or R10R11NSO2; or
R1 is taken together with W as described below;
R2 is hydrogen, halogen, C,_5 alkoxy, C,.5 alkyl, C2.5 alkenyl, C^ haloalkyl, cyano, or R48R49N; alternatively, R1 and R2 can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic; each of R3 and R4 is independently hydrogen or C,.5 alkyl; each of R5 and R6 is independently hydrogen, C,_5 alkyl, C2.5 alkenyl, C,.5 alkoxy,
Figure imgf000009_0002
alkylthio, halogen, or a 4-7 membered carbocyclyl or heterocyclyl; alternatively, R5 and R6 can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic, and may be optionally substituted with between one and three substituents independently selected from halo, cyano, amino, nitro, R40, R40O-, R 0S-, R40O(C ,_5 alkylene)-, R40O(C=O)-, R40(C=O)-, R40(C=S)-, R40(C=O)O-, R40O(C=O)(C=O)-, R40SO2, NHR62(C=NH)-, NHR62SO2-, and NHR62(C=O) -;
R 40 is H, C .,.5 alkyl, C2.5 alkenyl, phenyl, benzyl, phenethyl, C ^ heterocyclyl, (C ^s heterocyclyl)C ^ alkylene, amino, or mono- or di(C _5 alkyl)amino, or R58OR59-, wherein R58 is H, C ^ alkyl, C 2.5 alkenyl, phenyl, benzyl, phenethyl, C _5 heterocyclyl, or (C 5 heterocyclyl)C ^ alkylene and R59 is C ^g alkylene, phenylene, or divalent C ^ heterocyclyl; and
R62 can be H in addition to the values for R40;
R7 is hydrogen, C,^ alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl, C2.8 acyl, aroyl, R27OC=O, R28R29NC=O, R27SO, R27SO2, or R28R29NSO2; R8 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R7 and R8 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
R9 is C,_5 alkyl, phenyl, naphthyl, or C .,_5 heterocyclyl;
R21 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl,
C 2.8 acyl, aroyl, R30OC=O, R31R32NC=O, R30SO, R30SO2, or R31R32NSO2; R22 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R21 and R22can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R23, R26, R27, R30, R33, R44, R45, and R50 is C^ alkyl, phenyl, naphthyl, or
C ^g heterocyclyl; R24 is hydrogen, C,^ alkyl, C3.5 alkenyl, phenyl, naphthyl, C _5 heterocyclyl,
C 2.8 acyl, aroyl, R33OC=O, R34R35NC=O, R33SO, R33SO2, or R34R35NSO2; R25 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R24 and R25 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R10 and R11 is independently hydrogen, C^ alkyl, C2.5 alkenyl, phenyl, or C λ_5 heterocyclyl; alternatively, R 0 and R11 or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R28, R29, R31, R32, R34, R35, R46, R47, R51 and R52 is independently hydrogen, C,.5 alkyl, phenyl, or C 1 heterocyclyl; alternatively, R28 and R29, R31 and R32, R34 and R35, R46 and R47, or R51 and R52, independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; n is 1 or 2; • G represents C3.6 alkenediyl or C3.6 alkanediyl, optionally substituted with hydroxy, halogen,
Figure imgf000011_0001
alkoxy, oxo, hydroximino, CO2R60, R60R61NCO2, (L)-C L4 alkylene-, (LJ-C^ alkoxy, N3, or [(L)-C ^ alkylenejamino; each of R60 and R61 is independently hydrogen,
Figure imgf000011_0002
C 3.5 alkenyl, phenyl, benzyl, phenethyl, or C ^ heterocyclyl; alternatively R60 and R61 , can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; L is amino, mono- or di-C,.5 alkylamino, pyrrolidinyl, morpholinyl, piperidinyl homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with C,^ alkyl, benzyl, C2.5 acyl, C,..5 alkylsulfonyl or alkyloxycarbonyl; X is nitrogen or R12C; Y is nitrogen or R13C; Z is nitrogen or R14C;
R12 is hydrogen, halogen, C^ alkoxy, C,^ alkyl, C2.5 alkenyl, cyano, nitro, R21R22N, C 2.8 acyl, C,_5 haloalkyl, C 1-5 heterocyclyl, (C ^ heterocyclyl)C .,_ 5 alkylene, R23OC=O, R23O(C=O)NH-, R23SO, R22NHCO-, R22NH(C=O)NH-, R23(C Λ alkylene)NHCO-, R23SO2, or R23SO2NH-; R13 is hydrogen, halogen, G,^ alkoxy, G,^ alkyl, C2.5 alkenyl, cyano, nitro, R42R43N, C 2.8 acyl, C^ haloalkyl, C ^ heterocyclyl, (C ^ heterocyclyl)C ,. 5 alkylene, R44OC=O, R44O(C=O)NH-, R44SO, R43NHCO-, R43NH(C=O)NH-, R44(C Λ alkylene)NHCO-, R 4SO2, or R44SO2NH-; R14 is hydrogen, halogen, C^5 alkoxy, C^ alkyl, C2.5 alkenyl, cyano, nitro, R24R25N, C 2.8 acyl, C^ haloalkyl, C ^ heterocyclyl, (C ^ heterocydyl)C ,. 5 alkylene, R26OC=O, R26O(C=O)NH-, R26SO, R25NHCO-, R25NH(C=O)NH-, R26(C M alkylene)NHCO-, R26SO2, or R26SO2NH-; alternatively, R12 and R13 or R12 and R2 or R13 and R14 can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;
Ar represents a monocyclic or bicyclic aryl or heteroaryl ring, optionally substituted with between 1 and 3 substituents selected from halogen, C 5 alkoxy, C^ alkyl, C2.5 alkenyl, cyano, azido, nitro, R15R16N, R17SO2, R17S, R17SO, R17OC=O, R15R16NC=O, C^ haloalkyl, C,_5 haloalkoxy, C^ haloalkylthio, and C.,_5alkylthio; R15 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, benzyl, C ,.5 heterocyclyl, C 2. β acyl, aroyl, R53OC=O, R54R55NC=O, R53S, R53SO, R53SO2, or R54R55NS02;
R16 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, benzyl, or C .,_5 heterocyclyl; alternatively, R15 and R16 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R17 and R53 is C,.5 alkyl, phenyl, or C ^ heterocyclyl; each of R54 and R55 is independently hydrogen, C^ alkyl, C2.5 alkenyl, phenyl, benzyl, or C ^ heterocyclyl; alternatively, R54 and R55 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
W represents SO2, C=O, CHR20, or a covalent bond; or W and R1, taken together with the 6-membered ring to which they are both attached, form one of the following two formulae:
Figure imgf000012_0001
0(a) (l)(b)
wherein Xa is O, S, or N; and Xb is O, S or SO2; R20 is hydrogen, C,.5 alkyl, phenyl, benzyl, naphthyl, or C ^ heterocyclyl; R42 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, naphthyl, C 5 heterocyclyl, C 2.8 acyl, aroyl, R45OC=O, R46R47NC=O, R45SO, R45SO2, or R46R47NSO2;
R43 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R42 and R43can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; R44 is C|_5 alkyl, C2.5 alkenyl, phenyl, naphthyl, or C ^ heterocyclyl;
R48 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl, C
2.8 acyl, aroyl, R50OC=O, R51R52NC=O, R50SO, R50SO2, or R51R52NSO2; R49 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R48 and R49 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and
wherein each of the above hydrocarbyl or heterocarbyl groups, unless otherwise indicated, and in addition to any specified substituents, is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano, C ^ alkyl, C ^ alkoxy, -COOH, C 2.6 acyl, [di(C .,.4 alkyl)amino]C 2.5 alkylene, [di(C ΛΛ alkyl)amino] C 2.5 alkyl-NH- CO-, and C 1-β haloalkoxy;
or a pharmaceutically acceptable salt, ester, or amide thereof, including a stereoisomeric form thereof.
The disclosed compounds are high-affinity inhibitors of the proteolytic activity of human cathepsin S. For use in medicine, the preparation of pharmaceutically acceptable salts of compounds of formula (I) may be desirable.
Certain compounds of the present invention may have one stereogenic atom and may exist as two enantiomers. Certain compounds of the present invention may have two or more stereogenic atoms and may further exist as diastereomers. It is to be understood by those skilled in the art that all such stereoisomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
Another aspect of the invention provides pharmaceutical anti-allergic compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. A further embodiment of the invention is a process for making an anti-allergic pharmaceutical composition comprising mixing a disclosed compound as described above, with a suitable pharmaceutically acceptable carrier.
The invention also contemplates pharmaceutical compositions comprising more than one compound of formula (I) and compositions comprising a compound of formula (I) and another pharmaceutically active agent.
The invention features a method of treating allergic disorders or conditions mediated by the cathepsin S enzyme, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above. If more than one active agent is administered, the therapeutically effective amount may be a jointly effective amount. The compounds described herein inhibit the protease activity of human cathepsin S, an enzyme involved in the immune response. In preferred embodiments, cathepsin S inhibition is selective. As such, the disclosed compounds and compositions are useful in the prevention, inhibition, or treatment of allergic conditions, particularly atopic allergic conditions.
Additional features and advantages of the invention will become apparent from the detailed description and examples below, and the appended claims.
Brief Description of the Figures
FIG. 1 shows the inhibition of human T cell proliferative responses to two species of dust mites, Derp and Der f. Top panel, FIG. 1A: Dilution curve for purified PBMC from an allergy donor were cultured with titrated doses of allergen extracts prepared from Derp and Derf for seven days. Proliferation of T cells was scored by measuring 3H-thymidine incorporation for 18 h at the end of culture. Bottom panel, FIG. 1 B: Effect of titrated doses of LHVS on proliferative responses of T cells to dust mite extracts.
FIG. 2 is shows the inhibition of human T cell proliferative responses to ragweeds but not ConA by LHVS. Top panel, FIG. 2A: Dilution curve for purified PBMC from an allergy donor were cultured with titrated doses of allergen extracts prepared from Ragweed short and Ragweed giant for seven days. Proliferation of T cells was scored by measuring 3H-thymidine incorporation for 18 h at the end of culture. Bottom panel, FIG. 2B: Effect of titrated doses of LHVS on proliferative responses of T cells to ragweed extracts.
FIG. 3 shows the inhibition of human T cell proliferative responses to
Der f but not ConA by two Cathepsin S inhibitors, Example 11 (FIG. 3A) and Example 36 (FIG. 3B). Purified PBMC from an allergy donor were cultured with allergen extracts prepared from Derf in the presence of titrated doses of indicated example compounds for seven days. Proliferation of T cells was scored by measuring 3H-thymidine incorporation for 18 h at the end of culture.
Detailed Description of the Invention
A target of the present invention was to determine whether the presentation of particular antigens in a human system is affected by the inhibition of cathepsin S. According to the invention, it now has been found that inhibitors of cathepsin S block the presentation of several crude allergen extracts in a human ex vivo assay, thereby supporting the use of cathepsin S inhibitors for the treatment of such allergic conditions.
Blocking li degradation should decrease antigen presentation to CD4 T cells and disrupt the normal immune response. A cathepsin S inhibitor should specfically affect the activation of CD4 T cells, thus limiting the extent of concomitant immunosuppression, an undesirable side effect of corticosteroid therapy.
By using cathepsin S inhibitors according to the methods of the present invention, the immunological component of the allergic reaction can be blocked to varying degrees, with the advantage over current therapies of being more selective, having fewer or reduced side effects, or both. The present invention is based, in part, on the finding that cathepsin S inhibitors can block the presentation of crude allergen extracts in a human ex vivo assay. This ex vivo system closely mimics the process that occurs in the whole body wherein antigens enter the blood stream, and are presented by antigen presenting cells, which in turn activate CD4 T cells. In the case of treating a subject, the inhibitor or a metabolite thereof would also be present in the blood as in the ex vivo assay.
The invention features the treatment of an allergic condition using pyrazole compounds of formula (I). A. Terms
The following terms are defined below and by their usage throughout this disclosure.
"Alkyl" includes optionally substituted straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1- methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on. Alkyl includes cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
"Alkenyl" includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon double bond (sp2). Alkenyls include ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl, and so on. Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkenyl includes cycloalkenyl. Cis and trans or (E) and (Z) forms are included within the invention.
"Alkynyl" includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon triple bond (sp). Alkynyls include ethynyl, propynyls, butynyls, and pentynyls. Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten- 4-ynyl, are grouped as alkynyls herein. Alkynyl does not include cycloalkynyl.
"Alkoxy" includes an optionally substituted straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t- butoxy, pentoxy and so on. "Aminoalkyl", "thioalkyl", and "sulfonylalkyl" are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO2. Heteroalkyl includes alkoxy, aminoalkyl, thioalkyl, and so on.
"Aryl" includes phenyl, naphthyl, biphenylyl, tetrahydronaphthyl, and so on, any of which may be optionally substituted. Aryl also includes arylalkyl groups such as benzyl, phenethyl, and phenylpropyl. Aryl includes a ring system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system may be bicyclic, bridge, and/or fused. The system may include rings that are aromatic, or partially or completely saturated. Examples of ring systems include indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl, benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl, and so on.
"Heterocyclyl" includes optionally substituted aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO2, CO, CONH, COO) in the ring. Unless otherwise indicated, a heterocyclic radical may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or 1-pyrazolyl. Preferably a monocyclic heterocyclyl has between 4 and 7 ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5 heteroatoms or heteroatom moieties in the ring, and preferably between 1 and 3. A heterocyclyl may be saturated, unsaturated, aromatic (e.g., heteroaryl), nonaromatic, or fused.
Heterocyclyl also includes fused, e.g., bicyclic, rings, such as those optionally condensed with an optionally substituted carbocyclic or heterocyclic five- or six-membered aromatic ring. For example, "heteroaryl" includes an optionally substituted six-membered heteroaromatic ring containing 1 , 2 or 3 nitrogen atoms condensed with an optionally substituted five- or six- memebered carbocyclic or heterocyclic aromatic ring. Said heterocyclic five- or six-membered aromatic ring condensed with the said five- or six-membered aromatic ring may contain 1 , 2 or 3 nitrogen atoms where it is a six-membered ring, or 1 , 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where it is a five-membered ring.
Examples of heterocyclyls include thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl. For example, preferred heterocyclyls or heterocyclic radicals include morpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino,and more preferably, piperidyl.
Examples illustrating heteroaryl are thienyl, furanyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl.
"Acyl" refers to a carbonyl moiety attached to either a hydrogen atom (i.e., a formyl group) or to an optionally substituted alkyl or alkenyl chain, or heterocyclyl.
"Halo" or "halogen" includes fluoro, chloro, bromo, and iodo, and preferably chloro or bromo as a substituent.
"Alkanediyl" or "alkylene" represents straight or branched chain optionally substituted bivalent alkane radicals such as, for example, methylene, ethylene, propylene, butylene, pentylene or hexylene.
"Alkenediyl" represents, analogous to the above, straight or branched chain optionally substituted bivalent alkene radicals such as, for example, propenylene, butenylene, pentenylene or hexenylene. In such radicals, the carbon atom linking a nitrogen preferably should not be unsaturated. "Aroyl" refers to a carbonyl moiety attached to an optionally substituted aryl or heteroaryl group, wherein aryl and heteroaryl have the definitions provided above. In particular, benzoyl is phenylcarbonyl.
As defined herein, two radicals, together with the atom(s) to which they are attached may form an optionally substituted 4- to 7-, 5 - to 7-, or a 5- to 6- membered ring carbocyclic or heterocyclic ring, which ring may be saturated, unsaturated or aromatic. Said rings may be as defined above in the Summary of the Invention section. Particular examples of such rings are as follows in the next section.
"Pharmaceutically acceptable salts, esters, and amides" include carboxylate salts (e.g., C 1-8 alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic) amino acid addition salts, esters, and amides which are within a reasonable benefit risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate. These may include alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. See example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19 which is incorporated herein by reference. Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C ^ alkyl amines and secondary di (C ^ alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C ^ alkyl primary amines, and di (C ^alkyljamines. Representative pharmaceutically acceptable esters of the invention include C ^ alkyl, C 5.7cycloalkyl, phenyl, and phenyI(C ^ alkyl esters. Preferred esters include methyl esters.
"Patient" or "subject" includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experiment, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient or subject is a human.
"Composition" includes a product comprising the specified ingredients in the specified amounts as well as any product which results directly or indirectly from combinations of the specified ingredients in the specified amounts.
"Therapeutically effective amount" or "effective amount" means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
Concerning the various radicals in this disclosure and in the claims, three general remarks are made. The first remark concerns valency. As with all hydrocarbon radicals, whether saturated, unsaturated or aromatic, and whether or not cyclic, straight chain, or branched, and also similarly with all heterocyclic radicals, each radical includes substituted radicals of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims. The context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or more hydrogen atoms removed (multivalent). An example of a bivalent radical linking two parts of the molecule is G in formula (I) which links two rings.
Second, radicals or structure fragments as defined herein are understood to include substituted radicals or structure fragments. Hydrocarbyls include monovalent radicals containing carbon and hydrogen such as alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl (whether aromatic or unsaturated), as well as corresponding divalent radicals such as alkylene, alkenylene, phenylene, and so on. Heterocarbyls include monovalent and divalent radicals containing carbon/ hydrogen, and at least one heteroatom. Examples of monovalent heterocarbyls include acyl, acyloxy, alkoxyacyl, heterocyclyl, heteroaryl, aroyl, benzoyl, dialkylamino, hydroxyalkyl, and so on. Using "alkyl" as an example, "alkyl" should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents. The substituents may be the same (dihydroxy, dimethyl), similar (chlorofluoro), or different (chlorobenzyl- or aminomethyl-substituted). Examples of substituted alkyl include haloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, perfluoromethyl, and 3-iodocyclopentyl), hydroxyalkyl (such as hydroxymethyl, hydroxyethyl, 2- hydroxypropyl, aminoalkyl (such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and 2-aminopropyl), nitroalkyl, alkylalkyl, and so on. A di(C .,.6 alkyl)amino group includes independently selected alkyl groups, to form, for example, methylpropylamino and isopropylmethylamino, in addition dialkylamino groups having two of the same alkyl group such as dimethyl amino or diethylamino.
Third, only stable compounds are intended. For example, where there is an NR'R" group, and R can be an alkenyl group, the double bond is at least one carbon removed from the nitrogen to avoid enamine formation. Similarly, where a dashed line is an optional sp2bond, if it is absent, the appropriate hydrogen atom(s) is(are) included.
Preferred substitutions for Ar include methyl, methoxy, fluoromethyl, difluoromethyl, perfluoromethyl (trifluoromethyl), 1-fluoroethyl, 2-fluoroethyl, ethoxy, fluoro, chloro, and bromo, and particularly methyl, bromo, chloro, perfluoromethyl, perfluoromethoxy, methoxy, and fluoro. Preferred substitution patterns for Ar or A are 4-substituted or 3,4-disubstituted phenyl. Compounds of the invention are further described in the next section. B. Compounds
The invention features the use of compounds of formula (I) as described in the Summary section for the treatment of an allergic condition.
Preferred compounds include those wherein:
(a) R1 is hydrogen, halogen, C^ alkoxy, hydroxy, C^ alkyl, cyano, nitro, R7R8N, C 2.8 acyl, or R10R11NSO2;
(b) R1 is halogen, cyano, nitro, R7R8N, or R10R11NSO2; (c) R2 is hydrogen;
(d) each of R3 and R4 is independently hydrogen or C^ alkyl;
(e) one of R3 and R4 is hydrogen;
(f) each of R3 and R4 is hydrogen;
(g) one of R5 and R6 is hydrogen and the other is a 5-7 membered carbocyclyl or heterocyclyl, optionally substituted;
(h) R5 and R6 taken together form a six-membered heterocyclyl;
(i) R5 and R6 taken together form pyridinyl, pyrimidinyl, or piperazinyl, optionally N-substituted with R40O(C=O)(C=O)-, R40SO2, R40NHCO2, R40(C=O)- or R 0N(C=O)-; (j) each of R7, R8, R21, R22, R24, R25 is independently hydrogen or
C^ alkyl; or, independently, each of R7 and R8, R21 and R22, and R24 and R25 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; (k) at least one of R7 and R8, R2 and R22, and R24 and R25 , taken together, is morpholinyl, piperidinyl, or pyrrolidinyl;
(I) R9, R23, R26, and R27 is each independently hydrogen or C^ alkyl;
(m) G is C3.4 alkanediyl, optionally substituted with hydroxy, (L)- C^ alkyloxy-, or [(L)-C,.5 alkylenejamino-;
(n) G is C3 alkanediyl, optionally substituted with hydroxy, (L)-C^ alkyloxy-, or [(L)-C.,..5 alkylenejamino-;
(o) X is nitrogen; (p) Y is CR13;
(q) Z is CR14;
(r) X is CH;
(s) R12 is hydrogen, R22O(C=O)NH-, R22NH(C=O)NH-, R22SO2NH, R23SO, or R23SO2. and R13 is hydrogen, R43O(C=0)NH-,
R43NH(C=O)NH-, R43SO2NH, R44SO, or R44SO2;
(t) R14 is hydrogen, halogen, C,^ alkoxy, C^ alkyl, cyano, nitro, R25O(C=O)NH-, R25NH(C=O)NH-, R25SO2NH or R24R25N;
(u) R14 is halogen, R25O(C=O)NH-, R25NH(C=O)NH-, R25SO2NH or R24R25N; Ar represents a monocyclic ring, optionally substituted with between 1 and 2 substituents selected independently from halogen, G,^ alkyl, cyano, nitro, R15R16N, CF3 and OCF3;
(v) Ar is a six membered ring substituted with between 1 and 2 substituents selected from halo, CF3, OCF3, said substitutent or substitutents being at the 4-position or at the 3- and 4- positions, respectively;
(w) W is SO2) C=O, or CHR20;
(x) W is a covalent bond; (y) W and R1 taken together are formula (l)(a);
(z) W and R1 taken together are formula (l)(b);
(aa) one of R3 and R4 is hydrogen; Ar represents a monocyclic ring, optionally substituted with between 1 and 2 substituents selected from halogen, C,.5 alkyl, cyano, nitro, R15R16N, CF3 and OCF3; R 2 is hydrogen, R23SO, or R23SO2; R13 is hydrogen,
R44SO, or R44SO2; R14 is hydrogen, halogen, C^ alkoxy, C^ alkyl, cyano, nitro, or R24R25N; and G is C3 alkanediyl, optionally substituted with hydroxy, C ^ alkyl, (L)-C^ alkyloxy, or [(L)-C.,.5 alkylenejamino-; (bb) each of R3 and R4 is hydrogen; Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen, C,^ alkyl, cyano, nitro, R15R16N, CF3 and OCF3; R12 is hydrogen, R23SO, or R23SO2; R13 is hydrogen, R44SO, or R44SO2; R14 is hydrogen, halogen,
Figure imgf000025_0001
alkyl, cyano, nitro, or R24R25N; and G is C3 alkanediyl, optionally substituted with hydroxy, (L)-C,.5 alkyloxy-, or (L)-C,.5 alkylamino; (cc) Ar is phenyl; and
(dd) combinations of the above.
Specific preferred compounds include the examples herein, such as: 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2- ol ; 1 -[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]-3-methyl- urea ; 1 -[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)- phenyl]-3-methyl-urea ; 3-Amino-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}- piperazin-1-yl)-benzoic acid methyl ester ; 3-Chloro-2-(4-{3-[5-methanesulfonyl- 3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]- propyl}-piperazin-1 -yl)-phenylamine ; 1 -[2-(4-{3-[3-(4-Bromo-phenyl)-5- methanesulfonyI-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy- propyl}-piperazin-1 -yl)-3-chloro-phenyl]-3-methyl-urea ; 1 -{3-[4-(2-Chloro-6- methanesulfonylamino-phenyl)-piperazin-1-yl]-propyl}-3-(4-trifluoromethyl- phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide ; [3- Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4, 5,6,7- tetrahydro-pyrazo!o[4,3-cjpyridin-1 -yl]-propyl}-piperazin-1 -yl)-phenyl]-carbamic acid methyl ester ; 1-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3-(4- bromo-phenyl)-1 , 4,6, 7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide ; 2-(4-{3-[5-Acetyl-3-(4-trifluoromethyI-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-3-nitro-benzoic acid methyl ester ; 1-[4-(2-Chloro-6-nitro-phenyI)-piperazin-1-yl]-3-[5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1 -yl]-propan-2-ol ; 2-(4-{2-Hydroxy-3-[3-(4-iodo-phenyl)-5- methanesuIfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}- piperazin-1 -yl)-benzonitrile ; 3-(4-Bromo-phenyl)-1 -{3-[4-(2-nitro-phenyl)- piperazin-1-yl]-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxyIic acid amide ; 2-(4-{3-[5-Acetyl-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1 -yl]-2-hydroxy-propyl}-piperazin-1 -yl)-benzonitrile ; 2-(4- {3-[3-(4-Chloro-3-methyl-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile ; 1-(3- (4-Chloro-3-methyl-phenyl)-1-{3-[4-(2,4-dimethyl-phenyl)-piperazin-1-yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone ; 1-{3- [4-(3,5-Dichloro-pyridin-4-yl)-piperazin-1-yl]-propyl}-5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine ; 2-(4-{3- [5-Methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-ylj-propyl}-piperazin-1-yl)-benzonitrile; N-[3-Chloro-2-(4-{3-[5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1 -yl]-propyl}-piperazin-1 -yl)-phenyl]-methanesulfonamide ; 3-(3,4- Dichloro-phenyl)-1 -{3-[4-(2-nitro-phenyl)-piperazin-1 -yl]-propyl}-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide ; and 3-(4-Chloro-3- methyl-phenyl)-1-{3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl}- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.
Furthermore, preferred compounds include those wherein Ar is selected from 4-trifluoromethylphenyl, 4-bromophenyI, 4-chlorophenyl, 4-chloro-3- methylphenyl and 3,4-dichlorophenyl.
More preferred compounds include the compounds in Examples 19, 27, and 33.
Related Compounds
The invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, acids, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms. Related compounds also include compounds of the invention that have been modified to be detectable, e.g., isotopically labelled with 18F for use as a probe in positron emission tomography (PET) or single-photon emission computed tomography (SPECT).
The invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. See, e.g., Greene and Wuts, Protective Groups in Organic Synthesis. 3rd ed., (1999) John Wiley & Sons, NY. Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.
HYDROXYL PROTECTING GROUPS
Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.
Substituted Methyl Ethers
Examples of substituted methyl ethers include methyoxymethyl, methylthiomethyl, f-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, guaiacolmethyl, f-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2- methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4- methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1- [(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1 ,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl and 2,3, 3a,4, 5,6,7, 7a-octahydro-7, 8,8- trimethyl-4,7-methanobenzofuran-2-yl.
Substituted Ethyl Ethers
Examples of substituted ethyl ethers include 1-ethoxyethyl, 1-(2- chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1- methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyI, 2-trimethylsilylethyl, 2- (phenylselenyl)ethyl, f-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4- dinitrophenyl, and benzyl.
Substituted Benzyl Ethers
Examples of substituted benzyl ethers include p-methoxybenzyl, 3,4- dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6- dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2- picolyl N-oxido, diphenylmethyl, p, p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyIdiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'- bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-tris(4,5- dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(/midazol-1-ylmethyl)bis(4 ',4"- dimethoxyphenyl)methyl, 1 ,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1 ,3-benzodithiolan-2-yl, and benzisothiazolyl S,S-dioxido.
Silyl Ethers Examples of silyl ethers include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, t- butyldimethylsilyl, f-butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and f-butylmethoxyphenylsilyl.
Esters In addition to ethers, a hydroxyl group may be protected as an ester.
Examples of esters include formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P- phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4- (ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4- methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate(mesitoate)
Carbonates Examples of carbonate protecting groups include methyl, 9- fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethyIsilyl)ethyl, 2- (phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p- nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p- nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1 -naphthyl, and methyl dithiocarbonate. Assisted Cleavage
Examples of assisted cleavage include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2- formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-
(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.
Miscellaneous Esters Examples of miscellaneous esters include 2,6-dichloro-4- methylphenoxyacetate, 2,6-dichloro-4-(1 ,1 ,3,3- tetramethylbutyl)phenoxyacetate, 2,4-bis(1 ,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2- butenoate(tigloate), o-(methoxycarbonyl)benzoate, p-P-benzoate, α- naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N- phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4- dinitrophenylsulfenate.
Sulfonates
Examples of sulfonates include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.
AMINO PROTECTING GROUPS
Protection for the amino group includes carbamates, amides, and special -NH protective groups.
Examples of carbamates include methyl and ethyl carbamates, substituted ethyl carbamates, assisted cleavage carbamates, photolytic cleavage carbamates, urea-type derivatives, and miscellaneous carbamates. Carbamates
Examples of methyl and ethyl carbamates include methyl and ethyl, 9- fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7- di-f-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, and 4- methoxyphenacyl.
Substituted Ethyl Examples of substituted ethyl carbamates include 2,2,2-trichloroethyl, 2- trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1 ,1-dimethyl- 2-haloethyl, 1 ,1-dimethyl-2,2-dibromoethyI, 1 ,1-dimethyl-2,2,2-trichloroethyl, 1- methyl-1-(4-biphenylyI)ethyl, 1-(3,5-di-f-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(N,N-dicyclohexylcarboxamido)ethyl, ---butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, N- hydroxypiperidinyl, alkyldithio, benzyl, p-methoxybenzyl, p-nitrobenzyl, p- bromobenzyl, p-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9- anthrylmethyl and diphenylmethyl.
Assisted Cleavage
Examples of assisted cleavage include 2-methylthioethyl, 2- methylsulfonylethyl, 2-(p-toluenesulfonyl)ethyl, [2-(1 ,3-dithianyl)]methyl, 4- methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2- triphenylphosphonioisopropyl, 1 ,1-dimethyl-2-cyanoethyl, m-chloro-p- acyloxybenzyl, p-(dihydroxyboryl)benzyl, 5-benzisoxazolyImethyl, and 2- (trifluoromethyl)-6-chromonylmethyl.
Photolytic Cleavage Examples of photolytic cleavage include m-nitrophenyl, 3,5- dimethoxybenzyl, o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(o- nitrophenyl)methyI. Urea-Type Derivatives
Examples of urea-type derivatives include phenothiazinyl-(10)-carbonyl derivative, N' -p-toluenesulfonylaminocarbonyl, and N'- phenylaminothiocarbonyl.
Miscellaneous Carbamates
Examples of miscellaneous carbamates include f-amyl, S-benzyl thiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl methyl, p-decyloxybenzyl, diisopropylmethyl, 2,2- dimethoxycarbonylvinyl, o-(N,N-dimethylcarboxamido)benzyl, 1 ,1-dimethyl-3- (N,N-dimethylcarboxamido)propyl, 1 ,1-dimethylpropynyl, di(2-pyridyl)methyl, 2- furanylmethyl, 2-iodoethyl, isobomyl, isobutyl, isonicotinyl, p-(p'- methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1 -methyl-1 - cyclopropylmethyl, 1 -methyl-1 -(3,5-dimethoxyphenyl)ethyl, 1 -methyl-1 -(p- phenylazophenyl)ethyl, 1 -methyl-1 -phenylethyl, 1 -methyl-1 -(4-pyridyl)ethyl, phenyl, p-(phenylazo)benzyl, 2,4,6-tri-f-butylphenyl, 4- (trimethylammonium)benzyl, and 2,4,6-trimethylbenzyl.
Examples of amides include:
Amides
N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N- phenylacetyl, N-3-phenylpropionyl, N-picolinoyl, N-3-pyridyIcarboxamide, N- benzoylphenylalanyl derivative, N-benzoyl, N-p-phenylbenzoyl.
Assisted Cleavage
N-o-nitrophenylacetyl, N-o-nitrophenoxyacetyl, N-acetoacetyl, (N'- dithiobenzyloxycarbonylamino)acetyl, N-3-(p-hydroxyphenyl)propionyl, N-3-(o- nitrophenyl)propionyl, N-2-methyl-2-(o-nitrophenoxy)propionyl, N-2-methyl-2- (o-phenylazophenoxy)propionyl, N-4-chlorobutyryl, N-3-methyl-3-nitrobutyryl, N-o-nitrocinnamoyl, N-acetylmethionine derivative, N-o-nitrobenzoyl, N-o- (benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3-oxazolin-2-one. Cyclic Imide Derivatives
N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5- dimethylpyrrolyl, N-1 ,1 ,4,4-tetramethyldisilylazacyclopentane adduct, 5- substituted 1 ,3-dimethyl-1 ,3,5-triazacyclohexan-2-one, 5-substituted 1 ,3- dibenzyl-1 ,3,5-triazacyclohexan-2-one, and 1 -substituted 3,5-dinitro-4- pyridonyl.
SPECIAL - NH PROTECTIVE GROUPS
Examples of special NH protective groups include
N-Alkyl and N-Aryl Amines
N-methyl, N-allyl, N-[2-(trimethylsilyl)ethoxy]methyl, N-3-acetoxypropyl, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), quaternary ammonium salts, N- benzyl, N-di(4-methoxyphenyl)methyl, N-5-dibenzosuberyl, N-triphenylmethyl, N-(4-methoxyphenyl)diphenylmethyl, N-9-phenylfluorenyl, N-2,7-dichloro-9- fluorenylmethylene, N-ferrocenylmethyl, and N-2-picolylamine N'-oxide.
I mine Derivatives
N-1 ,1-dimethylthiomethylene, N-benzylidene, N-p-methoxybenzylidene,
N-diphenylmethylene, N-[(2-pyridyl)mesityl]methylene, and N-(N' ,N'- dimethylaminomethylene).
PROTECTION FOR THE CARBONYL GROUP
Acyclic Acetals and Ketals
Examples of acyclic acetals and ketals include dimethyl, bis(2,2,2- trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and diacetyl. Cyclic Acetals and Ketals
Examples of cyclic acetals and ketals include 1 ,3-dioxanes, 5- methylene-1 ,3-dioxane, 5,5-dibromo-1 ,3-dioxane, 5-(2-pyridyl)-1 ,3-dioxane, 1 ,3-dioxolanes, 4-bromomethyl-1 ,3-dioxolane, 4-(3-butenyI)-1 ,3-dioxolane, 4- phenyl-1 ,3-dioxolane, 4-(2-nitrophenyl)-1 ,3-dioxolane, 4,5-dimethoxymethyl- 1 ,3-dioxolane, O,0'-phenylenedioxy and 1 ,5-dihydro-3H-2,4-benzodioxepin.
Acyclic Dithio Acetals and Ketals
Examples of acyclic dithio acetals and ketals include S,S'-dimethyl, S.S'-dlethyl, S.S'-dipropyl, S.S'-dibutyl, S.S'-dipentyl, S.S'-diphenyl, S,S'- dibenzyl and S,S'-diacetyl.
Cyclic Dithio Acetals and Ketals
Examples of cyclic dithio acetals and ketals include 1 ,3-dithiane, 1 ,3- dithiolane and 1 ,5-dihydro-3H-2,4-benzodithiepin.
Acyclic Monothio Acetals and Ketals
Examples of acyclic monothio acetals and ketals include O-trimethylsilyl- S-alkyl, O-methyl-S-alkyl or -S-phenyl and O-methyl-S-2-(methylthio)ethyl.
Cyclic Monothio Acetals and Ketals
Examples of cyclic monothio acetals and ketals include 1 ,3- oxathiolanes.
MISCELLANEOUS DERIVATIVES
O-Substituted Cyanohydrins
Examples of O-substituted cyanohydrins include O-acetyl, O- trimethylsilyl, O-1-ethoxyethyl and O-tetrahydropyranyl. Substituted Hydrazones
Examples of substituted hydrazones include N,N-dimethyl and 2,4- dinitrophenyl.
Oxime Derivatives
Examples of oxime derivatives include O-methyl, O-benzyl and O- phenylthiomethyl.
Imines
Substituted Methylene Derivatives, Cyclic Derivatives
Examples of substituted methylene and cyclic derivatives include oxazolidines, 1-methyl-2-(1'-hydroxyalkyl)imidazoles, N,N'- dimethylimidazolidines, 2,3-dihydro-1 ,3-benzothiazoles, diethylamine adducts, and methylaluminum bis(2,6-di-^-butyl-4-methylphenoxide)(MAD)complex.
PROTECTION FOR THE CARBOXYL GROUP
Esters
Substituted Methyl Esters
Examples of substituted methyl esters include 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl, p-bromophenacyl, α-methylphenacyl, p-methoxyphenacyl, carboxamidomethyl, and N-phthalimidomethyl.
2-Substituted Ethyl Esters Examples of 2-substituted ethyl esters include 2,2,2-trichloroethyl,
2-haIoethyl, ω-chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 1 ,3- dithianyl-2-methyl, 2-(p-nitrophenylsulfenyl)ethyI, 2-(p-toluenesulfonyl)ethyl, 2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl, 1 -methyl-1 -phenylethyl, f-butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl, α-methylcinnamyl, phenyl, p-(methylmercapto)phenyl and benzyl.
Substituted Benzyl Esters
Examples of substituted benzyl esters include triphenylmethyl, diphenylmethyl, bis(o-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10- dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6- chromylmethyl, 2,4,6-trimethylbenzyl, p-bromobenzyl, o-nitrobenzyl, p- nitrobenzyl, p-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4- sulfobenzyl, piperonyl, 4-picolyl and p-P-benzyl.
Silyl Esters
Examples of silyl esters include trimethylsilyl, triethylsilyl, f-butyldimethylsilyl, /-propyldimethylsilyl, phenyldimethylsilyl and di-f- butylmethylsilyl. Activated Esters
Examples of activated esters include thiols.
Miscellaneous Derivatives
Examples of miscellaneous derivatives include oxazoles, 2-alkyl-1 ,3- oxazolines, 4-alkyl-5-oxo-1 ,3-oxazolidines, 5-alkyl-4-oxo-1 ,3-dioxolanes, ortho esters, phenyl group and pentaaminocobalt(lll) complex.
Stannyl Esters
Examples of stannyl esters include triethylstannyl and tri-n-butylstannyl.
AMIDES AND HYDRAZIDES
Amides Examples of amides include N,N-dimethyl, pyrrolidinyl, piperidinyl, 5,6- dihydrophenanthridinyl, o-nitroanilides, N-7-nitroindolyl, N-8-Nitro-1 , 2,3,4- tetrahydroquinolyl, and p-P-benzenesulfonamides.
Hydrazides
Examples of hydrazides include N-phenyl and N,N'-diisopropyl hydrazides.
C. Synthesis
The compounds of the present invention may be prepared by conventional synthetic organic chemistry and by matrix or combinatorial methods according to Schemes 1 to 11 below, and representative detailed Examples 1 to 24. Those of ordinary skill in the art will be able to modify and adapt the guidance provided herein to make the disclosed compounds.
Scheme 1
Figure imgf000038_0001
A = or ferf-butoxycarbonyl (BOC)
Figure imgf000038_0002
Scheme 2
Figure imgf000038_0003
Scheme 3
Figure imgf000039_0001
Scheme 4
Figure imgf000039_0002
P = S02Me, BOC, EtOCO, Ac, etc. X = O, CH2, covalent bond m = 1-4 Scheme 5
Figure imgf000040_0001
Scheme 6
Figure imgf000040_0002
+ (for J = CHOH)
Figure imgf000040_0003
Scheme 7
Figure imgf000041_0001
Scheme 8
Figure imgf000041_0002
RxNHRy reductant
Figure imgf000041_0003
Scheme 9
Figure imgf000041_0004
+ (for J = CHOH)
Figure imgf000041_0005
Scheme 10
Figure imgf000042_0001
l ^OTBS base
Figure imgf000042_0002
Scheme 11
Figure imgf000043_0001
base
Figure imgf000043_0002
D. Formulation and Administration
The present compounds inhibit the proteolytic activity of human cathepsin S and therefore are useful as a medicine especially in methods for treating patients suffering from allergic disorders or conditions which are modulated or regulated by the inhibition of cathepsin S activity.
The invention features a method for treating a subject with an allergic condition mediated by cathepsin S, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the invention. The invention also provides a method for inhibiting cathepsin S activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the invention.
In view of their inhibitory effect on the proteolytic activity of human cathepsin S the compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. To prepare these pharmaceutical compositions, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.
A carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for oral administration or parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. These include water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. In view of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are generally employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Such additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot- on, as an ointment. Acid addition salts of the compounds of formula (I), due to their increased water solubility over the corresponding base form, are more suitable in the preparation of aqueous compositions.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
Pharmaceutically acceptable acid addition salts include the therapeu- tically active non-toxic acid addition salt forms which the disclosed compounds are able to form. The latter can conveniently be obtained by treating the base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, palmoic and the like acids. The term addition salt also comprises the solvates which the disclosed componds, as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like. Conversely the salt form can be converted by treatment with alkali into the free base form.
Stereoisomeric form defines all the possible isomeric forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the (R)- or (S)-configuration; substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration. The invention encompasses stereochemically isomeric forms including diastereoisomers, as well as mixtures thereof in any proportion of the disclosed compounds. The disclosed compounds may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above and following formulae are intended to be included within the scope of the present invention.
Those of skill in the treatment of disorders or conditions mediated by the cathepsin S enzyme could easily determine the effective daily amount from the test results presented hereinafter and other information. In general it is contemplated that a therapeutically effective dose would be from 0.001 mg/kg to 5 mg/kg body weight, more preferably from 0.01 mg/kg to 0.5 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 250 mg, and in particular 0.5 to 50 mg of active ingredient per unit dosage form. Examples include 2 mg, 4 mg, 7 mg, 10 mg, 15 mg, 25 mg, and 35 mg dosage forms. Compounds of the invention may also be prepared in time-release or subcutaneous or transdermal patch formulations. Disclosed compound may also be formulated as a spray or other topical or inhalable formulations.
The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines.
The next section includes detailed information relating to the preparation, characterization, and use of the disclosed compounds.
E. Examples
EXAMPLE 1
Figure imgf000048_0001
1 -(3-(4-Chloro-phenyl 1 -f3-r4-(2-fluoro-phenyl Vpiperazin-1 -yl1-propyl)-1.4.6.7- tetrahydro-pyrazolo[4.3-c]pyridin-5-yl)-ethanone.
A. 1 -[3-(4-Chloro-phenyl)-1 ,4,6.7-tetrahvdro-pyrazolo[4,3-c]pyridin-5-yri- ethanone.
To a stirred solution of 50 g (0.35 mol) of /V-acetyl-4-piperidone and 31 g (0.35 mol) of morpholine in benzene (350 mL) was added a catalytic amount (~ 0.25 g) of p-toluenesulfonic acid. The mixture was heated to reflux for 10 h with a Dean-Stark trap. The solvent was removed under reduced pressure to give a brown oil. The crude product was diluted with CH2CI2 (175 mL) and 50.0 mL (0.35 mol) of Et3N was added. The mixture was cooled to 0 °C and a solution of 45.0 mL (0.35 mol) of 4-chlorobenzoyl chloride in CH2CI2 (50 mL) was added slowly by dropping funnel over 1 h. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was then diluted with 1 N HCI (150 mL) and stirred vigorously for 3 h. The aqueous layer was extracted with CH2CI2 (3 x 250 mL) and the combined extracts were dried over Na2SO4 and the solvent was removed under reduced pressure. The crude oil was diluted with EtOH (350 mL) and cooled to 0 °C. To this stirred solution was slowly added 33.0 mL (1.06 mol) of hydrazine and the mixture was allowed to warm to room temperature and stir overnight during which time a white precipitate formed. The volume of the reaction was reduced to -150 mL and EtOAc (750 mL) was added to the mixture. The suspension was stirred vigorously for 2 h and was filtered then washed with EtOAc (2 x 200 mL) and dried under vacuum to afford 41.4 g (42% over 3 steps) of a pale yellow solid. TLC (silica, 5% MeOH/CH2CI2): Rf = 0.3. MS (electrospray), mlz calculated for C14H14CIN3O [M+H]+ 276.08, observed 276.0. 1H NMR (400 MHz, CDCI3, a mixture of amide rotamers): 7.65 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 9.3 Hz, 2H), 7.58 (d, J = 10.5 Hz, 2H), 7.55 (d, J = 8.5 Hz, 2H), 4.94 (s, 2H), 4.78 (s, 2H), 4.08 (t, J = 5.9 Hz, 2H), 3.90 (t, J = 5.8 Hz, 2H), 3.02 (t, J = 5.8 Hz, 2H), 2.96 (t, J = 5.9 Hz, 2H), 2.36 (s, 3H), 2.31 (s, 3H).
B. 1 -ιr3-(4-Chloro-phenylV1 -(3-chloro-propyπ-1.4.6.7-tetrahvdro-pyrazolor4.3- c]pyridin-5-yl1-ethanone. Cs2CO3 (2.66 g, 8.2 mmol) was added to a solution of 1-[3-(4-chloro-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone (1.0 g, 5.4 mmol) in DMF (10 mL) and stirred for 15 min. 1-Bromo-3-chloropropane (1.28 g, 8.2 mmol) was added and stirred under N2 at room temperature for 36 h. Water (50 mL) was added to the reaction and stirred for 5 min. The product precipitated out. The aqueous portion was decanted and water was added to the residue and decanted again. The semisolid was taken up in CH2CI2 and passed through a short plug of SiO2 (5% MeOH/EtOAc) to obtain 1.06 g (83%) of a pale yellow semisolid. MS (electrospray): exact mass calculated for C17H19CI2N3O, 351.09; m/z found, 352.0 [M+H]+. 1H NMR (500 MHz, CDCI3, a mixture of 1 :1 rotamers): 7.60 (d, J = 8.3 Hz, 1 H), 7.53 (d, J = 8.3 Hz, 1 H), 7.40 (d, J = 8.3 Hz, 1 H), 7.36 (d, J = 8.3 Hz, 1 H), 4.77 (s, 1 H), 4.61 (s, 1 H), 4.20 (t, J = 6.2 Hz, 2H), 3.94 (t, J = 5.8 Hz, 1 H), 3.76 (t, J = 5.8 Hz, 1 H), 3.52 (q, J = 6.1 Hz, 2H), 2.84 (t, J = 5.5 Hz, 1 H), 2.77 (t, J = 5.6 Hz, 1 H), 2.37 (sextet, J = 6.1 Hz, 2 H), 2.21 (s, 1.5 H), 2.16 (s, 1.5 H).
C. 1 -(3-(4-Chloro-phenvπ-1 -(3-r4-(2-fluoro-phenvπ-piperazin-1 -yll-propylV 1.4.6.7-tetrahvdro-pyrazolo[4.3-c]pyridin-5-vπ-ethanone.
1 -[3-(4-Chloro-phenyl)-1 -(3-chloro-propyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-5-yl]-ethanone (0.053 g, 0.15 mmol) was dissolved in CH3CN (0.5 mL) and a solution of 1-(2-fluorophenyl)piperazine (0.053 g, 0.30 mmol) in CH3CN (0.5 mL) was added, followed by K2CO3 (0.031 g, 0.22 mmol) and Bu4NI (0.018 g, 0.05 mmol). The mixture was stirred at room temperature for 7 d. Preparative TLC (silica, 5% MeOH/EtOAc) afforded 30 mg (41 %) of the title compound. MS (electrospray): exact mass calculated for C27H31CIFN5O, 495.22; m/z found, 496.3 [M+H]+. 1H NMR (500 MHz, CDCI3, a mixture of 1 :1 rotamers): 7.60 (d, J = 8.3 Hz, 1 H), 7.54 (d, J = 8.3 Hz, 1 H), 7.39 (d, J = 8.3 Hz, 1 H), 7.35 (d, J = 8.3 Hz, 1 H), 7.06-6.90 (m, 4H), 4.77 (s, 1 H), 4.60 (s, 1 H), 4.10 (t, J = 6.8 Hz, 2H), 3.92 (t, J = 5.7 Hz, 1 H), 3.74 (t, J = 5.7 Hz, 1 H), 3.08 (br s, 4H), 2.83 (t, J = 5.6 Hz, 1 H), 2.77 (t, J = 5.7 Hz, 1 H), 2.58 (br s, 4H), 2.41-2.38 (m, 2H), 2.19 (s, 1.5H), 2.13 (s, 1.5H), 2.10-2.07 (m, 2H).
EXAMPLE 2
Figure imgf000050_0001
1 -{3-(4-Chloro-phenyl)-1 -[2-hydroxy-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone.
A. 1-[3-(4-Chloro-phenyl)-1-oxiranylmethyl-1.4.6.7-tetrahvdro-pyrazolo[4.3- clpyridin-5-yll-ethanone.
To a stirred solution of 1.00 g (3.63 mmol) of 1-[3-(4-chloro-phenyl)-1 ,4,6,7- tetrahydro-pyrazoIo[4,3-c]pyridin-5-yl]-ethanone and 2.85 mL (36.3 mmol) of epichlorohydrin was added 1.30 g (3.99 mmol) of solid Cs2CO3. The reaction was stirred for 48 h and the solvent was removed under reduced pressure. The residue was then diluted with H2O (50 mL) and EtOAc (50 mL). The layers were separated, and the organic layer was washed with H2O (25 mL) and brine (25 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. Purification by flash chromatography (silica, 0-15% acetone/CH2CI2) afforded 0.72 g (60%) of a white solid. TLC (silica, 5% MeOH/CH2CI2): Rf = 0.5. MS (electrospray): mlz calculated for C17H18CIN3O2 [M+H]+, 332.11 , observed 332.0. 1H NMR (400 MHz, CDCI3, a mixture of amide rotamers): 7.60 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 4.80 and 4.73 (A and B of AB quartet, Jah = 15.8 Hz, 2H), 4.60 (s, 2H), 4.47 (dd, J - 15.3, 2.5 Hz, 1 H), 4.42 (dd, J = 15.0, 2.7 Hz, 1 H), 4.11 (dd, J = 5.3, 2.5 Hz, 1 H), 4.08 (dd, J = 5.1 , 3.3 Hz, 1 H), 3.99-3.85 (m, 2H), 3.73 (dt, J = 5.9, 1.8 Hz, 2H), 3.37 (m, 2H), 2.87-2.80 (m, 3H), 2.80-2.69 (m, 3H), 2.53 (dd, J = 4.7, 2.5 Hz, 1 H), 2.48 (dd, J = 4.6, 2.6, 1 H), 2.19 (s, 3H), 2.15 (s, 3H).
B. 1 -f3-(4-Chloro-phenvO-1 -F2-hvdroxy-3-(4-o-tolyl-piperazin-1 -yl Vpropylj- 1.4.6,7-tetrahydro-pyrazolo[4.3-c1pyridin-5-yl}-ethanone. A solution of of 1-[3-(4-chloro-phenyI)-1-oxiranylmethyl-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-5-yl]-ethanone (0.8 g, 2.42 mmol) in CH2CI2 (12 mL) was treated with ytterbium(lll) triflate (0.15 g, 0.24 mmol) and 1-(0-tolyl)-piperazine (0.51 g, 2.90 mmol) at 25 °C. The reaction mixture was stirred for 24 h and diluted with EtOAc (100 mL) and H2O (50 mL). The organic layer was separated, washed with H2O (2 x 50 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 5% MeOH/CH2CI2) afforded 1.08 g (88%) of the target compound, a white powder. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.38. MS (electrospray): m/z 508.3 ([M+H]+, C28H34CIN5O2 requires 507.2). Η NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.60 and 7.37 (AB pattern, Jab = 8.8 Hz, 2H), 7.54 and 7.40 (AB pattern, Jab = 8.8 Hz, 2H), 7.18-7.14 (m, 2H), 7.00-6.97 (m, 2H), 4.85 and 4.73 (AB pattern, Jab = 15.5 Hz, 1 H), 4.62 (s, 1 H), 4.20-4.11 (m, 2H), 4.06-4.01 (m, 1 H), 3.88-3.70 (m, 2H), 2.97-2.87 (m, 6H), 2.85-2.75 (m, 2H), 2.65-2.55 (m, 2H), 2.51-2.48 (m, 2H), 2.29 (s, 3H), 2.21 (s, 1.5H), 2.17 (s, 1.5H).
EXAMPLE 3
Figure imgf000051_0001
1-{3-(4-Chloro-phenyl)-1-[2-methoxy-3-(4-o-toIyl-piperazin-1-yl)-propyl]-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone. A stirred solution of 1-{3-(4-chloro-phenyI)-1-[2-hydroxy-3-(4-o-toIyl-piperazin-1- yl)-propyl]-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone (25 mg, 0.05 mmol) in THF (0.2 mL) was treated with NaH (1.42 mg, 0.06 mmol) at 25 °C. After 20 min, methyl iodide (3.7 μL, 0.06 mmol) was added and the reaction mixture was stirred for an additional 2 h. Preparative TLC (silica, 5%
MeOH/CH2CI2) afforded 14.6 mg (56%) of a colorless film. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.38. MS (electrospray): m/z 522.2 ([M+H]+, C29H36CIN5O2 requires 521.3). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.62 and 7.37 (AB pattern, Jab = 8.8 Hz, 2H), 7.55 and 7.40 (AB pattern, Jab = 8.8 Hz, 2H), 7.18-7.14 (m, 2H), 7.02-6.95 (m, 2H), 4.82 and 4.75 (AB pattern, Jab = 15.5 Hz, 1 H), 4.62 (s, 1 H), 4.30-4.25 (m, 1 H), 4.09-3.73 (m, 4H), 3.29 (s, 1.5H), 3.27 (s, 1.5H), 2.93-2.55 (m, 12H), 2.30 (s, 3H), 2.21 (s, 1.5H), 2.16 (s, 1.5H).
EXAMPLE 4
Figure imgf000052_0001
1 -[1 -{2-Hydroxy-3-[4-(2-hydroxy-phenyl)-piperazin-1 -yl]-propyl}-3-(4-iodo- phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone.
A. 1 -r3-(4-lodo-phenyl)-1.4.6.7-tetrahvdro-pyrazolo[4.3-c1pyridin-5-yl]- ethanone.
A flask equipped with a Dean-Stark trap was charged with Λ/-acetyl-4- piperidone (27.29g, 137 mmol), piperidine (16.5 mL, 129 mmol), p-toluene- sulfonic acid (0.5 g) and benzene (150 mL). The mixture was heated to 125 °C. After 8 h the mixture was allowed to cool, and concentrated in vacuo to give the corresponding enamine (35 g). A solution of p-iodobenzoyl chloride (9.28 g, 34.8 mmol) in CH2CI2 (40 mL) was added dropwise to a 0 °C solution of the enamine (11.0 g, ca. 41 mmol) in CH2CI2 (80 mL) over 2 h. The mixture was then allowed to warm.to room temperature and stirred for an additional 17 h. The solution was treated with 1 N HCI (200 mL) and stirred vigorously for 5 h. The layers were separated and the aqueous layer was extracted with CH2CI2 (3 x 150 mL). The combined extracts were dried over Na2SO4 and concentrated. The residue was dissolved in EtOH (200 mL) and treated with NH2NH2 (16.0 mL, 51 mmol). The mixture was stirred for 17 h and H2O (300 mL) was added. The precipitate formed was collected by filtration and air dried to give 8.82 g (59%) of 1-[3-(4-iodo-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-5-yl]-ethanone which was suitable for use without further purification. TLC (silica, 5% MeOH/CH2CI2): Rf = 0.3. MS (electrospray): m/z calculated for C14H15IN3O [M+H]+ 368.03, found 368.0. Η NMR (CD3OD/CDCI3, 500 MHz, a mixture of amide rotamers): 7.72 (d, J = 8.2 Hz, 2H), 7.69 (d, J = 8.3 Hz, 2H), 7.24 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.3 Hz, 2H), 4.69 (s, 2H), 4.56 (s, 2H), 3.83 (t, J = 6.0 Hz, 2H), 3.69 (t, J = 5.8 Hz, 2H), 2.79, (t, J = 5.7 Hz, 2H), 2.72, (t, J = 5.8 Hz, 2H), 2.13 (s, 3H), 2.08 (s, 3H).
B. 1 -[3-(4-lodo-phenvD-1 -oxiranylmethyl-1.4.6.7-tetrahvdro-pyrazolor4.3- clpyridin-5-yll-ethanone.
Cs2CO3 (1.30 g, 4.01 mmol) was added to a solution of 1-[3-(4-iodo-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone (1.34 g, 3.65 mmol) and epichlorohydrin (2.85 mL, 36.4 mmol) in DMF (10.0 mL). The mixture was stirred for 17 h then partitioned between EtOAc (400 mL) and saturated
NaHCO3 (150 mL). The NaHCO3 layer was extracted with EtOAc (2 x 150 mL). The combined extracts were washed with H2O (2 x 150 mL), brine (150 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica, 10-25% acetone/CH2CI2) to give 890 mg (58%) of the title compound. HPLC , tR = 5.53 min. (Reverse phase conditions: HP 1100 LCMS, Phenomenex luna 2.1 x 150 mm column, 60% MeOH/ H2O (0.5% AcOH) to 90%MeOH/ H2O (0.5% AcOH), held at initial conditions for 2 min then ramped to final conditions over 5 min.) MS (electrospray), m/z calculated for C17H18IN3O2Na [M+Na]+ 445.04, found 445.95. 1H NMR (CDCI3, 500 MHz, a mixture of amide rotamers): 7.76 (d, J = 8.3 Hz, 2H), 7.75 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 4.80 and 4.73 (A and B of AB quartet, Jab = 15.6 Hz, 2H), 4.60 (s, 2H), 4.84 (dd, J = 15.1 , 2.1 Hz, 1 H), 4.42 (dd, = 15.0, 2.1 Hz, 1 H), 4.11 (t, J = 5.0, Hz, 1 H), 4.08 (t, J = 5.0 Hz, 1H), 3.98-3.87 (m, 2H), 3.74 (m, 2H), 3.34 (m, 2H), 2.87-2.72 (m, 6H), 2.52 (dd, J = 4.6, 2.6 Hz, 1 H), 2.48 (dd, J = 4.5, 2.6, 1 H), 2.20 (s, 3H), 2.14 (s, 3H).
C. 1 -[1 -(2-Hydroxy-3-[4-(2-hydroxy-phenvO-piperazin-1 -yl"j-propyl}-3-(4-iodo- phenyl)-1.4.6.7-tetrahvdro-pyrazolo[4.3-c1pyridin-5-vπ-ethanone.
1 -[3-(4-lodo-phenyl)-1 -oxiranylmethyl-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin- 5-yl]-ethanone (62 mg, 0.15 mmol) and 4-(2-hydroxyphenyl)-piperazine (34 mg, 0.19 mmol) were combined in CH2CI2 (0.5 mL) and the solution treated with Yb(OTf)3 »H2O (44 mg, 0.071 mmol). The mixture was shaken for 72 h then diluted with CH2CI2 (1 mL). Purification by preparative TLC (silica, 10% MeOH/CH2CI2) gave 45 mg (51 %) of an off-white powder. TLC (silica, 8% MeOH/CH2CI2): R, = 0.2. MS (electrospray): m/z calculated for C27H33IN5O3 [M+H]+ 602.15, found 602.2. 1H NMR (CDCI3, 500 MHz, a mixture of amide rotamers): 7.76 (d, J = 8.6 Hz, 1 H), 7.72 (d, J = 8.6 Hz, 1 H), 7.42 (d, J = 8.5 Hz, 1 H), 7.34 (d, J = 8.5 Hz, 1 H), 7.14 (m, 1 H), 7.80 (t, J = 7.7 Hz, 1 H), 6.94 (d, J = 8.1 Hz, 1 H), 6.86 (t, J = 7.7 Hz, 1 H), 4.83 and 4.72 (A and B of AB quartet, Jab = 15.6 Hz, 1 H), 4.61 (s, 1 H), 4.22-4.15 (m, 2H), 4.02 (m, 2H), 3.88 (m, 1 H), 3.76 (m, 3H), 3.00-2.49 (m, 11 H), 2.20 (s, 1.5H), 2.15 (s, 1.5H).
EXAMPLE 5
Figure imgf000054_0001
1 -[1 -[2-Hydroxy-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-3-(4-trifluoromethyl-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yI]-ethanone.
A. 1 -[3-(4-Trifluoromethyl-phenyπ-1 ,4,6,7-tetrahydro-pyrazolo[4.3-c]pyridin-5- yl]-ethanone. A solution of Λ/-acetyl-4-piperidone (2.82 g, 20 mmol), morpholine (1.93 mL, 22 mmol) and p-toluenesulfonic acid (5 mg) in benzene (8.5 mL) was refluxed for 8 h in a Dean-Stark apparatus. The solvent was removed and the residue dissolved in CH2CI2 (20 mL). Triethylamine (3.1 mL) was added and p- trifluoromethylbenzoyl chloride (3.27 mL, 22 mmol) in CH2CI2 (4 mL) was added dropwise into the solution at 0 °C. The reaction mixture was stirred at 25 °C for 24 h and diluted with aqueous HCI (5%, 25 mL). After stirring for another 30 min, the organic layer was separated, washed with H2O (20 mL), dried (Na2SO4), and concentrated. The residue was dissolved in EtOH (95%, 18 mL) and treated at 0 °C with hydrazine (2.9 mL, 60 mmol). The mixture was stirred at 25 °C for 3 h and H2O (4 mL) was added. Most of the volatiles were removed and the residue extracted with CH2CI2 (50 mL). The organic layer was separated, washed with H2O (20 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 5% MeOH/CH2CI2) provided 5.1 g (83%) of a white powder. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.30. MS (electrospray): m/z 332.0 ([M+Na]+, C15H14F3N3O requires 309.1 ). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.73-7.67 (m, 4H), 4.85 (s, 1.2H), 4.68 (s, 0.8H), 3.96 (t, J = 4.5 Hz, 0.8H), 3.78 (t, J = 4.5 Hz, 1.2H), 2.89 (t, J = 4.5 Hz, 1.2H), 2.83 (t, J = 4.5 Hz, 0.8H), 2.23 (s, 1.8H), 2.18 (s, 1.2H).
B. 1-[1-Qxiranylmethyl-3-(4-trifluoromethyl-phenyl)-1.4.6.7-tetrahvdro- pyrazolo[4.3-clpyridin-5-yl1-ethanone
A solution of 1-[3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-5-yl]-ethanone (2.4 g, 7.77 mmol) in DMF (15 mL) was treated with cesium carbonate (5.05 g, 15.5 mmol) and epichlorohydrin (6.1 mL, 77.7 mmol) at 25 °C and stirred for 24 h before it was diluted with EtOAc (100 mL) and H2O (50 mL). The organic layer was separated, washed with H2O (2 x 50 mL), brine (50 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 10% acetone/CH2CI2) provided 2.30 g (81 %) of a white powder. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.35. MS (electrospray): m/z 388.0 ([M+Na]\ C18H18F3N3O2 requires 365.1). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.77 and 7.63 (AB pattern, Jab = 8.2 Hz, 2H), 7.71 and 7.67 (AB pattern, Jab = 8.4 Hz, 2H), 4.82 and 4.76 (AB pattern, Jab = 15.5 Hz, 1.2H), 4.58 (s, 0.8H), 4.45-4.35 (m, 1 H), 4.08-4.02 (m, 1 H), 3.92-3.80 (m, 1 H), 3.70-3.63 (m, 1 H), 3.30 (m, 1 H), 2.80-2.67 (m, 3H), 2.48-2.42 (m, 1 H), 2.13 (s, 1.3H), 2.08 (s, 1.7H).
C. 1 -[1 -[2-Hvdroxy-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-3-(4-trifluoromethyl- phenyl)-1.4.6.7-tetrahydro-pyrazolo[4.3-c1pyridin-5-yll-ethanone.
A solution of 1-[1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-5-yl]-ethanone (1.16 g, 3.20 mmol) in CH2CI2 (15 mL) was treated with ytterbium(lll) triflate (0.40 g, 0.64 mmol) and l-(O-tolyl)- piperazine (0.84 g, 4.77 mmol) at 25 °C and stirred for 48 h before it was diluted with CH2CI2 (100 mL) and H2O (50 mL). The organic layer was separated, washed with H2O (2 x 50 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 5% MeOH/CH2CI2) afforded 1.54 g (89%) of a white powder. TLC (silica, 10% MeOH/CH2CI2): R, = 0.35. MS (electrospray): m/z 542.3 ([M+H]+, C29H34F3N5O2 requires 541.3). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.82 and 7.65 (AB pattern, Jab = 8.2 Hz, 2H), 7.72 and 7.68 (AB pattern, Jab = 8.4 Hz, 2H), 7.18-6.97 (m, 4H), 4.88 and 4.76 (AB pattern, Jab = 16 Hz, 0.9H), 4.65 (s, 1.1 H), 4.23-4.12 (m, 2H), 4.08-4.00 (m, 2H), 3.88-3.70 (m, 2H), 3.02-2.85 (m, 6H), 2.85-2.75 (m, 2H), 2.65-2.55 (m, 2H), 2.53-2.45 (m, 2H), 2.29 (s, 3H), 2.21 (s, 1.8H), 2.17 (s, 1.2H).
EXAMPLE 6
Figure imgf000056_0001
2-(4-{3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitriIe.
A solution of 1 -[1 -oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-5-yl]-ethanone (0.84 g, 2.30 mmol) in CH2CI2 (10 mL) was treated with ytterbium(lll) triflate (0.29 g, 0.46 mmol) and 1-(2- cyanophenyl)-piperazine (0.75 g, 3.5 mmol) at 25 °C and stirred for 48 h before it was diluted with CH2CI2 (100 mL) and H2O (50 mL). The organic layer was separated, washed with H2O (2 x 50 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 5% MeOH/CH2CI2) afforded 1.15 g (90%) of light yellow crystals. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.30. MS (electrospray): m/z 553.3 ([M+H]+, C29H31F3N6O2 requires 552.3). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.82 and 7.68 (AB pattern, Jab = 8.2 Hz, 2H), 7.76 and 7.72 (AB pattern, Jab = 8.4 Hz, 2H), 7.60-7.48 (m, 2H), 7.05-7.00 (m, 2H), 4.90 and 4.78 (AB pattern, Jab = 16 Hz, 1 H), 4.69 (s, 1 H), 4.30-3.71 (m, 6H), 3.25 (m, 4H), 3.02-2.75 (m, 4H), 2.70-2.65 (m, 2H), 2.60- 2.53 (m, 2H), 2.23 (s, 1.5 H), 2.18 (s, 1.5H).
EXAMPLE 7
Figure imgf000057_0001
1 -[3-(3,4-Dichloro-phenyl)-pyrazol-1 -yl]-3-(4-o-tolyl-piperazin-1 -yl)-propan-2-ol.
A. 3-(3.4-Dichloro-phenyπ-1-oxiranylmethyl-1 H-pyrazole. A stirred solution of 3-(3,4-dichlorophenyl)pyrazole (300 mg, 1.4 mmol) in DMF (5 mL) was treated with cesium carbonate (550 mg, 1.69 mmol) and epichlorohydrin (1.1 mL, 14.0 mmol) at room temperature for 18 h. The crude reaction mixture was then partitioned between EtOAc (50 mL) and water (35 mL). The aqueous phase was further extracted (2 x 50 mL) and the combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to yield crude product. Purification by column chromatography (silica, 25% EtOAc/hexanes) afforded 308 mg (82%) of the title compound. 1NMR (400 MHz, CDCI3): 7.83 (d, J = 2 Hz, 1 H), 7.54 (dd, J = 2, 8 Hz, 1 H), 7.44 (d, J =2 Hz, 1 H), 7.38 (d, J = 8 Hz, 1 H), 6.48 (d, J =2 Hz, 1H), 4.45 (dd, J = 3, 9.7 Hz, 1 H), 4.12 (dd, J = 6, 15 Hz, 1 H), 3.31 (m, 1H), 2.81 (dd, J = 4.0, 4.6 Hz, 1 H), 2.47 (dd, J = 2.6, 4.7 Hz, 1 H).
B. 1-r3-(3.4-Dichloro-phenvπ-pyrazol-1-vn-3-(4-o-tolyl-piperazin-1-vπ-propan-2- oL
A solution of 3-(3,4-dichloro-phenyl)-1-oxiranylmethyI-1 H-pyrazole (30 mg, 0.11 mmol) and 1-(2-methylphenyl)-piperazine (22 mg, 0.12 mmol) in EtOH (1 mL) was heated to 80 °C overnight. Removal of solvent and purification by column chromatography (silica, 0-5% acetone/CH2CI2) afforded 35 mg (70%) of the title compound. 1H NMR (400 MHz, CDCI3): 7.89 (d, J = 2 Hz, 1 H), 7.61 (dd, J = 2, 8.7 Hz, 1 H), 7.57 (d, J = 2 Hz, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 7.16 (m, 2H), 6.99 (m, 2H), 6.54 (d, J = 2.3 Hz, 1 H), 4.31 (m, 1 H), 4.18 (m, 2H), 2.93 (m, 4H), 2.60 (m, 2H), 2.47 (m, 3H), 2.88 (s, 3H).
EXAMPLE 8
Figure imgf000058_0001
1 -[1 -[2-(2-Piperazin-1 -yI-ethylamino)-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone.
A. 1-[5-Acetyl-3-(4-trifluoromethyl-phenvπ-4.5.6.7-tetrahydro-pyrazolo[4.3- c]pyridin-1 -yl1-3-(4-o-tolyl-piperazin-1 -vD-propan-2-one. A solution of DMSO (3.55 mL, 50 mmol) in CH2CI2 (7 mL) was treated with oxalyl chloride (2.90 mL, 33 mmol) at -78 °C and stirred for 30 min. A solution of 1 -[1 -[2-hydroxy-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-3-(4-trifluoromethyl- phenyl)-1 ,4,6,7-tetrahydro-pyrazoIo[4,3-c]pyridin-5-yl]-ethanone (1.8 g, 3.3 mmol) in CH2CI2 (7 mL) was then slowly added and the reaction mixture was stirred for an additional 30 min before it was quenched with addition of triethylamine (18.4 mL, 132 mmol). The reaction mixture was slowly warmed to 25 °C and diluted with EtOAc (50 mL) and sat. NaHCO3 (30 mL). The organic layer was separated, washed with H2O (2 x 50 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 2-5% MeOH/CH2CI2) afforded 1.50 g (83%) of a light yellow powder. TLC (silica, 10% MeOH/CH2CI2): R, = 0.35. MS (electrospray): m/z 540.3 ([M+H]\ C29H32F3N5O2 requires 539.3). Η NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.78 and 7.62 (AB pattern, Jab = 8.2 Hz, 2H), 7.70 and 7.64 (AB pattern, Jab = 8.4 Hz, 2H), 7.18-6.95 (m, 4H), 5.10 (s, 1 H), 5.07 (s, 1 H), 4.84 (s, 1 H), 4.68 (s, 1 H), 3.96 (t, J = 4.4 Hz, 1 H), 3.78 (t, J = 4.4 Hz, 1 H), 3.47 (3.47 (s, 4H), 3.34 (s, 2H), 2.74-2.65 (m, 6H), 2.29 (s, 3H), 2.20 (s, 1.5H), 2.17 (s, 1.5H).
B. 1 -[1 -[2-(2-Piperazin-1 -yl-ethylamino)-3-(4-o-tolyl-piperazin-1 -yl)-propyl1-3-(4- trifluoromethyl-phenvπ-1.4.6.7-tetrahvdro-pyrazolo[4.3-c]pyridin-5-yl]-ethanone. A solution of 1-[5-acetyI-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-3-(4-o-tolyl-piperazin-1-yl)-propan-2-one
(54 mg, 0.1 mmol) in 1 ,2-dichloroethane (0.5 mL) was treated with 1-(2- aminoethyl)piperazine (26 μL, 0.2 mmol) and glacial acetic acid (34 μL, 0.6 mmol) at 25 °C and stirred for 30 min. Sodium triacetoxyborohydride (63.6 mg, 0.3 mmol) was added and the reaction mixture was stirred for an additional 4 h before it was quenched with CH2CI2 (5 mL) and sat. NaHCO3 (5 mL). The organic layer was separated, washed with H2O (2 x 5 mL), dried over Na2SO4, and concentrated. Preparative TLC (silica, 10% MeOH/CH2CI2) afforded 22 mg (35%) of a light yellow film. TLC (10% MeOH/CH2CI2): Rf = 0.2. MS (electrospray): m/z 653.3 ([M+H]+, C35H47F3N8O requires 652.4). H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.78-7.60 (m, 4H), 7.18-6.82 (m, 4H), 4.88-4.30 (m, 2H), 4.23-3.90 (m, 2H), 3.85-3.70 (m, 2H), 3.22-2.85 (m, 10H), 2.85-2.30 (m, 15H), 2.30 (s, 3H), 2.21 (s, 1.5H), 2.17 (s, 1.5H). EXAMPLE 9
Figure imgf000060_0001
1 -{3-[4-(2-Cyano-phenyl)-piperazin-1 -yl]-2-hydroxy-propyl}-3-(4-iodo-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester.
A. 3-(4-lodo-phenyl)-1.4.6.7-tetrahvdro-pyrazolor4.3-c]pyridine-5-carboxylic acid tert-butyl ester. p-ToIuenesulfonic acid (0.055 g. 0.29 mmol) and morpholine (4.76 mL, 54 mmol) were added to a solution of tert-butyl 4-oxo-1-piperidinecarboxylate (10.3 g. 52 mmol) in benzene (22 mL). The reaction mixture was heated in a flask equipped with a condenser and a Dean-Stark trap at reflux for 20 h. The reaction mixture was cooled and concentrated in vacuo to give the enamine which was used without further purification. The enamine was dissolved in CH2CI2 (60 mL) and cooled to 0°C. Triethylamine (8.67 mL, 62 mmol) was added, followed by dropwise addition of 4-iodobenzoyI chloride (13.8 g, 52 mmol) dissolved in CH2CI2 (10 mL). The reaction mixture was allowed to warm to room temperature and stirred for 72 h. The reaction mixture was poured over water (200 mL) and the CH2CI2 layer was separated, dried (Na2SO4), and concentrated. The resulting oil was taken up in EtOH (200 mL) and treated with hydrazine (4.88 mL, 155 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 17 h. The mixture was concentrated and the resulting material was triturated with EtOAc to afford 9.52 g (43%) of a white solid. TLC (silica, 10% acetone/CH2CI2): Rf= 0.18. MS
(electrospray): m/z 426.0 (426.1 calculated for C17H20IN3O2, [M+H]+). 1H NMR (400 MHz, CDCI3): 7.74 (br s, 2H), 7.31 (br d, J = 8.0 Hz, 2H), 4.63 (br s, 2H), 3.73 (br s, 2H), 2.77 (br s, 2H), 1.49 (s, 9H). B. 3-(4-lodo-phenv0-1 -oxiranylmethyl-1 ,4,6.7-tetrahydro-pyrazolor4,3- c]pyridine-5-carboxylic acid tert-butyl ester.
Cesium carbonate (1.84 g, 5.65 mmol) was added to a solution of epichlorohydrin (3.68 mL, 47.05 mmol) and 3-(4-iodo-phenyl)-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (2.0 g, 4.71 mmol) in DMF (10 mL). The reaction mixture was allowed to stir for 24 h, then partitioned between aqueous NaHCO3 and EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica, 0-10% acetone/CH2CI2) afforded 2.26 g (69%) of a white foam. TLC (silica, 10% acetone/CH2CI2): Rf = 0.44. MS (electrospray): m/z 482.0 (482.1 calculated for C20H24IN3O3, [M+H]+). 1H NMR (400 MHz, CDCI3): 7.60 (br s, 2H), 7.28 (br d, J = 8.2 Hz, 2H), 4.48 (br s, 2H), 4.32 (br d, J = 14.8 Hz, 1 H), 3.99 (dd, J = 15.0, 5.4 Hz, 1 H), 3.61 (br s, 1 H), 3.26-3.20 (m, 1 H), 2.72 (t, J = 4.4 Hz, 1 H), 2.65-2.58 (m, 2H), 2.40 (br s, 1 H), 1.36 (s, 9H).
C. 1 -{3-[4-(2-Cvano-phenvO-piperazin-1 -vπ-2-hvdroxy-propyl)-3-(4-iodo- phenvO-1 ■4.6.7-tetrahvdro-pyrazolor4.3-clPyridine-5-carboxylic acid tert-butyl ester. Ytterbium (III) trifluoromethanesulfonate hydrate (0.193 g, 0.311 mmol) and 1- (2-cyanophenyl)-piperazine (0.292 g, 1.56 mmol) were dissolved in CH2CI2 (2 mL) and added to a solution of 3-(4-iodo-phenyl)-1-oxiranylmethyl-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester in CH2CI2 (5 mL). The reaction mixture was allowed to stir for 48 h at 25 °C. Purification by flash chromatography (silica, 0-15% acetone/CH2CI2) afforded 392 mg (56%) of a white foam. TLC (silica, 10% acetone/CH2CI2): Rf= 0.41. MS (electrospray): m/z 669.2 (669.2 calculated for C31H37IN6O3, [M+H]+). 1H NMR (400 MHz, CDCI3): 7.73 (br s, 2H), 7.58-7.56 (m, 1 H), 7.52-7.48 (m, 1 H), 7.39 (br d, J = 7.1 Hz, 2H), 7.04-7.00 (m, 2H), 4.60 (br s, 2H), 4.06-4.04 (m, 2H), 4.06-4.04 (m, 1 H), 3.76-3.70 (m, 2H), 3.26 (br s, 4H), 2.84-2.38 (m, 7H), 1.56-1.53 (m, 2H), 1.48 (s, 9H). EXAMPLE 10
Figure imgf000062_0001
1-{3-[4-(2-Cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl}-3-(4-iodo-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.
A. 2-(4-f2-Hvdroxy-3-r3-(4-iodo-phenvπ-4.5.6.7-tetrahvdro-pyrazolof4.3- c]pyridin-1 -yπ-propyl)-piperazin-1 -ylVbenzonitrile.
Trifluoroacetic acid (3 mL) was added to a solution of 1-{3-[4-(2-cyano-phenyl)- piperazin-1 -yl]-2-hydroxy-propyl}-3-(4-iodo-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (0.402 g, 0.601 mmol) in CH2CI2 (3 mL) and the reaction mixture was stirred for 2 h. The mixture was concentrated, then diluted with EtOAc. The organic layer was washed with aqueous NaHCO3 and brine, dried (Na2SO4), and concentrated to afford the amine (0.342 g, 100%) as a yellowish foam. TLC (silica, 10% acetone/CH2CI2): Rf= 0.14. MS (electrospray): m/z 569.2 (569.1 , calculated for C26H29IN6O, [M+H]+). 1H NMR (400 MHz, CDCI3:CD3OD(6:1 )): 7.73 (d, J = 8.6 Hz, 2H), 7.56 (dd, J = 7.6, 1.8 Hz, 1 H), 7.52 (t, J = 8.0 Hz, 1 H), 7.25 (d, J = 8.6 Hz, 2H), 7.09 (t, J = 7.6 Hz, 1 H), 7.02 (dd, J = 8.4 Hz, 1 H), 4.43-4.36 (m, 1 H), 4.31 (s, 2H), 4.21 (dd, J = 14.1 , 4.5 Hz, 1 H), 4.11 (dd, J = 14.5, 6.3 Hz, 1 H), 3.54-3.49 (m, 2H), 3.40-3.24 (m, 8H), 3.18-3.06 (m, 3H), 3.03-2.95 (m, 3H).
B. 1 -f3-[4-(2-Cyano-phenvπ-piperazin-1 -yl1-2-hydroxy-propyl}-3-(4-iodo- phenvO-1 ,4.6.7-tetrahvdro-pyrazolo[4.3-c]pyridine-5-carboxylic acid amide. Diisopropylethylamine (0.531 mL, 3.05 mmol), DMAP (5 mg), and trimethylsilyl isocyanate (0.413 mL, 3.05 mmol) were added to a solution of 2-(4-{2-hydroxy- 3-[3-(4-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}- piperazin-1-yl)-benzonitrile in pyridine (3 mL) and CH2CI2 (6 mL). The reaction mixture was stirred for 20 h, then partitioned between aqueous NaHCO3 and CH2CI2. The CH2CI2 layer was washed with brine, dried (Na2S04), and concentrated. The resulting product was dissolved in CH2CI2 (5 mL) and treated with 21 wt% sodium ethoxide in EtOH (0.5 mL) for 3 h. The reaction mixture was washed with brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica, 0-10% MeOH/CH2CI2) afforded 290 mg (78%) of the title compound. HPLC (reverse phase conditions), tR = 4.21 min. MS (electrospray): m/z 612.2 (612.5, calculated for C27H30IN7O2, M++H). 1H NMR (400 MHz, CDCI3): 7.73 (d, J = 8.6 Hz, 2H), 7.57 (dd, J = 7.6, 1.6 Hz, 1 H), 7.50 (t, J = 7.8 Hz, 1 H), 7.36 (d, J = 8.6 Hz, 2H), 7.05 (t, J = 7.6 Hz, 1 H), 7.00 (d, J = 8.4 Hz, 1 H), 4.64 (br s, 2H), 4.57 (br s, 2H), 4.30 (br s, 1 H), 4.20 (dd, J = 14.1 , 3.3 Hz, 1 H), 4.06 (dd, J = 14.1 , 6.3 Hz, 1 H), 3.82-3.65 (m, 2H), 3.29- 3.20 (m, 4H), 3.04-2.80 (m, 6H), 2.68 (br s, 2H).
EXAMPLE 11
Figure imgf000063_0001
Carbamic acid 1 ~[5-carbamoyI-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-ylmethyl]-2-[4-(2-cyano-phenyl)-piperazin-1-yl]-ethyl ester.
The title compound (13 mg, 3%) was obtained along with 1-{3-[4-(2-cyano- phenyl)-piperazin-1-yl]-2-hydroxy-propyl}-3-(4-iodo-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridine-5-carboxylic acid as described in example 10. MS (electrospray): m/z 655.2 (655.2, calculated for C28H31IN8O3, [M+H]+). HPLC (reverse phase conditions): tR = 6.29 min. 1H NMR (400 MHz, CDCI3): 7.69 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 7.52, 1 H), 7.43 (t, J = 8.1 Hz, 1 H), 7.31 (d, J = 8.1 Hz, 2H), 6.96 (t, J = 9.0 Hz, 2H), 4.64 (br s, 2H), 4.08 (d, J = 16.8 Hz, 2H), 3.96 (dd, J = 14.0, 6.6 Hz, 1 H), 3.80-3.69 (m, 2H), 3.10-2.80 (m, 4H), 2.66 (br s, 2H), 2.50 (br s, 2H). EXAMPLE 12
Figure imgf000064_0001
1 -{3-(3-Amino-4-chloro-phenyl)-1 -[2-hydroxy-3-(4-o-tolyl-piperazin-1 -yI)-propyl]- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone.
A. 1 -r3-(4-Chloro-3-nitro-phenv0-1 Aej-tetrahvdro-pyrazolo^.S-clpyridin-δ-yl]- ethanone.
A flask equipped with a Dean-Stark trap was charged with Λ/-acetyl-4- piperidone (27.29g, 137 mmol), piperidine (16.5 mL, 129 mmol), p-toluene- sulfonic acid (0.5 g) and benzene (150 mL). The mixture was heated to 125 °C. After 8 h the mixture was allowed to cool, and concentrated in vacuo to give the corresponding enamine (35 g). A solution of the enamine (3.87 g, 20.0 mmol) in dichloromethane (24 mL) was treated with triethylamine (3.07 mL, 22.0 mmol) and 4-chloro-3-nitrobenzoyl chloride (4.84 g, 22.0 mmol). The reaction mixture was stirred at 0 °C for 1 h and then at room temperature for 16 h. Hydrazine (1.88 mL, 60 mmol) was added to the reaction mixture. This solution was stirred at room temperature for an additional 16 h. The solvents were removed under reduced pressure. Ethyl acetate (100 mL) was added to the residue to form a suspension. This suspension was filtered and dried to afford 6.4 g (100%) of a yellow solid. MS (electrospray): m/z 321.0 (321.0, calculated for C14H13CIN4O3, [M+H]+). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 8.10-8.00 (m, 3H), 4.90 (s, 0.8H), 4.85 (s, 1.2H), 3.96 (m, 2H), 2.95 (m, 2H), 2.20 (s, 3H).
B. 1 -r3-(4-Chloro-3-nitro-phenvπ-1 -oxiranylmethyl-1 ,4.6.7-tetrahvdro- pyrazolor4.3-clpyridin-5-yr]-ethanone.
A solution of 1-[3-(4-chloro-3-nitro-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-5-yl]-ethanone (6.4 g, 20.0 mmol) in DMF (60 mL) was treated with cesium carbonate (13.0 g, 40 mmol) and epichlorohydrin (15.6 mL, 200.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for an additional 24 h before it was diluted with ethyl acetate (350 mL) and water (50 mL). The organic layer was separated, washed with water (2 x 50 mL), brine (50 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, 10% acetone/CH2CI2) to provide 7.5 g (83%) of a light yellow powder. MS (electrospray): m/z 377.0 (377.0, calculated for C17H17CIN4O4, [M+H]+). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 8.15-8.05 (m, 1 H), 7.75-7.65 (m, 1 H), 7.55-7.45 (m, 1 H), 4.80-4.65 (m, 1.2H), 4.60 (s, 0.8H), 4.45-4.35 (m, 1 H), 4.08-4.02 (m, 1 H), 3.92-3.80 (m, 1 H), 3.70-3.63 (m, 1 H), 3.30-3.20 (m, 1 H), 2.90-2.67 (m, 3H), 2.55-2.48 (m, 1 H), 2.15 (s, 1.7H), 2.10 (s, 1.3H).
C. 1 -{3-(4-Chloro-3-nitro-phenyl)-1 -[2-hvdroxy-3-(4-o-tolyl-piperazin-1 -vD- propyl]-1.4.6.7-tetrahydro-pyrazolo[4.3-c1pyridin-5-yl -ethanone.
A solution of 1-[3-(4-chloro-3-nitro-phenyl)-1-oxiranylmethyl-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-5-yl]-ethanone (0.754 g, 2.0 mmol) in dichloromethane (10 mL) was treated with ytterbium(lll) triflate (0.25 g, 0.40 mmol) and 1-(2- methylphenyl)-piperazine (0.705 g, 4.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h and diluted with dichloromethane (100 mL) and water (50 mL). The organic layer was separated, washed with water (2 x 50 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica, 5% MeOH/CH2CI2) to afford 0.98 g (90%) of the desired product as a light yellow solid. MS (electrospray): m/z 553.2 (553.2, calculated for C28H33CIN6O4, [M+H]+). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 8.25-8.15 (m, 1 H), 7.75-7.70 (m, 1 H), 7.63-7.55 (m, 1 H) 7.20- 7.10(m, 2H), 7.05-6.95 (m, 2H), 4.90-4.70 (m, 1 H), 4.65 (s, 1 H), 4.30-4.15 (m, 2H), 4.10-3.70 (m, 4H), 3.00-2.40 (m, 12H), 2.20(s, 3H), 2.15 (s, 1.5H), 2.10 (s, 1.5H).
P. 1 -(3-(3-amino-4-chloro-phenvπ-1 -[2-hvdroxy-3-(4-o-tolyl-piperazin-1 -ylV propyl1-1.4.6.7-tetrahvdro-pyrazolor4.3-c1pyridin-5-yl1-ethanone. To a solution of sodium hydrosulfite (1.28 g, 7.3 mmol) in 30 mL water was added 1 -{3-(4-chloro-3-nitro-phenyl)-1 -[2-hydroxy-3-(4-o-tolyl-piperazin-1 -yl)- propyl]-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone (810 mg, 1.5 mmol) in 15 mL THF. The reaction mixture was stirred at room temperature for 5 min. The color of the solution changed from light yellow to colorless.
Hydrochloride solution (1 N, 10 mL) was added to the reaction mixture. This solution was stirred at room temperature for 30 min, and treated with saturated sodium bicarbonate until the pH of the solution between 7 to 8. The product was extracted with dichloromethane (3 x 80 mL). The organic phases were combined, dried over sodium sulfate, and concentrated under reduced pressure to a residue. This residue was purified by column chromatography (silica, 5-20% MeOH/CH2CI2) to afford 644 mg (84.1 %) of the title compound. MS (electrospray): m/z 523.3 (523.3, calculated for C28H35CIN6O2, [M+H]+). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.30-6.70 (m, 7H), 4.80- 4.60 (m, 1 H), 4.55 (s, 1 H), 4.20-4.05 (m, 4H), 3.95-3.90 (m, 2H), 3.80-3.60 (m, 2H), 2.90-2.30 (m, 9H), 2.20 (s, 3H), 2.15 (s, 1.5H), 2.10 (s, 1.5H).
EXAMPLE 13
Figure imgf000066_0001
(f?)-1 -(3-(4-Bromo-phenyl)-1 -{3-[4-(5-chloro-2-methyl-phenyl)-piperazin-1 -yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone.
A. (2SV1 -.erf-Butyldimethylsilylαlvcidol. terf-Butylchlorodimethylsilane (9.41 g, 62.4 mmol) followed by Et3N (13.5 mL, 96.8 mmol) was added to a 0 °C solution of f?-(+)-glycidol (3.88 g, 52.4 mmol) in CH2CI2 (100 mL). The solution was allowed to warm to 23 °C with stirring over 17h. The resulting pink solution was diluted with Et20 (250 mL) and stirred an additional 30 min. The solution was partitioned between Et2O (800 mL) and sat. aqueous NaHCO3 (200 mL). The Et20 layer was washed with sat. aqueous NaHCO3 (250 mL), H2O (3 x 200 mL), brine (100 mL), dried over Na2SO4 and concentrated. Purification of the residue by column chromatography (silica, 5-10% Et2O/hexanes) provided 8.21 g (84%) of the title compound. TLC (silica, 10% Et2O/hexanes): Rf = 0.5. 1H NMR (CDCI3, 400 MHz): 3.85 (dd, J = 11.9, 3.2 Hz, 1 H), 3.66 (dd, J = 11.9, 4.8 Hz, 1 H), 3.09 (m, 1 H), 2.77 (dd, J = 5.0, 4.2 Hz, 1 H), 2.64 (dd, J = 5.2, 2.7 Hz, 1 H), 0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H).
B. 1 -r3-(4-Bromo-phenvπ-1 Aej-tetrahvdro-pyrazolo^.S-clpyridin-δ-yri- ethanone.
A flask equipped with a Dean-Stark trap was charged with /V-acetyl-4- piperidone (100.1 g, 709 mmol), piperidine (68 mL, 779 mmol), pTsOH (3.7 g) and benzene (500 mL). The mixture was heated to 125 °C. After 17 h the mixture was allowed to cool and divided into two portions. A solution of p- bromobenzoyl chloride (70.0 g, 319 mmol) in CH2CI2 (400 mL) was added dropwise to a 0 °C solution of the enamine (ca. 355 mmol) in CH2CI2 (320 mL) over 15 h. The mixture was then allowed to warm to 23 °C and stirred for an additional 5 h. The solution was treated with 1 N HCI (500 mL) and stirred vigorously for 1.5 h. The layers were separated and the aqueous layer was extracted with CH2CI2 (2 x 300 mL). The combined extracts were washed with sat. aqueous NaHCO3 (300 mL), H2O (300 mL), brine (300 mL), dried over Na2SO4 and concentrated. The residue was dissolved in MeOH (300 mL) and treated with NH2NH2 (50.0 mL, 1.59 mol). The mixture was stirred for 17 h before the precipitate formed was collected by filtration and air dried to give 52 g (50%) of the title compound which was suitable for use without further purification. TLC (silica, 5% MeOH/CH2CI2): Rf = 0.3. MS (electrospray): m/z calculated for C14H15 79BrN3O [M+H]+, 320.04, found 320. 1H NMR (CD3OD/CDCI3, 400 MHz, a mixture of amide rotamers): 7.53 and 7.35 (A and B of AA'BB', J = 8.5 Hz, 2H), 7.51 and 7.39 (A and B of AA'BB', J = 8.6 Hz, 2H), 4.72 (s, 2H), 4.58 (s, 2H), 3.85 (t, J = 5.9 Hz, 2H), 3.71 (t, J = 5.8 Hz, 2H), 2.81 , (t, J = 5.8 Hz, 2H), 2.74, (t, J = 5.8 Hz, 2H), 2.16 (s, 3H), 2.11 (s, 3H). C. (SV1 -[3-(4-Bromo-phenv0-1 -oxiranylmethyl-1 ,4,6,7-tetrahvdro-pyrazolor4,3- c]pyridin-5-yl]-ethanone.
A solution of KHMDS in toluene (0.5 M, 3.7 mL, 1.85 mmol) was added to a 0 °C solution of 1-[3-(4-bromo-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin- 5-yl]-ethanone (492 mg, 1.54 mmol) in DMF (4.0 mL). The mixture was stirred for 1 h before (2S)-1-te/ιf-butyldimethylsilylglycidol (870 mg, 4.62 mmol) was added neat via syringe. The mixture was stirred an additional 48 h and partitioned between EtOAc (300 mL) and sat. aqueous NaHCO3 (100 mL). The aqueous layer was extracted with EtOAc (2 x 100 mL). The combined extracts were washed with H2O (2 x 100 mL), brine (100 mL), dried over Na2SO4 and concentrated. The residue was dissolved in MeOH (50 mL) and treated with CSA (97 mg). The mixture was stirred for 17 h and concentrated to dryness. The residue was suspended in MeC(OMe)3 (50 mL) and stirred for an additional 17 h. The mixture was diluted with EtOAc (400 mL) and washed with saturated aqueous NaHCO3 (50 mL), H2O (2 x 50 mL), brine (50 mL), dried over Na2SO4 and concentrated. The crude orthoester was dissolved in CH2CI2 (5 mL), cooled to 0 °C, and treated with AcBr (0.18 mL, 2.4 mmol). The mixture was allowed to warm with stirring over 4 h before being worked up as described above. The crude acetyl-bromide obtained was dissolved in MeOH (50 mL), treated with K2CO3 (207 mg, 1.50 mmol) and stirred for 4 h. The reaction mixture was diluted with EtOAc (400 mL) and washed with saturated aqueous NH4CI (100 mL). The EtOAc layer was washed with H2O (2 x 100 mL), brine (100 mL), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (silica, 10-40% acetone/CH2CI2) to afford 158 mg (27%) of the title compound. Chiral HPLC (Daicel OD, 0.5% Et2NH/MeOH) analysis indicated >95% optical purity. HPLC (reverse phase conditions): fR = 4.90 min. MS (electrospray): m/z calculated for C17H19 79BrN3O2 [M++H], 376.07, found 376.0. 1H NMR (CDCI3, 400 MHz, a mixture of amide rotamers): 7.47 (d with fine splittings (partially obscured), J = 8.5, Hz, 2H), 7.44 (m, 4H), 7.38 (d with fine splittings, J = 8.5, Hz, 2H), 4.71 and 4.64 (A and B of AB quartet, Jab = 15.7 Hz, 2H), 4.51 (s, 2H), 4.39 (dd, J = 15.1 , 2.5 Hz, 1 H), 4.34 (dd, J = 15.0, 2.9 Hz, 1 H), 4.02 (dd, J = 5.2, 3.9 Hz, 1 H), 3.98 (dd, J = 5.3, 3.7 Hz, 1 H), 3.83 (m, 2H), 3.64 (m, 2H), 3.25 (br m, 2H), 2.80-2.60 (m, 6H), 2.46 (dd, J = 4.6, 2.6 Hz, 1 H), 2.38 (dd, J = 4.6, 2.6 Hz, 1 H), 2.10 (s, 3H), 2.06 (s, 3H).
P. (r?)-1 -(3-(4-Bromo-phenvO-1 -{3-[4-(5-chloro-2-methyl-phenyl)-piperazin-1 -
Figure imgf000069_0001
(S)-1 -[3-(4-Bromo-phenyl)-1 -oxiranylmethyl-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-5-yI]-ethanone (37 mg, 0.98 mmol) and 4-(2-methyl-5- chlorophenyl)piperazine (36 mg, 0.17 mmol) were combined in EtOH (0.4 mL) and heated to 70 °C. After 18 h the mixture was allowed to cool, diluted with CH2CI2 and purified by preparative TLC (silica, 8% MeOH/CH2CI2) to give 35 mg (61%) the title compound. HPLC (reverse phase conditions): tR = 4.41 min. MS (electrospray): m/z calculated for C28H34 35c 9BrN5O2 [M++H], 586.16, found 586.2. 1H NMR (CDCI3, 400 MHz, a mixture of amide rotamers): 7.56 (d (partially obscured), J = 8.5, Hz, 2H), 7.53 (s, 4H), 7.48 (d, J = 8.5 Hz, 2H), 7.08 (br d, J = 8.5 Hz, 1 H), 6.95 (m, 2H), 4.85 and 4.73 (A and B of AB quartet, Jab = 15.6 Hz, 1 H), 4.62 (s, 1 H), 4.20 (m, 2H), 4.04 (m, 2H), 3.90-3.71 (m, 2H), 2.92-2.53 (m, 11 H), 2.21 (s, 1.5H), 2.16 (s, 1.5H).
EXAMPLE 14
Figure imgf000070_0001
2-(4-{3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-2-fluoro-propyl}-piperazin-1-yl)-benzonitrile.
A solution of 2-(4-{3-[5-acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile (150 mg, 0.27 mmol) in CH2CI2 (1 mL) was treated with DAST (Et2NSF3, 7 μL, 0.60 mmol) at -78 °C. The reaction mixture was slowly warmed to 25 °C for 1 h and then to 60 °C for an additional 2 h. Preparative TLC (silica, 5% MeOH/CH2CI2) provided 75 mg (50%) of the title compound as a light yellow powder. TLC (5% MeOH/CH2CI2): R, = 0.28. MS (electrospray): m/z 555.2 ([M+H]+, C29H30F4N6O requires 554.2). 1H NMR (CDCI3, 400 MHz, a mixture of two rotamers): 7.71 and 7.59 (AB pattern, Jab = 8.2 Hz, 2H), 7.66 and 7.62 (AB pattern, Jab = 8.4 Hz, 2H), 7.50-7.38 (m, 2H), 6.96-6.92 (m, 2H), 5.01 (dp, J = 49.0, 3.0 Hz, 1 H), 4.77 and 4.73 (AB pattern, Jab = 15.7 Hz, 1.1 H), 4.59 (s, 0.9H), 4.41-4.18 (m, 2H), 3.95-3.80 (m, 1 H), 3.69 (dd, J = 5.5, 5.5 Hz, 1 H), 3.18 (m, 4H), 2.83-2.65 (m, 8H), 2.14 (s, 1.6H), 2.10 (s, 1.4H).
EXAMPLE 15
Figure imgf000071_0001
(3-(4-Chloro-3-methyl-phenyI)-1-{3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazo!o[4,3-c]pyridin-5-yl)-oxo-acetic acid methyl ester.
A. 4-Chloro-3-methyl-benzoyl chloride.
To a suspension of 52.55 g (0.31 mol) of 4-chloro-3-methyl-benzoic acid in CH2CI2 (1.2 L) with DMF (1 mL) at 0 °C under N2 with an outlet sparging through 2.5 N sodium hydroxide was added 29.56 mL (0.339 mol) of oxalyl chloride. The mixture was allowed to warm to room temperature over a 3 h period. The reaction mixture was concentrated and taken forward crude.
B. 3-(4-Chloro-3-methyl-phenvπ-1.4.6.7-tetrahydro-pyrazolo 4.3-c1pyridine-5- carboxylic acid tert-butyl ester.
To a stirred solution of 55.8 g (0.28 mol) of 4-oxo-piperidine-1-carboxylic acid tert-butyl ester and 25.7 g (0.29 mol) of morpholine in benzene (125 mL) was added a catalytic amount (~0.25 g) of p-toluenesulfonic acid. The mixture was heated to reflux for 10 h under a Dean-Stark trap. The solvent was removed under reduced pressure to give a brown oil. The crude product was diluted with CH2CI2 (400 mL), and 46.83 mL (0.34 mol) of Et3N was added. The mixture was cooled to 0 °C, and a solution of 4-chloro-3-methyl-benzoyl chloride (0.35 mol) in CH2CI2 (200 mL) was added slowly by dropping funnel over 2 h. The reaction mixture was poured over water (400 mL) and the
CH2CI2 layer was separated, dried (Na2SO4), and concentrated. The resulting oil was taken up in EtOH (400 mL) and treated with 35 mL of hydrazine at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 17 h, during which time a white precipitate formed. The volume of the reaction mixture was reduced to -150 mL, and Et2O (750 mL) was added. The suspension was stirred vigorously for 2 h and was filtered then washed with Et2O (2 x 200 mL) and dried under vacuum to afford 50.74 g (52% over 3 steps) of 3-(4-chIoro-3-methyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridine-5-carboxyIic acid tert-butyl ester as a pale orange solid. MS (electrospray): exact mass calculated for C18H22CIN3O2, 347.1 ; m/z found, 348.1 [M+H]+. H NMR (400 MHz, CDCI3): 7.26-7.43 (m, 4H), 4.65 (br s, 2H), 3.73 (br s, 2H), 2.77 (br s, 2H), 2.34 (s, 3H), 1.49 (s, 9H).
C. 3-(4-Chloro-3-methyl-phenvπ-1 -oxiranylmethyl-1 ,4,6,7-tetrahydro- pyrazolo|"4.3-c]pyridine-5-carboxylic acid tert-butyl ester.
To a solution of 3-(4-chloro-3-methyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridine-5-carboxylic acid tert-butyl ester (18.26 g, 53 mmol) and epichlorohydrin (41.12 mL, 526 mmol) in PMF (100 mL) was added cesium carbonate (20.56 g, 63 mmol). The reaction mixture was allowed to stir for 72 h, diluted with EtOAc (200 mL) and washed with saturated NaHCO3 and brine. The organic layer was dried over Na2SO4, concentrated and purified by column chromatography (silica, 20% acetone/CH2CI2) to afford 3-(4-chloro-3-methyl- phenyl)-1-oxiranylmethyl-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5- carboxylic acid tert-butyl ester (12.0 g, 57%). TLC (silica, 20% acetone/CH2CI2): Rf = 0.68. MS (electrospray) m/z 491.2 (491.2, calculated for C27H31CIN6O, [M+H]+). 1H NMR (400 MHz, CDCI3) 7.55 (s, 1 H), 7.36 (m, 2H), 4.61 (m, 2H), 4.38-4.47 (m, 1 H), 4.11 (dd, J = 14.3, 5.7 Hz, 1 H), 3.67-3.79 (m, 2H), 3.34 (m, 1 H), 2.83 (t, J = 4.5 Hz, 1 H), 2.75 (m, 2H), 2.51 (m, 1 H), 2.41 (s, 3H), 1.48 (s, 9H).
P. 3-(4-Chloro-3-methyl-phenvπ-1 -(3-r4-(2-cvano-phenvπ-piperazin-1 -yll-2- hvdroxy-propyl}-1.4.6.7-tetrahvdro-pyrazolof4.3-c1pyridine-5-carboxylic acid tert-butyl ester. 3-(4-Chloro-3-methyl-phenyl)-1-oxiranylmethyl-1 ,4,6,7-tetrahydro-pyrazolo[4,3- c]pyridine-5-carboxylic acid tert-butyl ester (5.33 g, 13.2 mmol) and 1-(2- cyanophenyl)-piperazine (2.97 g, 15.86 mmol) were partially dissolved in EtOH (50 mL) and triethylamine (2 mL). The reaction mixture was heated to 80 °C for 18 h. The mixture was concentrated and purified by column chromatography (silica, 20% acetone/CH2CI2) to give 3-(4-chloro-3-methyI- phenyl)-1 -{3-[4-(2-cyano-phenyl)-piperazin-1 -yl]-2-hydroxy-propyl}-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxyIic acid tert-butyl ester (6.51 g, 83%>) as a yellow solid. TLC (silica, 20% acetone/CH2CI2): Rf= 0.35. MS (electrospray): m/z 591.3 (591.3, calculated for C32H39CIN6O3, [M+H]+).
E. 2-(4-f3-f3-(4-Chloro-3-methyl-phenvn-4.5.6.7-tetrahvdro-pyrazolof4.3- c]pyridin-1-yl1-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile. 3-(4-Chloro-3-methyl-phenyl)-1-{3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (1.26 g, 2.13 mmol) was dissolved in trifluoroacetic acid (3 mL) and CH2CI2 (3 mL) and allowed to stir for 2 h. The reaction mixture was concentrated, taken up in EtOAc (50 mL) and washed with aqueous NaHCO3 (2 X 25 mL). The EtOAc layer was dried over Na2SO4 and concentrated to give 2-(4-{3-[3-(4-chloro-3-methyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin- 1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile (1.05 g, 99%) as a yellow foam. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.27. MS (electrospray): m/z 491.2 (491.2, calculated for C27H31CIN6O, [M+H]+). 1H NMR (400 MHz, CDCI3): 9.8 (br s, 1 H), 7.55 (d, J = 7.6 Hz, 1 H), 7.50 (t, J = 8.2 Hz, 1 H), 7.38 (s, 1 H), 7.31 (d, J = 8.2 Hz, 1 H), 7.20 (d, J = 8.2 Hz, 1 H), 7.11 (t, J = 8.2 Hz, 1 H), 6.98 (d, J = 8.2 Hz, 1 H), 4.56 (br s, 1 H), 4.12-4.32 (m, 4H), 2.98-3.51 (m, 13 H), 2.35 (s, 3H).
F. (3-(4-Chloro-3-methyl-phenvπ-1 -(3-r4-(2-cvano-pheny0-piperazin-1 -yll-2- hydroxy-propyl)-1.4.6.7-tetrahvdro-pyrazolo[4.3-c1pyridin-5-vπ-oxo-acetic acid methyl ester.
2-(4-{3-[3-(4-Chloro-3-methyI-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin- 1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile (58 mg, 0.118 mmol) was dissolved in CH2CI2 (0.59 mL) and treated with methyl chlorooxoacetate (16 mg, 0.129 mmol). The reaction mixture was allowed to stir for 18 h at room temperature. Column chromatography (silica, 2-10% MeOH/CH2CI2) gave (3- (4-chloro-3-methyl-phenyl)-1-{3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2-hydroxy- propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-oxo-acetic acid methyl ester (54 mg, 79%) as a white solid. MS (electrospray): m/z 577.3 (577.2, calculated for C30H33CIN6O4, [M+H]+). 1H NMR (400 MHz, CDCI3 ): 7.32-7.62 (m, 5H), 7.14 (t, J = 7.6 Hz, 1 H), 7.05 (d, J = 8.2 Hz, 1 H), 4.59-4.80 (m, 3H), 4.12-4.28 (m, 2H), 3.92 (s, 3H), 3.78-3.86 (m, 2H), 3.44-3.60 (m, 5H), 3.15- 3.40 (m, 4H), 2.83-3.05 (m, 2H), 2.41 (s, 3H).
EXAMPLE 16
Figure imgf000074_0001
5-Methanesulfonyl-1 -{3-[4-(2-nitro-phenyl)-piperazin-1 -yl]-propyl}-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine.
A. 1 -Methanesulfonyl-piperidin-4-one. Potassium carbonate (324 g, 2340 mmol) was added to a solution of 4- piperidone monohydrate hydrochloride (90 g, 586 mmol) in chloroform (300 mL) and water (300 mL). The slurry was cooled to 0 °C and treated with methylsulfonyl chloride (136 mL, 1760 mmol) by dropwise addition over a 1 h period (gas evolution was observed). The reaction mixture was allowed to shake for 72 h and was partitioned between CH2CI2(500 mL) and saturated aqueous NaHCO3 (500 mL). The aqueous layer was extracted with CH2CI2 (3 X 200 mL). The organic layer was washed with 1 % KHSO4 (250 mL), dried (Na2SO4), and concentrated to afford 90.5 g (87%) of a white solid. MS (electrospray): exact mass calculated for CβH^NO^, 177.1 ; m/z found, 178.1 [M+H]+. HPLC (reverse phase conditions): tR = 2.19 min. 1H NMR (400 MHz, CDCl3): 3.60 (t, J = 6.5 Hz, 4H), 2.89 (s, 3H), 2.59 (t, J = 6.3 Hz, 4H).
B. 5-Methanesulfonyl-3-(4-trifluoromethyl-phenvπ-4.5.6.7-tetrahvdro-1 H-
Figure imgf000074_0002
p-ToluenesuIfonic acid (1.34 g. 7.0 mmol) and morpholine (25.83 mL, 296 mmol) were added to a solution of 1-methanesulfonyl-piperidin-4-one (50.0 g. 282 mmol) in benzene (282 mL). The reaction mixture was heated in a flask equipped with a condenser and a Dean-Stark trap at reflux for 15 h. The reaction mixture was cooled and concentrated in vacuo to give the enamine which was used without further purification. The enamine was dissolved in CH2Cl2 (200 mL) and cooled to 0°C. To this was added triethylamine (47.2 mL, 339 mmol) followed by dropwise addition of 4-trifluoromethylbenzoyl chloride (42.3 mL, 285 mmol) dissolved in CH2CI2 (82 mL). The reaction mixture was allowed to warm to room temperature and stirred for 20 h. The reaction mixture was washed with 1 N aqueous HCI (250 mL) and the CH2CI2 layer was separated, dried (Na2SO4), and concentrated. The resulting oil was taken up in EtOH (300 mL) and treated with hydrazine (44.3 mL, 1.41 mol) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 24 h. The mixture was concentrated and the resulting solid was filtered with EtOH wash and dried in vacuo to afford 70 g (72%) of 5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine as a white solid. MS (electrospray): exact mass calculated for C14H14F3N3O2S, 345.0; m/z found, 346.0 [M+H]+. HPLC (reverse phase conditions): tR = 6.33 min. Η NMR (400 MHz, CDCI3): 7.72 (s, 4H), 4.58 (s, 2H), 3.69 (t, J = 5.7 Hz, 2H), 2.99 (t, J = 5.7 Hz, 2H), 2.92 (s, 3H).
C. S-Cδ-Methanesulfonyl-S-^-trifluoromethyl-phenyl .δ.e -tetrahvdro- pyrazolo 4.3-c1pyridin-1 -yl"l-propan-1 -ol. Cs2CO3 (33.74 g, 103.5 mmol) was added to a solution of 5-methanesuIfonyl-3- (4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine (29.8 g, 86.3 mmol) in anhydrous DMF (70 mL) and stirred for 25 min. 3-Bromo-1- propanol (8.6 mL, 13.2 g, 94.9 mmol) was added and stirred under N2 at room temperature for 18 h. Water (500 mL) was added to the reaction and stirred for 5 min. The precipitated material was filtered out and washed with water (4 X 100 mL) and dried in a Freeze Drying System. The crude material (31.0 g) was taken up in anhydrous DMF (65 mL) and Cs2CO3 (33.74 g, 103.5 mmol) was added, and stirred for 10 min. 3-Bromo-1-propanol (8.6 mL, 13.2 g, 94.9 mmol) and MeOH (6.0 mL, 4.75 g, 148 mmol) were added and stirring continued under N2 at room temperature for 15 h. Water (500 mL) was added to the reaction and stirred for 10 min. The precipitated material was filtered and washed with water (3 X 100 mL). The filter cake was dissolved in CH2CI2 (200 mL) and washed with brine (50 mL), dried (Na2SO4), and concentrated. The solid was triturated with Et2O (200 mL), filtered, washed with Et2O, and dried to furnish 16.0 g of the desired compound. The mother liquor was chromatographed (silica, 0-10% acetone/EtOAc) to obtain an additional 3.0 g of the title compound. The combined yield was 54.6%. MS (electrospray): calculated for C17H20F3N3O3S, 403.12; m/z found, 404.0 [M+H]+, 426.0 [M+Na]+. 1H NMR (400 MHz, CDCI3): 7.71 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 4.55 (s, 2H), 4.23 (t, J = 6.5 Hz, 2H), 3.70-3.63 (m, 4H), 2.90 (s, 3H), 2.90 (t, J = 5.1 Hz, 2H), 2.62 (t, J = 5.9 Hz, 1 H), 2.06 (q, J = 6.1 Hz, 2H).
P. S-rδ-Methanesulfonyl-S-^-trifluoromethyl-phenvπ^.δ.ej-tetrahvdro- pyrazolor4,3-c]pyridin-1-yl]-propionaldehvde.
Pess-Martin periodinane (3.45 g, 8.2 mmol) was added to a solution of 3-[5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-propan-1-ol (3.0 g, 7.4 mmol) in CH2CI2 (20 mL) at 0 °C under N2. After 15 min, the reaction was allowed to warm to room temperature and stirred for another 1.5 h. The reaction was diluted with Et2O (60 mL) and 20 % aq. NaHCO3 (35 mL) was added slowly. Then Na2S2O3 was added and stirred at room temperature for 30 min. The layers were separated and the aqueous portion was extracted with Et2O (2 x 30 mL). The combined organic extracts were washed with brine, dried (Na2SO4) and concentrated. MPLC (1-10% MeOH/CH2CI2) afforded 2.53 g of the desired aldehyde in 85% yield. MS (electrospray): calculated for C17H18F3N3O3S, 401.11 ; m/z found, 402.1 [M+H], 434.1 [M+MeOH+H]. Η NMR (400 MHz, COCI3): 9.82 (s, 1 H), 7.63 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 4.68 (s, 2H), 4.25 (t, J = 6.1 Hz, 2H), 3.63 (t, J = 5.8 Hz, 4H), 3.14 (t, J = 6.1 Hz, 2H), 2.92 (t, J = 5.8 Hz, 2H), 2.81 (s, 3H).
E. 5-Methanesulfonyl-1 -C3-r4-(2-nitro-phenvπ-piperazin-1 -yll-propylVS-M- trifluoromethyl-phenyl)-4.5.6.7-tetrahydro-1 H-pyrazolor4.3-c1pyridine. To a stirred solution of 3-[5-methanesuIfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6, 7-tetrahydro-pyrazoIo[4,3-c]pyridin-1-yl]-propionaldehyde (0.060 g, 0.15 mmol) and 1-(2-nitro-phenyl)-piperazine (0.032 g, 0.157 mmol) in CH2CI2 (0.5 mL), glacial AcOH (8.5 μL, 0.15 mmol) was added and stirred for 15 min at room temperature. NaBH(OAc)3 (0.041 g, 0.19 mmol) was added and stirred under nitrogen overnight. Saturated NaHCO3 (0.5 mL) was then added and stirred for 15 min. The layers separated and the aqueous layer was extracted with CH2CI2 (0.5 mL). MPLC purification (silica, 2-15% MeOH/CH2CI2) afforded the desired product as a white solid (0.063 g, 71 %). TLC (silica, 12% MeOH/CH2CI2): Rf = 0.67. MS (electrospray): exact mass calculated for
C27H31F3N6O4S, 592.21 ; m/z found, 593.2 [M+H]+. 1H NMR (400 MHz, COCI3): 7.80 (dd, J = 1.6, 8.2 Hz, 1 H), 7.77 (d, J = 8.3 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H), 7.52 (ddd, J = 1.6, 7.3, 8.3 Hz, 1 H), 7.19 (dd, J = 1.2, 8.3 Hz, 1 H), 7.09 (m, 1 H), 4.59 (s, 2H), 4.17 (t, J = 6.9 Hz, 2H), 3.71 (t, J = 5.8 Hz, 2H), 3.13 (br t, J = 4.8 Hz, 4H), 2.96 (t, J = 5.6 Hz, 2H), 2.95 (s, 3H), 2.66 (br t, J = 4.4 Hz, 4H), 2.51 (t, J = 7.0 Hz, 2H), 2.17 (q, J = 6.9 Hz, 2H).
EXAMPLE 17
Figure imgf000077_0001
1-[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyI}-piperazin-1-yl)-phenyl]-urea.
A. 4-(2-chloro-6-nitro-phenylVpiperazine-1-carboxylic acid tert-butyl ester. To a stirred solution of 1 ,2-dichloro-3-nitrobenzene (0.96 g, 5.0 mmol) and piperazine-1-carboxylic acid tert-butyl ester (0.93 g, 5.0 mmol) in acetonitrile (5 mL) was added of K2CO3 (1.38 g, 10 mmol). The mixture was heated at reflux for 48 h. The solvent was removed under reduced pressure. The crude material was partitoned between EtOAc (100 mL) and H2O (20 mL). The organic layer was washed with H2O (2 x 20 mL), dried over Na2SO4 and concentrated. Column chromatography (silica, 10-20% EtOAc/hexanes) provided 4-(2-chloro-6-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.2 g, 70%). TLC (silica, 20% EtOAc/hexanes): Rf = 0.45. MS (electrospray): exact mass calculated for C15H20CIN3O4, 341.1 ; m/z found, 364.1 [M+Na]+. 1H NMR (400 MHz, COCI3) 7.56 (dd, J = 8.2, 1.4 Hz, 1 H), 7.50 (dd, J = 8.2, 1.4 Hz, 1 H), 7.13 (t, J = 8.2 Hz, 1 H), 3.38-3.56 (m, 4H), 3.06 (m, 4H), 1.48 (s, 9H).
B. 1 -(2-chloro-6-nitro-phenyl)-piperazine.
4-(2-Chloro-6-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.87 g, 5.47 mmol) was dissolved in trifluoroacetic acid (5.0 mL) and CH2CI2 (5.0 mL) and allowed to stir for 2 h. The reaction mixture was concentrated, diluted with EtOAc, and washed with saturated aq. NaHCO3. The organic layer was dried over Na2SO4, concentrated and purified by column chromatography (silica, 100%, CH2CI2) to afford 1-(2-chloro-6-nitro-phenyl)-piperazine (1.26 g, 95%). MS (electrospray): exact mass calculated for C10H12CIN3O2, 241.1 ; m/z found, 242.1 [M+H]+. 1H NMR (400 MHz, CPCI3): 7.54 (dd, J = 8.2, 1.6 Hz, 1 H), 7.49 (dd, J = 8.2, 1.6 Hz, 1 H), 7.10 (t, J = 8.2 Hz, 1 H), 3.08 (br s, 4H), 2.99 (br s, 4H), 2.07-2.12 (m, 1 H).
C. 1 -{3- 4-(2-Chloro-6-nitro-phenyl)-piperazin-1 -yll-propyll-5-methanesulfonyl- 3-(4-trifluoromethyl-phenyπ-4.5.6.7-tetrahydro-1 H-pyrazolo[4.3-clpyridine. To a stirred solution of 3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propionaldehyde (0.5 g, 1.25 mmol) and 1-(2-chloro-6-nitrophenyl)-piperazine (0.301 g, 1.25 mmol) in CH2CI2(6 mL) was added sodium sulfate (0.354 g, 2.50 mmol) and sodium triacetoxyborohydride (0.396 g, 1.87 mmol). The mixture was allowed to stir at room temperature overnight. The mixture was diluted with CH2CI2 and washed with water. The CH2CI2 layer was dried over Na2SO4, and the solvent was removed under reduced pressure. The residue was purified by column chromatography (silica, 10% acetone/CH2Cl2) to afford of 1 -{3-[4-(2-chloro-6- nitro-phenyl)-piperazin-1-yl]-propyl}-5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (0.380 g, 49%). MS (electrospray): exact mass calculated for C27H30CIF3N6O4S, 626.2; m/z found, 627.2 [M+H]+. 1H NMR (400 MHz, CDCI3): 7.73 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.54 (dd, J = 8.2, 1.2 Hz, 1H), 7.49 (dd, J = 8.2,1.2 Hz, 1H), 7.10 (t, J = 8.2 Hz, 1 H), 4.58 (s, 2H), 4.13 (t, J = 6.5 Hz, 2H), 3.71 (t, J = 5.9 Hz, 2H), 3.01-3.11 (m, 4H), 2.95 (t, J = 5.9 Hz, 2H), 2.92 (s, 3H), 2.42-2.53 (m, 4H), 2.40 (t, J = 6.5 Hz, 2H), 2.12 (q, J = 6.5 Hz, 2H).
P. 3-Chloro-2-(4-f3-r5-methanesulfonyl-3-(4-trifluoromethyl-phenvπ-4.5.6.7- tetrahydro-pyrazolo[4.3-clpyridin-1-yl1-propyl}-piperazin-1-yl)-phenylamine. To a stirred solution of 1-{3-[4-(2-chloro-6-nitro-phenyl)-piperazin-1-yl]-propyl}- 5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H- pyrazolo[4,3-c]pyridine (0.153 g, 0.244 mmol) in EtOH (2.44 mL) was added zinc dust (0.80 mg, 1.22 mmol) and slow addition of acetic acid (0.70 mL). After 15 min the yellow solution became colorless and the access zinc dust was filtered through a plug of celite. The filtrate was concentrated and the residue was purified by column chromatography (silica, 0-10% MeOH/CH2CI2) to afford 3-chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1 -yl]-propyl}-piperazin-1 -yl)- phenylamine (0.146 g, 100%). MS (electrospray): exact mass calculated for C27H32CIF3N6O2S, 596.2; m/z found, 597.2 [M+H]+. 1H NMR (400 MHz, COCI3): 7.73 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 6.88 (t, J = 8.2 Hz, 1 H), 6.63 (t, J = 7.6 Hz, 2H), 4.55 (s, 2H), 4.36 (s, 2H), 4.15 (t, J = 6.5 Hz, 2H), 3.60-3.70 (m, 4H), 2.97 (t, J = 5.3 Hz, 2H), 2.90 (s, 3H), 2.83 (d, J = 10.8 Hz, 2H), 2.74 (d, J = 11.5 Hz, 2H), 2.37 (t, J = 6.6 Hz, 2H), 2.11-2.20 (m, 4H).
E. 1-r3-Chloro-2-(4-f3-r5-methanesulfonyl-3-(4-trifluoromethyl-phenvn-4.5.6.7- tetrahydro-pyrazolo[4.3-c1pyridin-1-yl1-propyl}-piperazin-1-yl)-phenyl1-urea. To a stirred solution of 3-chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)- phenylamine (0.062 g, 0.104 mmol) in CH2CI2 (0.52 mL) was added trimethylsilyl isocyanate (0.017 mL, 0.125 mmol). The reaction mixture was allowed to stir for 48 h at room temperature. The reaction had not gone to completion, so an additional 0.017 mL (0.125 mmol) of trimethylsilyl isocyanate was added and the reaction was heated to 45 °C for 10 h. Column chromatography (silica, 3-10% MeOH/CH2CI2) afforded 1-[3-chloro-2-(4-{3-[5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]-urea (0.015 g, 22%). MS (electrospray): exact mass calculated for C28H33CIF3N7O3S, 639.2; m/z found, 640.2 [M+H]+. 1H NMR (400 MHz, CPCI3): 8.26 (br s, 1 H), 8.05 (d, J = 8.2 Hz, 1 H), 7.73 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.09 (t, J = 8.2 Hz, 1 H), 6.92 (d, J = 8.2 Hz, 1 H), 4.65 (s, 2H), 4.55 (s, 2H), 4.15 (t, J = 6.7 Hz, 2H), 3.65-3.73 (m, 4H), 2.96 (t, J = 5.6 Hz, 2H), 2.87-2.92 (m, 2H), 2.91 (s, 3H), 2.70 (d, J = 11.4 Hz, 2H), 2.40 (t, J = 6.7 Hz, 2H), 2.09-2.22 (m, 4H).
EXAMPLE 18
Figure imgf000080_0001
1-{3-[4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazin-1-yl]-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-sulfonic acid amide.
A. 3-(4-Trifluoromethyl-phenyl)-1.4.6.7-tetrahydro-pyrazolo[4.3-c1pyridine-5- carboxylic acid tert-butyl ester. To a stirred solution of 500 g (2.51 mol) of 1-te/ιf-butoxycarbonyl-4-piperidone and 87.1 g (2.76 mol) of morpholine in benzene (1.25 L) was added a catalytic amount (~ 0.25 g) of p-TsOH. The mixture was heated to reflux for 36 h with a Oean-Stark trap. One half of the solvent was removed under reduced pressure and the resulting solution was cooled and filtered. The filtrate was then concentrated to yield 630 g (94%) of an orange red oil. The eneamine was divided and 320 g (1.19 mol) was diluted with CH2CI2 (1.0 L) and 165.0 mL (1.19 mol) of Et3N was added. The mixture was cooled to 0 °C and a solution of 225 g (1.08 mol) of 4-trifluoromethylbenzoyl chloride in CH2CI2 (0.5 L) was added slowly by dropping funnel over 1 h. The mixture was allowed to warm to rt and stir overnight. The reaction was then diluted with 1 N HCI (450 mL) and stirred vigorously for 3 h. The aqueous layer was extracted with CH2CI2 (3 x 500 mL) and the combined extracts were dried over Na2SO4 and the solvent was removed under reduced pressure. The crude oil was diluted with EtOH (1 L) and cooled to 0 °C. To this stirred solution was slowly added 115 g (3.57 mol) of hydrazine and the mixture was allowed to warm to rt and stir overnight during which time a white precipitate formed. The volume of the reaction was reduced to -500 mL and cooled. The precipitate was collected to afford 285 g (72% from eneamine) of a white solid. 1H NMR (400 MHz, COCL : 7.63-7.55 (m, 4H), 4.58 (br s, 2H), 3.69-3.62 (br m, 2H), 2.74-2.68 (br m, 2H), 1.47 (s, 9H).
B. 1-('2-Methoxycarbonyl-ethyl)-3-(4-trifluoromethyl-phenyl)-1.4.6.7-tetrahydro- pyrazolo[4.3-c1pyridine-5-carboxylic acid tert-butyl ester. 3-(4-Trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5- carboxylic acid tert-butyl ester (1.85g, 5.04 mmol) and methyl acrylate (0.50 mL, 5.6 mmol) were combined in toluene (30 mL) and heated to 75 °C. The resulting mixture was treated with f-BuONa (100 mg), and heating continued for 48 h. The mixture was allowed to cool and partitioned between EtOAc (300 mL) and NaHCO3 (75 mL). The aqueous layer was extracted with EtOAc (3 x 75 mL). The combined extracts were dried over Na2SO4 and concentrated. Column chromatography (silica, 30-60% EtOAc/hexanes) afforded 343 mg (15%) of the title compound. TLC (silica, 50% EtOAc/hexanes): Rf = 0.4. MS (electrospray): m/z calculated for C22H27F3N3O4 [M++H] 454.20, found 454.1. 1H NMR (CDCI3- 400 MHz): 7.75 (br d, J = 8.1 Hz, 2H), 7.64 (br s, 2H), 4.63 (br s, 2H), 4.30 (t, J = 6.6 Hz, 2H), 3.75 (br s, 2H), 3.68 (s, 3H), 2.98 (t, J = 6.6 Hz, 2H), 2.79 (br t, J = 5.6 Hz, 2H), 1.48 (s, 9H). C. 1 -(3-Hvdroxy-propyO-3-(4-trifluoromethyl-phenyD-1 ,4,6,7-tetrahydro- pyrazolo[4.3-clpyridine-5-carboxylic acid tert-butyl ester . A solution of LiBH4 (26 mg, 1.2 mmol) in THF (0.5 mL) was added to a 0 °C solution of 1-(2-methoxycarbonyl-ethyl)-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (317 mg, 0.70 mmol) in THF (4.0 mL). The mixture was stirred for 5 min then additional LiBH4 (15 mg) was added and stirring continued for 17 h. The mixture was partitioned between EtOAc (80 mL) and saturated aqueous NaHCO3 (20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined extracts were dried over Na2SO4 and concentrated. Column chromatography (silica, 0-8% MeOH/CH2CI2) afforded 268 mg (95%) of the title compound. HPLC (reverse phase conditions), tR = 6.82 min. MS (electrospray): m/z calculated for C21H26F3N3O3 [M++Na] 448.18, found 448.10. 1H NMR (COCI3, 400 MHz): 7.73 (br d, J = 8.2 Hz, 2H), 7.65 (br s, 2H), 4.64 (br s, 2H), 4.21 (t, J = 6.4 Hz, 2H), 3.76 (br s, 2H), 3.66 (t, J = 5.7 Hz, 2H), 2.73 (br t, J = 5.4 Hz, 2H), 2.04 (q, J = 6.1 , 2H), 1.48 (s, 9H).
P. 1 -(3-Oxo-propyO-3-(4-trifluoromethyl-phenyl)-1.4.6.7-tetrahydro- pyrazolof4.3-c1pyridine-5-carboxylic acid tert-butyl ester. Pess-Martin periodinane (1.43 g, 3.36 mmol) was added portion wise to a stirred solution of 1-(3-hydroxy-propyl)-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7- tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (1.30 g, 3.05 mmol) in CH2CI2 (15 mL) at 0 °C under N2.Then the reaction was stirred at 0 °C for 15 min and allowed to warm to room temperature. After stirring at room temperature for 1.5 h the reaction was diluted with Et2O (50 mL) and saturated NaHCO3 (15 mL) was added slowly (caution! gas evolution). Then Na2S2O3.5H2O (5.31 g, 21.4 mmol) was added and stirred for 30 min. The layers were separated and the aqueous layer was extracted with Et2O (2 x 30 mL). The combined extracts were washed with brine, dried (Na2SO4) and concentrated. MPLC (1-10% MeOH/CH2CI2) afforded the aldehyde in 79% yield (1.02 g). TLC (silica, 10% MeOH/CH2CI2): R, = 0.67. MS (electrospray) calculated for C21H24F3N3O3, 424.2 ([M+H]+), m/z found, 424.2. 1H NMR (400 MHz, CPCI3): 9.82 (s, 1 H), 7.65 (br d, J = 8.0 Hz, 2H), 7.54 (br s, 2H), 4.53 (s, 2H), 4.21 (t, J = 6.2 Hz, 2H), 3.68 (br s, 2H), 3.04 (t, J = 6.2 Hz, 2H), 2.70 (t, J = 5.6 Hz, 2H), 1.39 (s, 9H).
E. 4-(2-Chloro-6-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester. To a stirred solution of 0.96 g (5.0 mmol) of 1 ,2-dichloro-3-nitrobenzene and 0.93 g (5.0 mmol, 1 eq) of 1-fe/ιf-butyloxycarbonylpiperazine in acetonitrile (5 mL) was added 1.38 g (10 mmol, 2 eq) of K2CO3. The mixture was heated to reflux for 48 h. The solvent was removed under reduced pressure. The crude product was partitioned between EtOAc (100 mL) and 20 mL of H2O. The organic layer was washed with H2O (2 x 20 mL), dried over Na2SO4 and concentrated. Column chromatography (silica, 10-20% EtOAc/hexanes) provided 1.2 g (70%) of 4-(2-chIoro-6-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester. TLC (silica, 20% EtOAc/hexanes): Rf = 0.45. 1H NMR (400 MHz, CPCI3): 7.56 (dd, J = 8.2, 1.4 Hz, 1 H), 7.50 (dd, J = 8.2, 1.4 Hz, 1 H), 7.13 (t, J = 8.2 Hz, 1 H), 3.56-3.38 (m, 4H), 3.10-3.00 (m, 4H), 1.48 (s, 9H).
F. 1 -{3-[4-(2-Chloro-6-nitro-phenyD-piperazin-1 -yl1-propyl}-3-(4-trifluoromethyl- phenvD-1 ,4.6.7-tetrahydro-pyrazolof4.3-clpyridine-5-carboxylic acid tert-butyl ester. 4-(2-Ch!oro-6-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (940 mg, 2.75 mmol) in 10 mL of CH2CI2 was treated with 5 mL of trifluoroacetic acid and stirred at 25 °C for 1 h. The volatiles were then removed. The residue was taken up in CH2Cl2 (60 mL) and KOH (4 N, 20 mL). The organic layer was separated, dried over Na2SO4, and concentrated. The yellow oil was dissolved in CH2CI2 and added into the 996 mg (2.35 mmol) of 1 -(3-oxo-propyl)-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxy lie acid tert-butyl ester. The yellow solution was treated with glacial acetic acid (0.8 mL, 6 eq) and stirred at 25 °C for 1 h. NaBH(OAc)3 (1.5 g, 7.05 mmol) was added and stirred under nitrogen for 2 h. Then saturated NaHCO3 (20 mL) was added and stirred for 30 min, and the layers were separated. The organic extract was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. Column chromatography (silica, 2-5% MeOH/CH2CI2) afforded 1 -{3-[4-(2-chloro-6-nitro-phenyl)-piperazin-1 -yl]-propyl}-3-(4- trifIuoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxyIic acid tert-butyl ester as a white solid (1.40 g, 92%). TLC (silica, 5% MeOH/CH2CI2): Rf = 0.3. MS (electrospray): exact mass calculated for C31H36CIF3N6O4, 648.24; m/z found 649.3 [M+H]+. 1H NMR (400 MHz, COCI3): 7.69 (d, J = 8.2 Hz, 1 H), 7.60-7.50 (m, 1 H), 7.45-7.37 (m, 4H), 7.02 (t, J = 8.2 Hz, 1 H), 4.58 (br s, 2H), 4.04 (t, J = 6.7 Hz, 2H), 3.73-3.65 (m, 2H), 3.05-2.95 (m, 4H), 2.71 (t, J = 5.6 Hz, 2H), 2.50-2.35 (m, 4H), 2.30 (t, J = 6.8 Hz, 2H), 2.05-1.95 (m, 2H), 1.41 (s, 9H).
G. 1 -l3-[4-(2-Amino-6-chloro-phenvO-piperazin-1 -yl1-propyl)-3-(4- trifluoromethyl-phenyπ-1.4.6.7-tetrahvdro-pyrazolo["4.3-clpyridine-5-carboxylic acid tert-butyl ester.
A solution of 360 mg (0.56 mmol) of 1-{3-[4-(2-chloro-6-nitro-phenyl)-piperazin-
1-yl]-propyl}-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazoIo[4,3- c]pyridine-5-carboxylic acid tert-butyl ester in 4 mL of MeOH was treated with 182 mg (5 eq) of zinc dust and glacial acetic acid (1.57 mL, 50 eq) at 25 °C. The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was then filtered through a pad of celite and concentrated to obtain a thick oil. The residue was taken up in CH2CI2 (50 mL) and sat. NaHCO3 (20 mL). The organic layer was separated, washed with H2O (2x 10 mL), dried over Na2SO4, and concentrated to afford 1-{3-[4-(2-amino-6-chloro-phenyl)-piperazin-1-yl]-propyl}- 3-(4-trifluoromethyI-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5- carboxylic acid tert-butyl ester. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.3. MS (electrospray): exact mass calculated for C31H38CIF3N6O2, 618.27; m/z found, 619.3 [M+H]+.
H. 1-{3-[4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazin-1-ylj-propyl}-3- (4-trifluoromethyl-phenyl)-1.4.6.7-tetrahvdro-pyrazolo[4.3-c1pyridine-5- carboxylic acid tert-butyl ester. A solution of 1 -{3-[4-(2-amino-6-chloro-phenyl)-piperazin-1 -yl]-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (257 mg, 0.42 mmol) in 4 mL of CH2CI2 was treated with 32 L (0.42 mmol, 1.0 eq) of methanesulfonyl chloride and 116 L (0.83 mmol, 2 eq) of triethylamine and the reaction mixture stirred at 25 °C for 1 h. EtOAc (40 mL) and sat. NaHCO3 (20 mL) were added. The organic layer was separated and washed with H2O (20 mL), brine (20 mL), dried over Na2SO4, and concentrated to afford the crude 1-{3-[4-(2-chloro-6-methanesulfonylamino- phenyl)-piperazin-1 -yl]-propyl}-3-(4-trifluoromethyI-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridine-5-carboxyIic'acid tert-butyl ester. TLC (silica, 10% MeOH/CH2CI2): Rf = 0.3. MS (electrospray): exact mass calculated for C32H40CIF3N6O4S, 696.25; m/z found, 697.2 [M+H]+.
I. 1-{3-[4-(2-Chloro-6-methanesulfonylamino-phenvπ-piperazin-1-yl1-propyl}-3- (,4-trifluoromethyl-phenvh-1.4.6.7-tetrahvdro-pyrazolor4.3-c1pyridine-5-tert- butoxycarbonyl-sulfonic acid amide.
A solution of 97 mg (0.14 mmol) of 1-{3-[4-(2-chloro-6-methanesulfonylamino- phenyl)-piperazin-1-yI]-propyl}-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro- pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester in 3 mL of CH2CI2 was treated with 1.5 mL of trifluoroacetic acid. The reaction mixture was stirred at 25 °C for 1 h before all volatiles were removed. To this crude material in 0.5 mL of CH2CI2 was added dropwise a premixed solution of chlorosulfonyl isocyanate (18 μL, 0.209 mmol) and 2-methyl-2-propanol (20 μL, 0.209 mmol) in CH2CI2 (0.150 mL). The reaction mixture was allowed to stir at 25 °C overnight.
Preparative TLC (silica, 2-10% MeOH/CH2CI2) provided the title compound (84 mg, 78%). TLC (silica, 10% MeOH/CH2CI2): Rf = 0.3. MS (electrospray): exact mass calculated for C32H41CIF3N7O6S2, 775.22; m/z found, 776.2 [M+H]+.
J. 1 -(3-[4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazin-1 -yl1-propyl}-3- (4-trifluoromethyl-phenyπ-1.4.6.7-tetrahydro-pyrazolo[4.3-c1pyridine-5-sulfonic acid amide.
1-{3-[4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazin-1-yl]-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-tert- butoxycarbonyl-sulfonic acid amide (84 mg, 0.11 mmol) was dissolved in trifluoroacetic acid (0.75 mL) and CH2CI2 (0.75 mL). The reaction mixture was allowed to stir at 25 °C for 2 h. Removal of volatiles under a stream of nitrogen provided 1 -{3-[4-(2-chloro-6-methanesulfonylamino-phenyI)-piperazin-1 -yl]- propyl}-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]ρyridine- 5-sulfonic acid amide in quantitative yield as a trifluoroacetic acid salt. MS (electrospray): exact mass calculated for C27H33CIF3N7O4S2, 675.17; m/z found, 676.2 [M+H]+. 1H NMR (400 MHz, COCI3 ): 7.73 and 7.63 (AB pattern, J = 8.2 Hz, 4H), 7.37 (d, J = 7.8 Hz, 1 H), 7.13 (t, J = 7.8 Hz, 1 H), 7.04 (d, J = 7.8 Hz, 1 H), 4.32 (s, 2H), 4.20 (t, J = 6.3 Hz, 2H), 3.87-3.80 (m, 2H), 3.80-3.75 (m, 4H), 3.70-3.25 (m, 7H), 3.00-2.75 (m, 4H), 2.25-2.15 (m, 2H).
EXAMPLE 19
Figure imgf000086_0001
N-[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]- methanesulfonamide.
A. 5-Methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyπ-4.5.6.7- tetrahvdro-1 H-pyrazolo[4,3-c]pyridine.
5-Methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H- pyrazolo[4,3-c]pyridine (10.0 g, 29.0 mmol) and epichlorohydrin (24 mL, 307 mmol) were set stirring in PMF (150 mL) containing Cs2CO3 (10.4 g, 31.9 mmol). After stirring at room temperature for 4 days the mixture was evaporated, brought up in EtOAc and washed with water. The organics were dried (MgSO4) and evaporated to give a light yellow solid. Column chromatography (silica, 5% acetone/CH2CI2) gave 4.1g (35%) of a white solid. TLC (silica, 5% acetone/CH2CI2): Rf =0.28. MS (electrospray): exact mass calculated for C17H18F3N3O3S, 401.10; m/z found, 402.1 [M+H]+. 1H NMR (400 MHz, CDCI3): 7.84 (d, J = 8.3 Hz, 2H), 7.79 (d, J = 8.3 Hz, 2H), 4.70-4.62 (m, 3H), 4.25 (d, J = 5.4 Hz, 1 H), 3.90-3.70 (m, 2H), 3.47 (m, 1 H), 3.10-2.9 (m, 6H), 2.65-2.60 (m, 1 H).
B. 4-(2-Chloro-6-nitro-phenvπ-piperazine-1 -carboxylic acid tert-butyl ester. To a stirred solution of 0.96 g (5.0 mmol) of 1 ,2-dichloro-3-nitrobenzene and
0.93 g (5.0 mmol, 1 eq) of 1-terf-butyloxycarbonylpiperazine in acetonitrile (5 mL) was added 1.38 g (10 mmol, 2 eq) of K2CO3. The mixture was heated to reflux for 48 h. The solvent was removed under reduced pressure. The crude product was partitioned between EtOAc (100 mL) and 20 mL of H2O. The organic layer was washed with H2O (2 x 20 mL), dried over Na2SO4 and concentrated. Column chromatography (silica, 10-20% EtOAc/hexanes) provided 1.2 g (70%) of 4-(2-chloro-6-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester. TLC (silica, 20%o EtOAc/hexanes): Rf = 0.45. Η NMR (400 MHz, CDCI3): 7.56 (dd, J = 8.2, 1.4 Hz, 1 H), 7.50 (dd, J = 8.2, 1.4 Hz, 1 H), 7.13 (t, J = 8.2 Hz, 1 H), 3.56-3.38 (m, 4H), 3.10-3.00 (m, 4H), 1.48 (s, 9H).
C. 4-(2-Amino-6-chloro-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester. A solution of 342 mg (1 mmol) of 4-(2-chloro-6-nitro-phenyl)-piperazine-1- carboxylic acid tert-butyl ester in 5.0 mL of MeOH was treated with 630 mg (10 mmol, 10 eq) of ammonium formate and a catalytic amount of 10% Pd-C (34 mg). The reaction mixture was stirred at 65 °C for 30 min. The reaction mixture was then filtered through a pad of celite and concentrated to obtain a yellow solid. TLC (silica, 5% acetone/CH2CI2): Rf = 0.40. MS (electrospray): exact mass calculated for C15H22CIN3O2, 311.14; m/z found, 312.1 [M+H]+.
P. 4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester.
4-(2-Amino-6-chloro-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester (163 mg, 0.53 mmol) in CH2CI2 was treated with 62 L (0.80 mmol, 1.5 eq) of methanesulfonyl chloride and 148 L (1.06 mmol, 2 eq) of triethylamine and the reaction mixture stirred at 25 °C for 1 h. EtOAc (40 mL) and sat. NaHCO3 (20 mL) were added. The organic layer was separated and washed with H2O (20 mL), brine (20 mL), dried over Na2SO4, and concentrated. Column chromatography (silica, 0-5% acetone/CH2CI2) provided 145 mg (70%) of 4-(2- chloro-6-methanesulfonylamino-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester. TLC (silica, 5% acetone/CH2CI2): Rf = 0.35. MS (electrospray): exact mass calculated for C16H24CIN3O4S, 389.12; m/z found, 388.1 (negative). 1H NMR (400 MHz, CDCI3): 7.41 (dd, J = 8.2, 1.6 Hz, 1 H), 7.11 (t, J = 8.2 Hz, 1 H), 6.99 (dd, J = 8.2, 1.6 Hz, 1 H), 4.25-3.91 (m, 2H), 3.66-3.52 (m, 2H), 3.01 (s, 3H), 3.01-2.84 (m, 2H), 2.70-2.56 (m, 2H), 2.55-2.43 (m, 2H), 1.44 (s, 9H).
E. N-ιr3-Chloro-2-(4-{2-hvdroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4.5.6.7-tetrahydro-pyrazolo("4.3-c1pyridin-1-yll-propyl)-piperazin-1-yl)- phenylj-methanesulfonamide.
4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazine-1 -carboxylic acid tert- butyl ester (145 mg, 0.37 mmol) was dissolved in 3 mL of CH2CI2 and treated with 1.5 mL of trifluoroacetic acid. The reaction mixture was stirred at 25 °C for 1 h before all volatiles were removed. The solid was treated with CH2CI2 (20 mL) and aqueous KOH (4 N, 10 mL). The organic layer was separated, dried over Na2S04, and concentrated. The crude oil (90 mg) was dissolved in absolute EtOH (1.0 mL) and treated with 96 mg (0.24 mmol) of 5- methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-4, 5,6,7- tetrahydro-1 H-pyrazolo[4,3-c]pyridine. The reaction mixture was refluxed at 85 °C for 3 h and then the solvent was removed. Column chromatography (silica, 0-5% MeOH/CH2CI2) provided 138 mg (20% over 4 steps) of N-[3-chloro-2-(4- {2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazoIo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]- methanesulfonamide. TLC (silica, 5% MeOH/CH2CI2): Rf = 0.45. MS
(electrospray): exact mass calculated for C28H34CIF3N6O5S2, 690.17; m/z found, 691.2 [M+H]+. 1H NMR (400 MHz, CDCI3): 8.28 (s, 1 H), 7.65 and 7.59 (AB pattern, J = 8.4 Hz, 4H), 7.36 (d, J = 8.1 Hz, 1 H), 7.07 (t, J = 8.2 Hz, 1 H), 6.95 (d, J = 8.2 Hz, 1 H), 4.54-4.44 (m, 2H), 4.21-3.94 (m, 3H), 3.77-3.52 (m, 4H), 3.41 (m, 2H), 2.96 (s, 3H), 2.81 (s, 3H), 3.05-2.73 (m, 4H), 2.66-2.20 (m, 4H). EXAMPLE 20
Figure imgf000089_0001
1 -[4-(2,6-Dinitro-phenyl)-piperazin-1 -yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2- ol.
A. 4-(2,6-Dinitro-phenv0-piperazine-1 -carboxylic acid tert-butyl ester . To a stirred solution of 1.01 g (5.0 mmol) of 1-chloro-2, 6-dinitrobenzene and 0.93 g (5.0 mmol) of 1-terf-butyloxycarbonylpiperazine in acetonitrile (5 mL) was added 1.38 g (10 mmol) of K2CO3. The mixture was heated to reflux for 48 h. The solvent was removed under reduced pressure. The crude product was partitioned between EtOAc (100 mL) and 20 mL of H2O. The organic layer was washed with H2O (2 x 20 mL), dried over Na2SO4 and concentrated. Column chromatography (silica, 10-20% EtOAc/hexanes) provided 1.31 g (85%) of 4- (2, 6-dinitro-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester TLC (silica, 20% EtOAc/hexanes): Rf = 0.35. 1H NMR (400 MHz, CDCI3): 7.75 (d, J = 8.2 Hz, 2H), 7.25 (t, J = 8.2 Hz, 1 H), 3.30 (m, 4H), 2.95 (m, 2H), 1.44 (s, 9H).
B. 1 -[4-C2.6-Dinitro-phenvπ-piperazin-1 -vn-3-r5-methanesulfonyl-3-(4- trifluoromethyl-phenvπ-4.5.6.7-tetrahydro-pyrazolo[4.3-c]pyridin-1-yl1-propan-2- oL 4-(2,6-Dinitro-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester (220 mg, 0.63 mmol) was dissolved in 5.0 mL of CH2CI2 and treated with 3.0 mL of trifluoroacetic acid. The reaction mixture was stirred at 25 °C for 1 h before all volatiles were removed. The solid was treated with CH2CI2 (20 mL) and aqueous KOH (4 N, 10 mL). The organic layer was separated, dried over Na2SO4, and concentrated. The crude oil (67 mg) was dissolved in absolute EtOH (1.2 mL) and treated with 141 mg (0.35 mmol, 1.3 eq) of 5- methanesuIfonyl-1-oxiranyImethyl-3-(4-trifluoromethyl-phenyl)-4, 5,6,7- tetrahydro-1 H-pyrazolo[4,3-c]pyridine. The reaction mixture was refluxed at 85 °C for 3 h and then the solvent was removed. Column chromatography purification (silica, 10-20% acetone/CH2CI2) provided 150 mg (85%) of 1-[4- (2,6-dinitro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1 -yl]-propan-2-ol. TLC (silica, 10% acetone/CH2CI2): Rf = 0.3. MS (electrospray): exact mass calculated for C27H30F3N7O7S, 653.19; m/z found, 654.2 [M+H]+. 1H NMR (400 MHz, CDCI3): 7.71 (d, J = 8.2 Hz, 2H), 7.64 and 7.58 (AB pattern, J = 8.4 Hz, 4H), 7.20 (t, J = 8.2 Hz, 1 H), 4.54 (s, 2H), 4.29-4.12 (m, 2H), 3.66 (t, J = 5.3 Hz, 2H), 3.70-2.95 (m, 9H), 2.91 (s, 3H), 2.67-2.32 (m, 4H).
EXAMPLE 21
Figure imgf000090_0001
2-(4-{2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyI)-4, 5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-3- methanesulfonylamino-benzoic acid methyl ester.
A. 4-f2-Methoxycarbonyl-6-nitro-phenyl)-piperazine-1 -carboxylic acid tert-butyl ester.
To a stirred solution of 736 mg (2.83 mmol) of ethyl 2-bromo-3-nitrobenzoate and 579 mg (3.1 mmol, 1.1 eq) of 1-te/ιf-butyloxycarbonylpiperazine in n- butanol (6 mL) was added 330 mg (3.1 mmol, 1.1 eq) of Na2CO3. The mixture was heated to reflux for 4 h. The solvent was removed under reduced pressure. The crude product was partitioned between EtOAc (100 mL) and 20 mL of H2O. The organic layer was washed with H2O (2 x 20 mL), dried over Na2SO4 and concentrated. Column chromatography (silica, 10-20% EtOAc/hexanes) provided 744 mg (72%) of 4-(2-methoxycarbonyl-6-nitro- phenyl)-piperazine-1 -carboxylic acid tert-butyl ester. TLC (silica, 20% EtOAc/hexanes): Rf = 0.5. 1H NMR (400 MHz, CDCI3): 7.67 (dd, J = 8.2, 1.4 Hz, 1 H), 7.62 (dd, J = 8.2, 1.4 Hz, 1 H), 7.16 (t, J = 8.2 Hz, 1 H), 3.86 (s, 3H), 3.44-3.36 (m, 4H), 3.03-2.95 (m, 4H), 1.48 (s, 9H).
B. 2-f4- 2-Hvdroxy-3-["5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4.5.6.7- tetrahvdro-pyrazolo 4.3-c1pyridin-1-ylj-propyl}-piperazin-1-yl)-3- methanesulfonylamino-benzoic acid methyl ester. A solution of 1.0 g (2.73 mmol) of 4-(2-methoxycarbonyl-6-nitro-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester in 18 mL of MeOH was treated with 893 mg (13.7 mmol, 5 eq) of zinc dust and glacial acetic acid (8 mL). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was then filtered through a pad of celite and concentrated to obtain a thick oil. The residue was taken up in EtOAc (200 mL) and sat. NaHCO3(100 mL). The organic layer was separated, washed with H2O (2x 50 mL), dried over Na2S04, and concentrated. Column chromatography (silica, 10-30% EtOAc/hexanes) provided the desired amine (844 mg, 92%). The amine (42 mg, 0.13 mmol) in CH2CI2 (0.5 mL) was treated with 9.7 μL (0.13 mmol, 1.0 eq) of methanesulfonyl chloride and 34.9 μL (0.25 mmol, 2 eq) of triethylamine and the reaction mixture stirred at 25 °C for 1 h. EtOAc (20 mL) and sat. NaHCO3 (10 mL) were added. The organic layer was separated and washed with H2O (10 mL), brine (20 mL), dried over Na2SO4, and concentrated. The crude oil was dissolved in 2 mL of CH2CI2 and treated with 0.5 mL of trifluoroacetic acid. The reaction mixture was stirred at 25 °C for 1 h before all volatiles were removed. The crude oil was dissolved in absolute EtOH (1.0 mL) and treated with 40 mg (0.1 mmol)*of 5-methanesulfonyl-1-oxiranylmethyl-3-(4- trifluoromethyl-phenyI)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine and 200 μL of triethylamine. The reaction mixture was refluxed at 85 °C for 4 h and then the solvent was removed. Preparative TLC (silica, 7% MeOH/CH2CI2) provided 35 mg (49% over 3 steps) of the title compound. TLC (silica, 5% MeOH/CH2CI2): Rf = 0.30. MS (electrospray): exact mass calculated for C30H37F3N6O7S2, 714.21 ; m/z found, 715.2 [M+H]+. 1H NMR (400 MHz, CDCI3): 8.11 (s, 1 H), 7.74-7.59 (m, 5H), 7.30 (d, J = 8.1 Hz, 1 H), 7.21 (t, J = 8.2 Hz, 1 H), 4.62-4.49 (m, 2H), 4.25-3.99 (m, 3H), 3.90 (s, 3H), 3.80-3.57 (m, 3H), 3.53-3.27 (m, 2H), 3.14-2.78 (m, 4H), 3.05 (s, 3H), 2.86 (s, 3H), 2.76-2.65 (m, 2H), 2.61-2.20 (m, 4H).
EXAMPLE 22
Figure imgf000092_0001
1-{3-[4-(1 ,1-Dioxo-1 H-1 l6-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-propyl}-5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H- pyrazolo[4,3-c]pyridine.
A. 3-Piperazin-1-yl-benzo[d1isothiazole 1.1 -dioxide. POCI3 (10.2 mL, 109.2 mmol) was added to saccharin (5.0 g, 27.3 mmol) and heated at 120 °C for 20 h. The excess reagent was removed in a rotary evaporator and water (50 mL) was added to the residue to form a precipitate. The solid was filtered, washed with water (2 x 20 mL), and dried. A portion of the above crude material (2.0 g, 9.95 mmol) and piperazine (4.28 g, 49.75 mmol) was taken in dioxane (10 mL), and heated at 100 °C for 24 h. The reaction was allowed to cool to room temperature and poured into ice water (50 g), and neutralized by addition of 10% aqueous NaOH. The mixture was extracted with CH2CI2 (3 x 25 mL) and the combined organic extracts were washed with brine, dried (Na2SO4) and concentrated. MPLC (silica, 5-20% MeOH/CH2CI2) afforded the piperazinyl derivative (0.07 g, 4.2%). MS
(electrospray): exact mass calculated for C11H13N3O2S, 251.07; m/z found, 252.1 [M+H]+. 1H NMR (400 MHz, CDCI3): 7.72 (dd, J = 0.8, 7.4 Hz, 1 H), 7.64 (d, J = 7.8 Hz, 1 H), 7.49 (dt, J = 0.8, 7.4 Hz, 1 H), 7.43 (dt, J = 1.2, 7.8 Hz, 1 H), 3.80 (s, 4H), 2.85 (br t, J = 5.0 Hz, 4H), 2.07 (br s, 1 H). 13C NMR (100 MHz, CDCI3): 160.8, 145.3, 133.3, 133.0, 128.5, 125.9, 123.2, 49.8, 46.3.
B. 1-(3-[4-(1.1-Dioxo-1 H-1 l6-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-propyl}-5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4.5.6.7-tetrahydro-1 H- pyrazolo[4.3-clpyridine.
To a stirred solution of 3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propionaldehyde (0.040 g, 0.13 mmol) and 3-piperazin-1-yl-benzo[d]isothiazole 1 ,1-dioxide (0.050 g, 0.21 mmol) in CH2C12 (0.5 mL), glacial AcOH (12 μL, 0.21 mmol) was added and stirred for 15 min at room temperature. NaBH(OAc)3 (0.058 g, 0.27 mmol) was added and stirred under nitrogen overnight. Saturated NaHCO3 (0.5 mL) was then added and stirred for 15 min. The layers separated and the aqueous layer was extracted with CH2CI2 (0.5 mL). MPLC (silica, 2-15% MeOH/CH2CI2) afforded the desired product as a white solid (0.048 g, 76%). TLC (silica, 12% MeOH/CH2CI2): Rf = 0.50. MS (electrospray): exact mass calculated for C28H31F3N6O4S2, 636.18; m/z found, 637.2 [M+H]+. 1H NMR (400 MHz, CDCI3): 7.94 (dd, J = 0.8, 7.6 Hz, 1 H), 7.86 (d, J = 7.8 Hz, 1 H), 7.75 (d, J = 8.3 Hz, 2H), 7.73-7.63 (m, 2H), 7.68 (d, J = 8.3 Hz, 2H), 4.57 (s, 2H), 4.17 (t, J = 6.9 Hz, 2H), 4.04 (br s, 4H), 3.69 (t, J = 5.7 Hz, 2H), 2.94 (s, 3H), 2.92 (t, J = 6.2 Hz, 2H), 2.62 (t, J = 5.0 Hz, 4H), 2.44 (t, J = 6.6 Hz, 2H), 2.13 (q, J = 6.6 Hz, 2H).
EXAMPLE 23
Figure imgf000094_0001
1 -[1 -{3-[4-(6-Chloro-benzothiazol-2-yl)-piperazin-1 -yl]-2-hydroxy-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone
A. 6-Chloro-2-piperazin-1 -yl-benzothiazole.
To a stirred solution of 1.07 g (5.24 mmol) of 2,6-dichlorobenzothiazole in dry DMF (25 mL) was added 2.4 g of potassium carbonate (15.7 mmol) and 0.5 g of piperazine (5.8 mmol). The mixture was stirred at room temperature for 4 h. When the reaction was complete it was partitioned between EtOAc (150 mL) and water (50 mL) and separated. The aqueous layer was extracted with EtOAC (2 x 100 mL). The combined organic layers were then washed with water (2 x 25 mL), brine, dried over Na2SO4, and the solvent was removed under reduced pressure to give 1.33 g (100%) of desired product as a white solid. MS (electrospray): exact mass calculated for C^H^CI^S, 253.04; m/z found, 254.0 [M+H]+.
B. 1 -M -l3-[4-(6-Chloro-benzothiazol-2-vO-piperazin-1 -yl1-2-hvdroxy-propyl}-3- (4-trifluoromethyl-phenyl)-1.4.6.7-tetrahydro-pyrazolo 4.3-c]pyridin-5-yl1- ethanone.
To a stirred solution of 144 mg (0.39 mmol) of 1-[1-oxiranylmethyl-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone in 4 mL of EtOH was added 100 mg (0.39 mmol) 6-chloro-2-piperazin-1 -yl- benzothiazole. The solution was heated to 60 °C overnight. The solvent was then removed by rotary evaporation and the crude product was purified by column chromatography (silica, 0-10% MeOH/EtOAc) to afford 220 mg (90%) of a white solid. MS (electrospray): exact mass calculated for C29H30CIF3N6O2S: 618.18; m/z found, 619.2 [M+H]+. HPLC (reverse phase conditions 40-90%): tR = 8.27 min. 1H NMR (CDCI3, 400 MHz, a mixture of amide rotamers): 7.70 (d, J = 8.34 Hz, 1 H), 7.62 (m, 2H), 7.57 (d, J = 8.59 Hz, 1 H), 7.48 (d, J = 2.53 Hz, 1 H), 7.36 (d, J = 8.59 Hz, 1 H), 7.16 (dd, J = 8.59, 2.53 Hz, 1 H), 4.80 and 4.68 (A and B of AB quartet, J = 15.92 Hz, 1 H), 4.58 (s, 1 H), 4.18-4.08 (m, 2H), 4.01-3.89 (m, 2H), 3.85-3.60 (m, 2H), 3.59-3.47 (m, 4H), 2.94-2.75 (m, 2H), 2.72-2.62 (m, 2H), 2.55-2.47 (m, 2H), 2.46-2.39 (m, 2H), 2.13 (s, 1.5H), 2.08 (s, 1.5H).
EXAMPLE 24
Figure imgf000095_0001
1 -[1 -[3-(4-Benzo[d]isoxazol-3-yl-piperazin-1 -yl)-2-hydroxy-propyl]-3-(4- trifIuoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone.
A. 4-Benzo[d]isoxazol-3-yl-piperazine-1 -carboxylic acid tert-butyl ester. To a stirred solution of 100 mg (0.65 mmol) of 3-chloro-1 ,2-benzisoxazole in pyridine (1 mL) was added 145 mg of piperazine-1 -carboxylic acid tert-butyl ester (0.78 mmol) and 0.18 mL of DBU (0.78 mmol). The mixture was stirred at 100 °C overnight and then partitioned between EtOAC (50 mL) and water (20 mL) and separated. The aqueous layer was extracted with EtOAC (2 x 30 mL). The combined organic layers were then washed with water (25 mL), brine, dried over Na2SO4, and the solvent was removed under reduced pressure to give crude product. Purification by column chromatography (silica, 60-100%CH2CI2/hexanes) gave 82 mg (42%) of the desired product as a light yellow solid. MS (electrospray): exact mass calculated for C16H21N3O3, 303.16; m/z found, 326.1 [M+Na]+. 1H NMR (CDCI3, 400 MHz): 7.68 (dt, J = 8.02, 0.98 Hz, 1 H), 7.52-7.44 (m, 2H), 7.24 (ddd, J = 8.42, 6.46, 1.57 Hz, 1 H), 3.66-3.61 (m, 4H), 3.56-3.49 (m, 4H), 1.49 (s, 9H).
B. 1 -H -re-^-BenzoFdlisoxazol-S-yl-piperazin-l -vπ-2-hvdroxy-propyl]-3-(4- trifluoromethyl-phenyl)-1.4.6.7-tetrahydro-pyrazolo[4.3-clpyridin-5-yl]-ethanone. A solution of 82 mg (0.27 mmol) of 4-benzo[d]isoxazol-3-yl-piperazine-1- carboxylic acid tert-butyl ester in 2 mL of CH2CI2was treated with trifluoroacetic acid (0.5 mL) at room temperature overnight. The solvent was then removed and the crude product dissolved in EtOH and stirred over 100 mg of sodium bicarbonate for 1 h, the solid was then filtered off and the filtrate concentrated. The crude piperazine was then dissolved in 4 mL EtOH and treated with 100 mg (0.27 mmol) of 1-[1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone. The solution was heated to 60 °C overnight. The solvent was then removed by rotary evaporation and the crude product was purified by column chromatography (silica, 0-10%
MeOH/EtOAc) to afford 105 mg (68%) of a white solid. MS (electrospray), exact mass calculated for C29H31F3N6O3, 568.24; m/z found, 569.2 [M+H]+. 1H NMR (CDCI3, 400 MHz, a mixture of amide rotamers): 7.77 (d, J = 8.41 Hz, 1 H), 7.69 (m, 2H), 7.67-7.62 (m, 2H), 7.50-7.44 (m, 1 H), 7.45-7.42 (m, 1 H), 7.23-7.18 (m, 1 H), 4.93 (br m, 1 H), 4.87 and 4.75 (A and B of AB quartet, J = 15.65 Hz, 1 H), 4.65 (br s, 1 H), 4.27-4.15 (m, 2.3H), 4.09-3.95 (m, 1.7H), 3.91- 3.82 (m, 0.7H), 3.81-3.66 (m, 1.3H), 3.62-3.49 (m, 4H), 3.01-2.85 (m, 1.5H), 2.85-2.74 (m, 2.5H), 2.71-2.60 (m, 2H), 2.58-2.45 (m, 2H), 2.20 (s, 1.5H), 2.15 (s, 1.5H).
EXAMPLE 25
Figure imgf000097_0001
1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2- ol.
EXAMPLE 26
Figure imgf000097_0002
1-[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yI)-phenyl]-3-methyl- urea.
EXAMPLE 27
Figure imgf000097_0003
1-[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-
4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]-3- methyl-urea. EXAMPLE 28
Figure imgf000098_0001
3-Amino-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyI-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-benzoic acid methyl ester.
EXAMPLE 29
Figure imgf000098_0002
3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenylamine.
EXAMPLE 30
Figure imgf000098_0003
1-[2-(4-{3-[3-(4-Bromo-phenyl)-5-methanesuIfonyl-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-3-chloro-phenyl]-
3-methyl-urea. EXAMPLE 31
Figure imgf000099_0001
1-{3-[4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazin-1-yl]-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.
EXAMPLE 32
Figure imgf000099_0002
[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]-carbamic acid methyl ester.
EXAMPLE 33
Figure imgf000099_0003
1-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3-(4-bromo-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxyIic acid amide. EXAMPLE 34
Figure imgf000100_0001
2-(4-{3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1 -yl]-2-hydroxy-propyl}-piperazin-1 -yl)-3-nitro-benzoic acid methyl ester.
EXAMPLE 35
Figure imgf000100_0002
1-[4-(2-Chloro-6-nitro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yI]-propan-2- ol.
EXAMPLE 36
Figure imgf000100_0003
2-(4-{2-Hydroxy-3-[3-(4-iodo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-benzonitrile. EXAMPLE 37
Figure imgf000101_0001
3-(4-Bromo-phenyl)-1 -{3-[4-(2-nitro-phenyl)-piperazin-1 -yl]-propyl}-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.
EXAMPLE 38
Figure imgf000101_0002
2-(4-{3-[5-Acetyl-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1- yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile.
EXAMPLE 39
Figure imgf000101_0003
2-(4-{3-[3-(4-Chloro-3-methyl-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitriIe. EXAMPLE 40
Figure imgf000102_0001
1 -(3-(4-Chloro-3~methyl-phenyl)-1 -{3-[4-(2,4-dimethyl-phenyl)-piperazin-1 -yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazoIo[4,3-c]pyridin-5-yl)-ethanone.
EXAMPLE 41
Figure imgf000102_0002
1-{3-[4-(3,5-Dichloro-pyridin-4-yl)-piperazin-1-yl]-propyl}-5-methanesulfonyl-3- (4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine.
EXAMPLE 42
Figure imgf000102_0003
2-(4-{3-[5-Methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-benzonitrile. EXAMPLE 43
Figure imgf000103_0001
N-[3-Chloro-2-(4-{3-[5-methanesulfonyI-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]- methanesulfonamide.
EXAMPLE 44
Figure imgf000103_0002
3-(3,4-Dichloro-phenyl)-1 -{3-[4-(2-nitro-phenyl)-piperazin-1 -yl]-propyl}-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.
EXAMPLE 45
Figure imgf000103_0003
3-(4-Chloro-3-methyl-phenyl)-1-{3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide. EXAMPLE 46
Cathepsin S Inhibition Assay.
Recombinant human cathepsin S (CatS) was expressed in the baculovirus system and purified in one step with a thiopropyl-sepharose column. 10-L yielded -700 mg of CatS and N-terminal sequencing confirmed identity. The assay is run in 100 mM sodium acetate pH 5.0 containing 1 mM DTT and 100 mM NaCl. The substrate for the assay is
(Aedens)EKARVLAEAA(Dabcyl)K-amide
The Km for the substrate is around 5 μM but the presence of substrate inhibition makes kinetic analysis difficult. With 20 μM substrate the assay rate is linear over the range of 1-8 ng CatS in 100 μl reaction. Using 2 ng/well of CatS, the production of product is linear and yields -7-fold signal after 20 min with only 20%) loss of substrate. Primary assays are run by quenching the reaction after 20 min with 0.1 % SDS and then measuring the fluorescence. For other assays, measurements are taken every min for 20 min. The rate is calculated from the slope of the increase and the percent inhibition is calculated from this (See Tables 1 and 2 below).
Table 1
Figure imgf000105_0001
Table 2
Figure imgf000106_0001
Example 47
Ex vivo inhibition by cathepsin S inhibitors of the allergenic response The following assay demonstrates that cathepsin S inhibitors block the response of human T cells to crude allergen extracts.
Materials and Methods.
Reagents. Glycerinated crude allergen extracts of house dust mites
(Dermataphagoides pteronyssinus, Dermataphagoides farinae) and ragweed [Ambrosia trifida (giant), Ambrosia artemisiifolia (short)] were purchased from Hollister-Stier Laboratories (Minneapolis, MN). Concanavalin A (ConA) was purchased from Calbiochem (La Jolla, CA).
Donors. All allergic donors were prescreened for their specific allergies using RAST tests. The HLA class II haplotypes of these donors were determined using PCR.
Cell culture. Human peripheral blood mononuclear cells (PBMC) were purified from blood of allergic donors using Ficoll-Hypaque gradient followed by washes with phosphate buffered saline (PBS). PBMC were cultured in triplicate or duplicate at 0.5-1.0 x 106 cells/well with titrated doses of allergen extracts, in the presence or absence of a known cathepsin S inhibitor, LHVS (morpholinurea-leucine-homo-phenylalanine-vinylsulfonephenyl) (Palmer et al. (1995), J. Med. Chem. 38:3193 and Riese et al. (1996), Immunity 4:357). Serial diluted stock solutions of LHVS were first made in 100% DMSO and then diluted 1 :15 in 40% Hydroxypropynyl cyclodextrin (HPCD). Three microliters of LHVS in HPCD was added into PBMC cultures (200 μL/well). After 6 days of culture, 1 μCi/well of 3H-thymidine (TdR) was added. Eighteen hours later, cells were harvested using a Filtermate Harvester (Packard) and counted for 3H-TdR incorporation on Topcount (Packard). Inhibition of T cell proliferative responses to house dust mites.
About 10%) of most populations are allergic to house dust mites (HDM) of the genus Dermatophagoides with Dermatophagoides pteronyssinus (Der p) and D. farinae (Der f) being the two major species present in varying proportions in most countries. The major clinical manifestations are asthma and perennial rhinitis.
Effect of cathepsin S inhibition on activation of HDM allergen-specific
CD4 T cells was tested in an ex vivo human T cell-proliferation assay. Culturing PBMC with crude extracts from either Derp or Derf, resulted in strong proliferation (Figure 1A). This proliferation consisted primarily of allergen-specific CD4 T cells. When cathepsin S activity was blocked by a specific cathepsin S inhibitor, LHVS (cf. Riese et al. (1996) Immunity 4:357) the proliferation was strongly inhibited (Figure 1 B). Inhibition by LHVS was specific for responses induced by HDM extracts since T cell proliferative responses induced by ConA, a pan-T cell mitogen, were not affected. Furthermore, this inhibition was observed for all four HDM-allergic donors tested regardless of the different HLA class II haplotypes (DR4; DR7, 15; DR11 , 15; and DR4, 11 ).
This system is very similar to an in vivo situation. The allergic subject would be exposed to a crude mixture of allergens that would lead to the proliferation of T cells and an allergic response. The observation of inhibition of CD4 T cell activation by a cathepsin S inhibitor shows that such inhibitors can be effective in treating a generalized population of patients allergic to house dust mites.
Inhibition of T cell proliferative responses to ragweed
About 10%) of population in US are allergic to ragweed pollen, making it one of the most important allergens in terms of clinical diseases. Allergens from pollens are a common precipitant of rhinitis and asthma in this population. The effect of cathepsin S inhibition on activation of ragweed allergen- specific CP4 T cells was tested in an ex vivo human T cell-proliferation assay. Culturing PBMC with crude extracts from both short and giant ragweed resulted in strong proliferation (Figure 2A). This proliferation consisted mainly of allergen-specific CP4 T cells. When cathepsin S activity was blocked by a specific cathepsin S inhibitor, LHVS (cf. Riese et al. (1996) Immunity 4:357) the proliferation was strongly inhibited (Figure 2B). Inhibition by LHVS was specific for responses induced by ragweed since T cell proliferative responses induced by ConA, a pan-T cell mitogen, were not affected. Furthermore, this inhibition was observed for the two ragweed-allergic donors tested regardless of the different HLA class II haplotypes (PR7, 15 and PR4, 11 ).
A similar experiment was run using two additional CatS inhibitors, compounds from Example 11 and Example 36 above, with the results shown in FIGS. 3A and 3B, respectively.
This system is very similar to an in vivo situation. The allergic subject would be exposed to a crude mixture of allergens that would lead to the proliferation of T cells and an allergic response. The observation of inhibition of CP4 T cell activation by a cathepsin S inhibitor shows that such inhibitors can be effective in treating a generalized population of patients allergic to ragweed.
Example 48
Monitoring cathepsin S inhibition in human blood.
The effect of in vivo administration of cathepsin S inhibitors, in a clinical trial setting, can be monitored by measuring accumulation of an intermediate degradation product of invariant chain (li), i.e. the p10li fragment, in blood of dosed subjects. After administration of a cathepsin inhibitor for a certain period of time, for example, between 0.01 and 50 mg/kg/day, to result in a blood concentration of between 1 nM-10 μM, for 16-30 h, blood is drawn and white blood cells are purified, e.g. either by lysis of red blood cells or by a Ficoll- Hypaque gradient centrifugation. Whole cell lysates of WBC are then made and analyzed by either a Western blot assay or an ELISA assay. For the Western blot assay, cell lysates are first resolved on SPS-PAGE gels. After transferring to nitrocellulose membranes, li and its intermediate degradation products, including the p10li, can be detected using a mouse mAb against li, e.g. Pin1.1 , or rabbit polyclonal antibodies specific for the C-terminus of the p1 ON fragment or against the entire p1 Oli fragment. For ELISA assay, a pair of antibodies against li, including Pin1.1 , and a rabbit polyclonal antibody or a mouse monoclonal antibody specific for p10Ii, can be used. The same assay can also be applied to monitor the effect of cathepsin S inhibitors in vivo in animal studies, for example in monkeys, dogs, pigs, rabbits, guinea pigs, and rodents.
In the present example PBMC from human blood were incubated with the cathepsin S inhibitor, LHVS (morpholinurea-leucine-homo-phenylalanine- vinylsulfonephenyl, also referred to as 4-morpholinecarboxamide, N-[(1 S)-3- methyl-1 -[[[(1 S,2E)-1 -(2-phenylethyl)-3-(phenylsulfonyl)-2- propenyl]amino]carbonyl]butyl]-. This compound has been described in US Patent No. 5,976,858 and in Palmer et al. (1995) J. Med. Chem. 38:3193 and Riese et al. (1996) Immunity 4:357. After incubation for 24 h the samples were run using standard SPS-PAGE protocols, transferred to nitrocellulose membranes and probed with an antibody that recognizes the invariant chain including the p10li fragment. In the presence of LHVS the p10li fragment was seen, representing a block in the degradation of li due to inhibition of cathepsin S.
Example 49
Monitoring in vivo inhibition of allergenic response by cathepsin S inhibitors. To demonstrate the efficacy of cathepsin S inhibitors for suppressing allergic responses in vivo, allergic volunteers are dosed with cathepsin S inhibitors to levels where invariant chain degradation is inhibited. Allergens are deposited subcutaneously, and the size of the cutaneous reactions are determined at 15 min, 6 h and 24 h. Skin biopsies are performed at 24 h. The immediate weal and flare response is not mediated by a T cell response and is not expected to be influenced by cathepsin S inhibitors, while the late phase induration (noticeable at 6 ho.urs, more pronounced at 24 hours) is characterized by activation and infiltration of CP4 T cells (as well as of eosinophils) and should be inhibited by administration of inhibitors of cathepsin S. The skin biopsies are used to determine the cellular composition in the induration, and cathepsin S treated subjects are expected to have fewer activated CD4 T cells present than placebo-treated subjects.
References for these procedures are provided in Eberlein-Konig et al.
(1999) Clin. Exp. Allergy 29:1641-1647 and in Gaga et al. (1991 ) J. Immunol. 147:816-822.
As controls for the experiment, prednisone and cyclosporine A will be used. Prednisone will inhibit both the immediate and the late phase responses, while cyclosporin A will inhibit only the late phase response.
F. Other Embodiments
The features and advantages of the invention are apparent to one of ordinary skill in the art. Based on this disclosure, including the summary, detailed description, background, examples, and claims, one of ordinary skill in the art will be able to make modifications and adaptations to various conditions and usages. These other embodiments are also within the scope of the invention.
What is claimed is:

Claims

1. A method for treating a subject with an allergic condition, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I) below:
Figure imgf000113_0001
(I) wherein:
R1 is hydrogen, azido, halogen, C^ alkoxy, hydroxy, C^ alkyl, C2.5 alkenyl, cyano, nitro, R7R8N, C 2.8 acyl, R9OC=O, R10R11NC=O, or R10R11NSO2; or R1 is taken together with W as described below; R2 is hydrogen, halogen, C,_5 alkoxy, C^ alkyl, C2.5 alkenyl, C^ haloalkyl, cyano, or R48R49N; alternatively, R1 and R2 can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic; each of R3 and R4 is independently hydrogen or C,^ alkyl; each of R5 and R6 is independently hydrogen, C.,.5 alkyl, C2.5 alkenyl, C,_5 alkoxy, C,_g alkylthio, halogen, or a 4-7 membered carbocyclyl or heterocyclyl; alternatively, R5 and R6 can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic, and may be optionally substituted with between one and three substituents independently selected from halo, cyano, amino, nitro, R40, R40O-, R40S-, R40O(C ,.δ alkylene)-, R40O(C=O)-, R40(C=O)-, R40(C=S)-, R40(C=O)O-, R40O(C=O)(C=O)-, R40SO2,
NHR62(C=NH)-, NHR62SO2-, and NHR62(C=O) -; R40 is H, C ^g alkyl, C2.5 alkenyl, phenyl, benzyl, phenethyl, C ^ heterocyclyl,
(C .,_5 heterocyclyl)C 1-5 alkylene, amino, or mono- or di(C ^ alkyl)amino, or R58OR59-, wherein R58 is H, C ^ alkyl, C 2.5 alkenyl, phenyl, benzyl, phenethyl, C ^ heterocyclyl, or (C ^ heterocyclyl)C ^ alkylene and R59 is C ^g alkylene, phenylene, or divalent C ^ heterocyclyl; and R62 can be H in addition to the values for R40;
R7 is hydrogen, C,^ alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl, C2.8 acyl, aroyl, R27OC=O, R28R29NC=O, R27SO, R27SO2, or R28R29NSO2;
R8 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R7 and R8 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; R9 is C^ alkyl, phenyl, naphthyl, or C ^ heterocyclyl;
R21 is hydrogen, C.,.5 alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl,
C 2.8 acyl, aroyl, R30OC=O, R31R32NC=O, R30SO, R30SO2, or R31R32NSO2; R22 is hydrogen, C,^ alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R21 and R22can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R23, R26, R27, R30, R33, R44, R45, and R50 is C^ alkyl, phenyl, naphthyl, or
C .,.5 heterocyclyl; R24 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl, C 2.8 acyl, aroyl, R33OC=O, R34R35NC=O, R33SO, R33SO2, or R34R35NSO2;
R25 is hydrogen, C,_5 alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R24 and R25 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R10 and R11 is independently hydrogen, C^ alkyl, C2.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R10 and R11 or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R28, R29, R31, R32, R34, R35, R46, R47, R51 and R52 is independently hydrogen, C^ alkyl, phenyl, or C ^ heterocyclyl; alternatively, R28 and R29, R31 and R32, R34 and R35, R46 and R47, or R51 and R52, independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; n is 1 or 2;
G represents C3.6 alkenediyl or C3.6 alkanediyl, optionally substituted with hydroxy, halogen, C^ alkyl, C.,.5 alkoxy, oxo, hydroximino, CO2R60,
R60R61NCO2, (L)-C M alkylene-, (L)-C^ alkoxy, N3, or [(L)-C ,.5 alkylenejamino; each of R60 and R61 is independently hydrogen, C^ alkyl, C 3.5 alkenyl, phenyl, benzyl, phenethyl, or C ^ heterocyclyl; alternatively R60 and R61 , can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; L is amino, mono- or di-C,.5 alkylamino, pyrrolidinyl, morpholinyl, piperidinyl homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with C^5 alkyl, benzyl, C2.5 acyl, C|„5 alkylsulfonyl or C^ alkyloxycarbonyl;
X is nitrogen or R12C; Y is nitrogen or R13C; Z is nitrogen or R14C;
R12 is hydrogen, halogen, C,^ alkoxy, C,.5 alkyl, C2.5 alkenyl, cyano, nitro, R21R22N, C 2.8 acyl, C^ haloalkyl, C 5 heterocyclyl, (C ^ heterocyclyl)C .,_
5 alkylene, R23OC=O, R23O(C=O)NH-, R23SO, R22NHCO-,
R22NH(C=O)NH-, R23(C 1-φ alkylene)NHCO-, R23SO2, or R23SO2NH-; R13 is hydrogen, halogen, C^ alkoxy, C^ alkyl, C2.5 alkenyl, cyano, nitro,
R42R43N, C 2.8 acyl, C^ haloalkyl, C ^ heterocyclyl, (C ^ heterocyclyl)C ,. 5 alkylene, R44OC=O, R44O(C=O)NH-, R44SO, R43NHCO-,
R43NH(C=O)NH-, R44(C M alkylene)NHCO-, R44SO2, or R44SO2NH-; R14 is hydrogen, halogen, C,^ alkoxy, C,_g alkyl, C2.5 alkenyl, cyano, nitro,
R24R25N, C 2.8 acyl, C,.5 haloalkyl, C ^ heterocyclyl, (C 5 heterocyclyl)C ,. 5 alkylene, R26OC=O, R26O(C=O)NH-, R26SO, R25NHCO-, R25NH(C=O)NH-, R26(C M alkylene)NHCO-, R26S02, or R26SO2NH-; alternatively, R12 and R13 or R12 and R2 or R13 and R14 can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;
Ar represents a monocyclic or bicyclic aryl or heteroaryl ring, optionally substituted with between 1 and 3 substituents selected from halogen,
C^s alkoxy, C,.5 alkyl, C2.5 alkenyl, cyano, azido, nitro, R15R16N, R17SO2,
R17S, R17SO, R17OC=O, R15R16NC=O, C^ haloalkyl, C^ haloalkoxy, C,.s haloalkylthio, and C^alkylthio;
R15 is hydrogen, C,.5 alkyl, C3.5 alkenyl, phenyl, benzyl, C .,_5 heterocyclyl, C 2.8 acyl, aroyl, R53OC=O, R54R55NC=O, R53S, R53SO, R53SO2, or R54R55NSO2;
R16 is hydrogen, C,.5 alkyl, C3^ alkenyl, phenyl, benzyl, or C ^ heterocyclyl; alternatively, R15 and R16 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; each of R17 and R53 is C,^ alkyl, phenyl, or C ^ heterocyclyl; each of R54 and R55 is independently hydrogen, C.,_5 alkyl, C2.5 alkenyl, phenyl, benzyl, or C ^ heterocyclyl; alternatively, R54 and R55 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
W represents SO2, C=O, CHR20, or a covalent bond; or W and R1, taken together with the 6-membered ring to which they are both attached, form one of the following two formulae:
Figure imgf000116_0001
(l)(a) (l)(b) wherein Xa is O, S, or N; and Xb is O, S or SO2; R20 is hydrogen, C.,.5 alkyl, phenyl, benzyl, naphthyl, or C .,_5 heterocyclyl; R42 is hydrogen, C,.5 alkyl, C3^ alkenyl, phenyl, naphthyl, C ^ heterocyclyl,
C 2.8 acyl, aroyl, R45OC=O, R46R47NC=O, R45SO, R45SO2, or R46R47NSO2; R43 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, or C ^ heterocyclyl; alternatively, R42 and R43can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; R44 is C^ alkyl, C2.5 alkenyl, phenyl, naphthyl, or C ^ heterocyclyl; R48 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, naphthyl, C ^ heterocyclyl, C
2.8 acyl, aroyl, R50OC=O, R51R52NC=O, R50SO, R50SO2) or R51R52NSO2; R49 is hydrogen, C^ alkyl, C3.5 alkenyl, phenyl, or C 5 heterocyclyl; alternatively, R48 and R49 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and
wherein each of the above hydrocarbyl or heterocarbyl groups, unless otherwise indicated, and in addition to any specified substituents, is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano, C ^ alkyl, C ^ alkoxy, -COOH, C 2.6 acyl, [di(C !_4 alkyl)amino]C 2.5 alkylene, [di(C M alkyl)amino] C 2.5 alkyl-NH- CO-, and C ^ haloalkoxy;
or a pharmaceutically acceptable salt, ester, or amide thereof.
2. A method of claim 1 , wherein each of R3 and R4 is hydrogen; Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen, C^ alkyl, cyano, nitro, R15R16N, CF3 and OCF3; R12 is hydrogen, R23SO, or R23SO2; R13 is hydrogen, R44SO, or R44SO2; R14 is hydrogen, halogen, C,^ alkoxy, C^ alkyl, cyano, nitro, or R24R25N; and G is C3 alkanediyl, optionally substituted with hydroxy, (L)-C,.5 alkyloxy-, or (LJ-C^ alkylamino.
3. A method of claim 2, wherein Ar is phenyl.
4. A method of claim 1 , wherein said compound is selected from: 1 -[4-(2-Amino-6-chloro-phenyl)-piperazin-1 -yl]-3-[5-methanesulfonyl-3-
(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]- propan-2-ol ;
1-[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]-3- methyl-urea ;
1-[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)- phenyl]-3-methyl-urea ;
3-Amino-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1 -yl]-propyl}-piperazin-1 -yl)- benzoic acid methyl ester ;
3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1 -yl]-propyl}-piperazin-1 -yl)-phenylamine ; 1-[2-(4-{3-[3-(4-Bromo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1 -yl]-2-hydroxy-propyl}-piperazin-1 -yl)-3-chloro-phenyl]- 3-methyI-urea ; and 1 -{3-[4-(2-Chloro-6-methanesuIfonylamino-phenyl)-piperazin-1 -yl]- propyl}-3-(4-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine- 5-carboxylic acid amide .
5. A method of claim 1 , wherein said compound is selected from: [3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-
4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]- carbamic acid methyl ester ; 1 -[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1 -yl)-propyl]-3-(4-bromo- phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide ;
2-(4-{3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydroτ pyrazolo[4,3-cjpyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-3-nitro-benzoic acid methyl ester ;
1-[4-(2-Chloro-6-nitro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2- ol ; 2-(4-{2-Hydroxy-3-[3-(4-iodo-phenyl)-5-methanesulfonyl-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-benzonitrile ;
3-(4-Bromo-phenyl)-1-{3-[4-(2-nitro-phenyl)-piperazin-1-yl]-propyl}- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-cjpyridine-5-carboxylic acid amide ;
2-(4-{3-[5-Acetyl-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile ;
2-(4-{3-[3-(4-Chloro-3-methyl-phenyl)-5-methanesulfonyl-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)- benzonitrile;
1-(3-(4-Chloro-3-methyl-phenyl)-1-{3-[4-(2,4-dimethyl-phenyl)-piperazin- 1-yl]-2-hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone;
1-{3-[4-(3,5-Oichloro-pyridin-4-yl)-piperazin-1-yl]-propyl}-5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H- pyrazolo[4,3-c]pyridine ;
2-(4-{3-[5-Methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4, 5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1 -yl]-propyl}-piperazin-1 -yl)-benzonitrile;
N-[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyI)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyI}-piperazin-1-yl)-phenyl]- methanesulfonamide ;
3-(3,4-Pichloro-phenyl)-1-{3-[4-(2-nitro-phenyl)-piperazin-1-yl]-propyl}- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide; and 3-(4-Chloro-3-methyl-phenyl)-1 -{3-[4-(2-cyano-phenyl)-piperazin-1 - yI]-2-hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.
6. A method of claim 1 , wherein said compound is selected from :
1 -(3-(4-Chloro-phenyl)-1 -{3-[4-(2-fluoro-phenyl)-piperazin-1 -yl]-propyl}-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone; 1 -{3-(4-Chloro-phenyl)-1 -[2-hydroxy-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-5-yI}-ethanone;
1 -{3-(4-Chloro-phenyl)-1 -[2-methoxy-3-(4-o-tolyl-piperazin-1 -yI)-propyl]-1 ,4,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone; 1 -[1 -{2-Hydroxy-3-[4-(2-hydroxy-phenyl)-piperazin-1 -yl]-propyl}-3-(4-iodo- phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;
1 -[1 -[2-Hydroxy-3-(4-o-tolyl-piperazin-1 -yl)-propyl]-3-(4-trifluoromethyl-phenyl)-
1 ,4,6,7-tetrahydro-pyrazolo[4,3-cjpyridin-5-yl]-ethanone;
2-(4-{3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1 -yl]-2-hydroxy-propyl}-piperazin-1 -yl)-benzonitrile;
1 -[3-(3,4-Pichloro-phenyl)-pyrazol-1 -yl]-3-(4-o-tolyl-piperazin-1 -yl)-propan-2-oI;
1 -[1 -[2-(2-Piperazin-1 -yl-ethylamino)-3-(4-o-toIyl-piperazin-1 -yl)-propyl]-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;
1-{3-[4-(2-Cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl}-3-(4-iodo-phenyl)- 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxyIic acid tert-butyl ester;
1-{3-[4-(2-Cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl}-3-(4-iodo-phenyl)-
1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
Carbamic acid 1 -[5-carbamoyl-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro- pyrazolo[4,3-c]pyridin-1-ylmethyl]-2-[4-(2-cyano-phenyl)-piperazin-1-yl]-ethyl ester;
1 -{3-(3-Amino-4-chloro-phenyl)-1 -[2-hydroxy-3-(4-o-tolyl-piperazin-1 -yl)-propylj-
1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone;
(R)-1 -(3-(4-Bromo-phenyl)-1 -{3-[4-(5-chloro-2-methyl-phenyl)-piperazin-1 -yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone; 2-(4-{3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3- c]pyridin-1-yl]-2-fluoro-propyI}-piperazin-1-yl)-benzonitrile;
(3-(4-Chloro-3-methyl-phenyl)-1-{3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2- hydroxy-propyl}-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-oxo-acetic acid methyl ester; 5-MethanesuIfonyl-1 -{3-[4-(2-nitro-phenyl)-piperazin-1 -yl]-propyl}-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine;
1-[3-Chloro-2-(4-{3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazoIo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]-urea; 1-{3-[4-(2-Chloro-6-methanesulfonylamino-phenyI)-piperazin-1-yl]-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-sulfonic acid amide;
N-[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1 -yl]-propyI}-piperazin-1 -yl)-phenylj- methanesulfonamide;
1-[4-(2,6-Pinitro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4- trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2- ol; 2-(4-{2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7- tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-3- methanesulfonylamino-benzoic acid methyl ester;
1-{3-[4-(1 ,1-Pioxo-1 H-1 l6-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-propyl}-5- methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1 H- pyrazolo[4,3-c]pyridine;
1 -[1 -{3-[4-(6-Chloro-benzothiazol-2-yl)-piperazin-1 -yl]-2-hydroxy-propyl}-3-(4- trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; and
1 -[1 -[3-(4-Benzo[d]isoxazol-3-yl-piperazin-1 -yl)-2-hydroxy-propyl]-3-(4- trifluoromethyI-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone.
7. A method of claim 1 , wherein said compound is selected from: N-[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyI-phenyl)- 4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)-phenyl]- methanesulfonamide;
1-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3-(4-bromo- phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide; and
1-[3-Chloro-2-(4-{2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl- phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperazin-1-yl)- phenyl]-3-methyl-urea.
8. A method of claim 1 , wherein said pharmaceutical composition is formulated in a dosage amount appropriate for the treatment of an allergic condition.
PCT/US2001/027479 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles WO2002020012A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2002524496A JP2004508329A (en) 2000-09-06 2001-09-05 Treatment of allergies using substituted pyrazoles
MXPA03001964A MXPA03001964A (en) 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles.
AU8873001A AU8873001A (en) 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles
DE60122171T DE60122171T2 (en) 2000-09-06 2001-09-05 USE OF SUBSTITUTED PYRAZOLES FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING ALLERGIES
CA002421505A CA2421505A1 (en) 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles
NZ524680A NZ524680A (en) 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles
EP01968486A EP1315491B1 (en) 2000-09-06 2001-09-05 Use of substituted pyrazoles for the manufacture of a medicament for the treatment of allergies
CNB018182720A CN100384420C (en) 2000-09-06 2001-09-05 A method for treating allergies using substituted pyrazoles
AU2001288730A AU2001288730B2 (en) 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles
HK03105865A HK1053606A1 (en) 2000-09-06 2003-08-15 Use of substituted pyrazoles for the manufacture of a medicament for the treatment of allergies
CY20061101469T CY1106196T1 (en) 2000-09-06 2006-10-12 USE OF SUBSTITUTED PYRAZOLES FOR THE MANUFACTURE OF A DRUG FOR THE TREATMENT OF ALPINE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23040700P 2000-09-06 2000-09-06
US60/230,407 2000-09-06
US09/928,122 US7309703B2 (en) 2000-08-14 2001-08-10 Substituted pyrazoles
US09/928,122 2001-08-10

Publications (2)

Publication Number Publication Date
WO2002020012A2 true WO2002020012A2 (en) 2002-03-14
WO2002020012A3 WO2002020012A3 (en) 2002-06-13

Family

ID=26924204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027479 WO2002020012A2 (en) 2000-09-06 2001-09-05 Method for treating allergies using substituted pyrazoles

Country Status (15)

Country Link
EP (1) EP1315491B1 (en)
JP (1) JP2004508329A (en)
CN (1) CN100384420C (en)
AT (1) ATE335472T1 (en)
AU (2) AU2001288730B2 (en)
CA (1) CA2421505A1 (en)
CY (1) CY1106196T1 (en)
DE (1) DE60122171T2 (en)
DK (1) DK1315491T3 (en)
ES (1) ES2269454T3 (en)
HK (1) HK1053606A1 (en)
MX (1) MXPA03001964A (en)
NZ (1) NZ524680A (en)
PT (1) PT1315491E (en)
WO (1) WO2002020012A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512272A (en) * 2000-08-14 2004-04-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted pyrazoles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254241A1 (en) * 1986-07-22 1988-01-27 Yoshitomi Pharmaceutical Industries, Ltd. Pyrazolopyridine compounds, their preparation and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944312B2 (en) * 1974-11-22 1984-10-29 中外製薬株式会社 Production method of indazole derivatives
JPS5936627B2 (en) * 1975-07-25 1984-09-05 中外製薬株式会社 Production method of indazole derivatives
DK27383A (en) * 1982-02-17 1983-08-18 Lepetit Spa PROCEDURE FOR PREPARING PYRAZOLE (4,3-C) PYRIDINES
WO1998056785A1 (en) * 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Pyrazole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254241A1 (en) * 1986-07-22 1988-01-27 Yoshitomi Pharmaceutical Industries, Ltd. Pyrazolopyridine compounds, their preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKATSUKA, MASASHI ET AL: "Preparation of pyrazole derivatives as immunosuppressants" retrieved from STN Database accession no. 130:52417 XP002193692 -& WO 98 56785 A (SUMITOMO PHARMACEUTICALS CO., LTD., JAPAN) 17 December 1998 (1998-12-17) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512272A (en) * 2000-08-14 2004-04-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted pyrazoles

Also Published As

Publication number Publication date
CN100384420C (en) 2008-04-30
EP1315491B1 (en) 2006-08-09
CY1106196T1 (en) 2011-06-08
DK1315491T3 (en) 2006-10-30
EP1315491A2 (en) 2003-06-04
HK1053606A1 (en) 2003-10-31
NZ524680A (en) 2004-09-24
PT1315491E (en) 2006-10-31
AU2001288730B2 (en) 2006-01-19
CA2421505A1 (en) 2002-03-14
MXPA03001964A (en) 2004-03-26
ATE335472T1 (en) 2006-09-15
CN1482911A (en) 2004-03-17
JP2004508329A (en) 2004-03-18
WO2002020012A3 (en) 2002-06-13
ES2269454T3 (en) 2007-04-01
DE60122171T2 (en) 2007-07-05
AU8873001A (en) 2002-03-22
DE60122171D1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
US6579896B2 (en) Method for treating allergies using substituted pyrazoles
DE60126286T2 (en) SUBSTITUTED PYRAZOLE
AU2001281255A1 (en) Substituted pyrazoles
EP1315490A2 (en) A method for treating allergies using substituted pyrazoles
AU2001288706A1 (en) A method for treating allergies using substituted pyrazoles
AU2001284823A1 (en) Substituted pyrazoles
EP1309592A2 (en) Substituted pyrazoles
US20070117785A1 (en) Substituted pyrazoles and methods of treatment with substituted pyrazoles
US20030073672A1 (en) Method for treating allergies using substituted pyrazoles
US7332494B2 (en) Method for treating allergies using substituted pyrazoles
EP1315492B1 (en) Use of substituted pyrazoles for the treatment of allergies
US20020055497A1 (en) Method for treating allergies using substituted pyrazoles
US20070105841A1 (en) Method for treating allergies using substituted pyrazoles
AU2001288731A1 (en) A method for treating allergies using substituted pyrazoles
RU2277909C2 (en) Method for treatment allergy by using substituted pyrazoles
EP1315491B1 (en) Use of substituted pyrazoles for the manufacture of a medicament for the treatment of allergies
RU2259202C2 (en) Method for treatment of allergy by using substituted pyrazoles
AU2001288730A1 (en) Method for treating allergies using substituted pyrazoles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 262/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001288730

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2003106191

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001964

Country of ref document: MX

Ref document number: 2421505

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002524496

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 524680

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001968486

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/02630

Country of ref document: ZA

Ref document number: 200302630

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 018182720

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2001968486

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 524680

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524680

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001288730

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001968486

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 983/KOLNP/2007

Country of ref document: IN